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Abstract 
The peculiar magnetic properties of Gd(III) ion make it ideal for use as contrast agent 
(CA) for Magnetic Resonance Imaging (MRI). However, due to its high toxicity, 
gadolinium ions must be administered in the form of thermodynamically and kinetically 
stable complexes. The relatively high doses required and the low efficiency of the 
commercially available CA currently in use, have stimulated the search for new classes 
of such diagnostic compounds. In the first part of this work a new stable, high relaxivity, 
di-aqua gadolinium complex has been synthesized and its properties studied in detail. 
The presence of two water molecules in the coordination sphere of the complex 
increases its efficiency as a contrast agent. So far the failure to develop practicable di- 
hydrated systems has arisen mainly from the insufficient kinetic and thermodynamic 
stability associated with such complexes. In addition, each of the di-aqua complexes 
published in the literature have exhibited a high affinity towards the binding, either of 
endogenous anions (e. g. phosphate or carbonate) or of proteins, such as Human Serum 
Albumin (HSA). This binding contributes strongly to the decrease of the relaxivity of 
the complexes. In contrast, the anionic di-aqua complex herein described should be 
suitable as the basis of an MRI agent, because it possesses sufficient stability, with 
respect to acid or cation mediated dissociation pathways, has a fast rate of water 
exchange (30ns at 298K), a high relaxivity (12.3 mM's-1 at 20 MHz and 298K) and 
minimizes competing anion/protein binding. In the second part of this work new 
targeted contrast agents have been prepared and studied. In order to target specifically 
cancerous tissues, gadolinium chelates have been coupled to folic acid, which is 
overexpressed in certain types of cancerous cells. A tetra a-substituted DOTA derivative 
complex, has been chosen which for its optimal intrinsic relaxometric properties (i. e. 
faster water exchange, enhanced relaxivity). The affinity of its folate derivative for 
folate binding protein (FBP) has been investigated and compared to that of a non- 
specific protein (i. e HSA). The 83% enhancement in relaxivity in the presence of FBP 
clearly demonstrated that this receptor protein FBP is capable of recognizing this 
complex selectively. 
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Chapter One: 
Introduction 
0 
1.1. Introduction 
In the last decade there has been a great development of nuclear magnetic resonance 
imaging techniques for the diagnosis of diseases. 1-4 This has prompted the need for a 
new class of pharmaceuticals. Principally these drugs are administered to a patient in 
order to enhance the image contrast between normal and diseased tissue and to indicate 
the status of organ function or blood flow. Since the image intensity in these techniques 
depends on nuclear relaxation times, complexes of paramagnetic transition and 
lanthanide ions, which are able to decrease the relaxation times of nearby nuclei via 
dipolar interactions, have received the most attention as contrast agents (CA). 5,6 
As a consequence of its own unique magnetic properties, the Gd3+ ion has become 
the most important paramagnetic ion used in nuclear magnetic resonance techniques, 
and since the approval of [Gd(DTPA)H20]2" (Magnevist) in 1988, it can be estimated 
that over 30 metric tons of gadolinium have been administered to millions of patients 
worldwide. 6 However, gadolinium complexes are not the only contrast agents 
nowadays used in clinical practice; for example another important class is represented 
by polysaccharide coated iron oxide particles. 5,7 
1.2. Magnetic Resonance Imaging (MRI) 
Magnetic resonance imaging is a powerful technique that is used to obtain images of 
body tissues and organs 2-4,8,9 It is based on the detection of the NMR signals of 
water protons. Since the body is composed principally of water (more then 60 %), its 
protons are the most abundant and readily detected in vivo. Different kinds of tissues 
contain different amount of water, as showed in Table I. I. 
Tissue Water Content Tissue Water Content 
Brain 71-84% Kidney 81% 
Muscle 79% Teeth 10% 
Liver 71% Femur 12% 
Table 1.1- Water content of some tissue types. 
10 
2 
Spatial information is obtained by imposing a linear gradient magnetic field 
across the sample. It is known that the precessional Larmor frequency of nuclei ((Oo) is 
field dependent according to the equation (1.1): 
wo=YBo (1.1) 
where y is the gyromagnetic ratio and Bo the magnetic field. So if a gradient magnetic 
field is applied, protons in different spatial positions will resonate at different 
frequencies. Consequentially the resulting free induction decay (FID) will contain 
spatially encoded information. This "encoded" signal is Fourier transformed to give a 
one-dimensional projection of signal amplitude along a particular line through the 
subject. Images can be reconstructed repeating the scan. After each scan, the field 
gradient is rotated in the plane of interest, and a collection of one-dimensional images is 
obtained. Using adapted algorithms it is possible to reconstruct two-dimensional 
images. The equipment used in MRI is very similar to that used in the common NMR 
experiments. However since a gradient field has to be applied, an additional set of 
gradient coils is needed. In addition because of larger size sample, larger magnets are 
required. 
The measured signal intensity depends on many factors, in particular on the 
values of the water relaxation times T1 (the longitudinal or spin-lattice relaxation time) 
and T2 (the transverse or spin-spin relaxation time), and on the nature of the pulse 
sequence used. For the most common spin-echo pulse sequences, the signal intensity 
(S. I. ) is given by equation (1.2): 11 
S. I. = [H2O]H, (exp(- 
T E) [1- exp(TR )]) (1.2) TZ T, 
where [H20] is the concentration of water protons in the volume element, H, r is a motion 
factor of the water proton, Tl and T2 are the longitudinal and transverse relaxation time 
respectively, TE is the echo delay time and TR is the pulse repetition rate. It is easy to see 
that reduction in the relaxation times gives opposite effects; a decrease in Ti increases 
signal intensity, while a decrease in T2 decreases it. Adjusting the TE and TR values with 
adapted pulse sequences, it is possible to weight the two effects (Ti and T2 weighted 
scan) appropriately. 
3 
Improvements in signal intensity can be achieved using paramagnetic compounds. 
The presence of one or more unpaired electrons in paramagnetic centres causes a strong 
decrease in both the water proton relaxation times Tl and T2. Otherwise the T2 values of 
water in tissues are very short and they are not decreased appreciably by paramagnetic 
compounds at the concentration usually administred to the patients (ca. 0.1 mmol kg-1). 
So the paramagnetic centre causes a perceptible decrease in Ti only, and not in T2, and 
this results in an enhancement of the signal intensity. 5,6 
The value of relaxation times of water depends on its chemical and physical 
environment, so it is possible to discriminate between different tissue types. 5,6 
Moreover, cancerous tissue has shown to possess different values of Ti compared to 
healthy tissue (as indicated in Table 1.2), and this opens up the possibility for tumour 
diagnosis results. 12 
Tissue Tj Cancerous (s) T1 Normal (s) 
Skin 1.047 0.616 
Bone 1.027 0.554 
Muscle 1.413 1.023 
Breast 1.080 0.367 
Liver 0.832 0.570 
Table 1.2 - Values of T, for water in a variety of tissues. 
12 
1.3. Relativity of metal complexes 
The presence of a paramagnetic centre induces a decrease in the longitudinal and 
transverse relaxation times Tl and T2. Rather than referring to these parameters, it is 
common to refer to their inverse, 1/ T1 (R1) and 1/T2 (R2), which represent respectively 
the longitudinal and the transverse relaxation rates of the solvent nuclei. 
The diamagnetic and paramagnetic contributions to the relaxation rates are 
additive, and the observed solvent relaxation rate R; obs, in the presence of a 
paramagnetic centre, is given by equation (1.3): 6 
R1 obs = (Rj)d +(R1)p l =1,2 (1.3) 
4 
where (R; )d is the diamagnetic solvent relaxation rates and (R1)p is the additional 
paramagnetic contribution. In the absence of solute-solute interactions, a linear 
dependence between the solvent relaxation rates and the concentration of the 
paramagnetic centre is observed. So equation (1.3) can be written as: 
(Rj)obs = (Rj)d + ri[M] (1.4) 
where rj is the relaxivity measured in units of M'Is"1, or more commonly in mM''s'1. 
The relaxivity represents the enhancement of the water proton relaxation rate per 
unit concentration of contrast agent. 13 It indicates the ability of the paramagnetic 
complex to shorten the water relaxation rate. The presence of the paramagnetic centre 
causes a large fluctuating local magnetic field. The solvent nuclei around the 
paramagnetic metal, feeling this additional field, will relax more quickly. The local 
magnetic field falls off rapidly with the distance from the paramagnetic centre. So the 
relaxation mechanism will depend on how close the solvent nuclei are to the metal. 
Three classes of water molecules can be distinguished (Figure 1.1). 
0-H PH 
O -H 
H 
outer sphere water H 
,H 
Hý 
d 
0H2 
o. 0K 
AJ 
Ho0 
inner sphere water 
]fr j 
O 
O-H 
2nd sphere water 
Figure 1.1 - Three classes of solvent molecules. 
The first class is represented by water molecules bounded directly to the metal 
ion, in the primary cordination sphere. The solvent relaxation mechanism involving 
these molecules is called "inner sphere relaxation". 
Water molecules in the second coordination sphere, which are bound via 
hydrogen bonding are considered as another class. The contribution from these 
molecules is difficult to treat separately, and usually it is not distinguished from water 
molecules, which closely diffuse outside the second sphere. The solvent relaxation 
5 
mechanism involving these two kinds of solvent molecules is generalised in the term of 
"outer sphere relaxation ". 
Thus, the paramagnetic relaxation rate (R, )p can be split into two contributions, 
one due to the water molecules in the inner sphere and the other due to unbound water 
molecules (equation 1.5): 
(R)p = (R, )os +(R, ); s 
(1.5) 
where i =1,2, and os and is, indicate outer sphere an inner sphere. 
1.3.1. Inner sphere relaxation 
Paramagnetic complexes with one or more directly bonded water molecules (q>_1) show 
higher relaxivity values than those completely saturated by the ligand (q=0). 6 Since the 
protons of coordinated water molecules are very close to the metal ion, they will relax 
very quickly'. Moreover, due to the rapid exchange with the surrounding water 
molecules, a degree of relaxation will be "transferred" to bulk molecules, resulting in a 
highly efficient relaxation pathway. The contribution given by this mechanism to the 
longitudinal and transverse relaxation rates, is expressed by equations (1.6), (1.7) and 
(1.8): 14-16 
1_ [C] 4 (1.6) 
T, 's 55.6 T, M + rM 
1 q[C] zMTiM 
(TM 
+7 
)+, äc02 (1.7) 
TZS 55.6 (zM +I )2 + ýwM 
Ac ,, s = g[c] _ 
ew" (1.8) ohs 55.6 ZM TZA +TM +Ao)M 
where IS stands for inner sphere, [C] is the concentration of the paramagnetic agent, q is 
the number of bound water nuclei per metal ion (i. e. the hydration number), TM is the 
residence lifetime of the bound solvent molecule, Mrefers to the solvent molecule in the 
6 
inner sphere, and Ow is the chemical shift difference between the paramagnetic complex 
and a similar diamagnetic complex taken as reference. 
The values of Tim (i=1,2) can be calculated by the Solomon-Bloembergen-Morgan 
equations (1.9-1.15). 15-18 
11+1i 
=1,2 (1.9) T-7. 
r°° 7. 
sc 
1_2y; S2p S(S+1) 3r, 7r c2 (1.10) 
T°D 5 r6 
[(1ý) 
l+cvsr2 
c2) 
12 S(S + 1) A2 zee 1.11 
TIC 3 
(ý) 
(l+C ei) 
() 
1_1y; g2p2S(S+1) 3zß, 13r 2 
T2" 15 r6 
[(1+r1) + 22 +4Dc, 
(1.12) 
1 
=i S(S+1)(A2 
Zee 
+r (1.13) Tx3 h1 (l + w2r2 ) e' 
1_1+1+1 (1.14) 
Tcl Tie ZM ZR 
1_1+1 (1.15) 
ref Tie TM 
DD and SC refer to the two relaxation mechanisms operative for protons, Dipole-Dipole 
and Scalar or Contact. yj is the nuclear magnetogyric ratio, g is the electronic factor, µB 
is the Bohr magneton, r is the proton metal ion distance, ws and co, are the electron and 
nuclear Larmor procession frequencies, respectively, and A/h is the electron-nuclear 
hyperfine coupling constant. Both dipolar and scalar relaxation mechanisms are 
modulated by the correlation times tic; and iel described by the equations (1.14) and 
(1.15). TI, and Tee (sometime refers as ist and tis2) are respectively the longitudinal and 
the transverse electron spin relaxation times and ER is the rotational correlation time. 
7 
Equations (1.9-1.15) are field dependent, the electron Larmor frequency being 
related to the magnetic field through the gyromagnetic factor (equation 1.1). Also 
electronic spin relaxation rates are field dependent, due to a transient zero field splitting 
(ZFS) (equation 1.16): 6 
T1 +Cvz2 
+1 
+4tvZt2 
(1.16) 
to 3y 
where B is a constant related to the magnitude of the transient ZFS and T is the 
correlation time for the modulation of this ZFS. 
The inner sphere relaxivity 1/Tlis depends on (equations 1.9-1.15) Tm, TR, q, r, Ti. 
and Tee. The influences of these variables on the relaxivity values can be investigated by 
measuring Rl at different magnetic fields. The plot of the relaxivty versus the magnetic 
field results in a Nuclear Magnetic Relaxation Dispersion (NMRD) profile. The 
magnetic field is varied over a range corresponding to proton Larmor frequencies of 
0.01- 50 MHz This can be achieved by using a field cycling spectrometer such as the 
one developed by Koenig and Brown. 19 In Figure 1.2 the NMRD profiles of 
[Gd(DTPA)]2' (Magnevist) and [Gd(DOTA)]" (Dotarem) are shown-5 These complexes 
have similar molecular weight and both have one water molecule coordinated (q=1). 
".. - - 25 
it 
.. -; 
ter sc^er°........ 
Mme- 
ýý' 
. cc ccc 
.. acr ecuencvMhZ 
Figure 1.2 - NMRD profile of [Gd(DTPA)J' and [Gd(DOTA) f at 298K. 
The profiles exhibit two different regions. In the first one (high field region) the 
two complexes show evidence of similar relaxivities. In the low field region a big 
difference is observed. At high field the effective correlation time tc is determined 
8 ý.. 
mainly by TR, whilst at low field it is controlled principally by 'rs. Since TR depends 
mainly on the molecular dimensions of the complex, the similar high field behaviour 
may be rationalised. Furthermore, the differences in the Ts values for the two complexes 
(rs=700 ps for [Gd(DOTA)]" and Ts=80 ps for [Gd(DTPA)]2) explain the low field 
behaviour. 
1.3.2. Outer Sphere relaxation 
The outer sphere contribution to the overall relaxivity of a paramagnetic complex is 
difficult to quantify. Comparison of several q=0 complexes, reveals that longer values 
of the longitudinal electronic relaxation times (Tie) result in enhanced relaxivity. 5 The 
outer sphere relaxation arises from the translational diffusion of water molecules near 
the gadolinium complex. Water molecules and the complex are often treated as hard 
spheres and the relaxation rate is expressed by the equation (1.17): 20 
1 32ýt 
yi92fUBS(S+1) 
N' C 
f(T, 
e, ZO, C0i, 0') 
(1.17) 
T 
os 
405 1000 dD 
where C is the concentration of the paramagnetic compound, NA is the Avogadro's 
number, d is the distance of closest approach of the solvent molecule to the metal 
complex, and TD is the relative translational diffusion correlation time (equation 1.18): 
2 d 
(1.18) T° 3(D, +DS) 
D1 and Ds indicate the diffusion coefficients of the water and the metal complex 
respectively. They can be estimated, assuming a motion of rigid spheres of ratio a in a 
medium of viscosity i according to equation 1.19. 
D= 
kT 
(1.19) 
9 
1.4. Gadolinium (III) complexes as contrast agents for MRI 
In order to enhance the MRI signal intensity, it has become routine practice to 
administer paramagnetic complexes to the patient, at a dose of about 0.1 mmol kg"1. 
The first paramagnetic agent was ferric chloride, 21 orally administrated in order to 
enhance the images of the gastrointestinal tract. Other compounds were later 
investigated, mostly based on iron (III), 22 manganese (11)23 and particularly gadolinium 
(III). 24,25 However, the first diagnostic imaging agent adopted in the medical protocol 
was [GdDTPA(H2O)]2' (Magnevist) in 1988. Injected intravenously, it was used to 
enhance the images of the lesions caused by cerebral tumours. 26 
At the outset of this work, four extra cellular contrast agents currently in clinical 
use are the gadopentate dimetglumine injection (Magnevist, [GdDTPA]2) by Schering, 
godoterate meglumine injection (Dotarem, [GdDOTA]) by Guerbet, gadoteridol 
injection (ProHance, [GdHPDO3A]) by Squibb diagnostic Bracco, and gadodiamide 
injection (Omniscan, [GdDTPABMA] by Nycomed-Amersham (Figure 1-3). 27 
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Figure 1.3 - MRI contrast agents in clinical use. 
Gadolinium (III) ion has an electronic configuration with seven unpaired 
electrons, it has the highest spin quantum number (S=7/2) of any stable element in the 
periodic table. Unfortunately, it is a highly toxic aqua ion. Free gadolinium is known to 
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bind to serum proteins, eventually much of the released metal comes to reside in the 
bone, where it becomes tightly and irreversibly associated. 6 So, this paramagnetic ion 
must be administered in the form of a thermodynamically and kinetically stable 
complex, to reduce the possible release of the free ion in the body. Due to its large size, 
the Gd3+ ion, like all other lanthanides, tends to form complexes with high co-ordination 
number in aqueous media. Currently, all gadolinium (III) contrast agents used in MRI, 
are nine co-ordinate. A ligand occupies eight binding sites at the metal centres, whereas 
the ninth co-ordination site is occupied by a water molecule. The complexes can adopt 
two possible geometries, tricapped trigonal prism (TPP) or capped square antiprism 
(CSAP). However, the two geometries are closely related and sometimes a particular 
structure is well described by both. 
Since Gd3+ is a hard metal ion, it prefers to coordinate hard cr-donors like nitrogen or 
oxygen, thus ligands with carboxylic or amine groups are indeed very common. Data 
accumulated over the past ten years indicate that all the chelates used in the 
commercially available products are remarkably stable with respect to dissociation in 
vivo, 6 assuring the first requirement for a contrast agent: its safety (Table 1.3). 
Ligand Log KGdL kobs (1 s) 
EDTA 17 .7 140000 
DTPA 22.2 1.2 
DOTA 25.3 0.021 
HPDO3A 23.8 0.064 
DTPA-BMA 16.85 >20 
Table 1.3 - Stability constants and acid catalized dissociation constants at 25 
°C. 6 
Another important requirement of MRI contrast agents is represented by high 
water solubility. Since the amount of metal chelate required for a sufficient increment in 
image contrast is relatively high (0.1-0.3 mmol/kg total body weight), the concentration 
of the injected solution must be also high (typically 0.5 M). 6' 28 Thus, the metal 
chelates used as contrast agents must very soluble in water. For this reasons ligands that 
form non-ionic complexes with Gd3" have been provided with hydrophilic groups as 
side chains or functional groups (e. g. alcoholic group in HP-DO3A). 
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The high concentration required also means high osmolality of the solutions 
injected, which may result in severe shocks in the patients. 6' 28 As is clear from the data 
given Table 1.4, the osmolality is particularly high for ionic metal chelates and thus 
neutral complexes may be preferred. 
Ligand Osmol (kg" ) 
DTPA 1.96 
DOTA 1.35 
HPDO3A 0.63 
DTPA-BMA 0.65 
Blood plasma 0.30 
Table 1.4- Osmolality measured in 0.5 MGdL solutions at 37 °C. 
6,28 
1.5 How to improve the efficiency of MRI contrast agents 
The first generation of gadolinium (III) MRI contrast agents is represented by low 
molecular weight chelates (Figure 1.3). Their low efficiency and the high dose required 
have prompted the need for new classes of these compounds. The development of 
improved contrast agents offers several advantages. Firstly the amount of contrast agent 
injected to the patients may be significantly reduced. As a consequence the pain 
deriving from osmotic shocks upon injection may be reduced. In addition the use of 
more efficient contrast agents would short the acquisition time required to record an 
image, with obvious economical and timesaving advantages. 
Inspection of the equations (1-6)-(1-15), shows that in addition to the 
concentration of contrast agent, the number of bound water molecules (q) and a series of 
correlation times (TR, TM and is) determine the inner sphere relaxivity of a paramagnetic 
complex. The challenge is to design new ligands capable of optimising these parameters 
and thus improving the relaxivity of the complexes. In particular the two variables, 
which can have an effect upon relaxivity and can be "adjusted" by the chemist are 
represented by the hydration number, q, and by the rotational correlation time, 'yR. 
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1.5.1 Polyhydrated contrast agents 
A way to improve the relaxivity of low molecular weight contrast agents is to increase 
the hydration number q, as is clear from the equation (1.6). However, an increment in 
the number of water molecules bounded to the metal center has so far always been 
accompanied by a reduction in the thermodynamic stability, as well as in the kinetic 
inertness. Moreover, the possible formation of ternary adducts with endogenous anions, 
such as phosphate or carbonate, which can "replace" the inner sphere molecules and 
thus reduce the relaxivity, must be taken into account. In recent years many papers have 
been published on di- or tri-hydrated chelates, this aspect will be described in more 
detail in Chapter Two. 
1.5.2. Macromolecular conjugates 
Another way to improve the relaxivity of a gadolinium chelate can be achieved by 
"operating" on the rotational correlation time TR. For spherical rigid molecules it can be 
estimated using equation (1.20): 6 
zR = 
3kT3 
(1.20) 
where a is the ratio of the sphere and il is the viscosity. 
In theory tiR can be increased in two ways, either by increasing the size of the 
complex, or by increasing the viscosity of the medium. However, the viscosity of 
extracellular fluid (the medium) cannot be changed, so the only practicable way consists 
in changing the size of the contrast agent. The most common approaches used to 
prepare macromolecular gadolinium contrast agents involve conjugation of 
functionalized chelates to polymers, dendrimers or biological molecules. Conjugation 
methods for linking chelates to macromolecules are well established in the literature. 
29 
Usually they involve functionalization of primary amines using acylation, alkylation, 
urea or thiourea formation and reductive amination. The majority of papers published 
using commercially available reagents, such as DTPA. Reaction of these reagents with a 
reactive primary amine on the macromolecule generates an amide bond using one of the 
DTPA carboxylates. 
13 
Polylysines (commercially available in a variety of molecular weight ranges) have 
been derivatized with gadolinium chelates. 6 The reactive c-amino groups of the lysine 
backbone have been modified with acyclic and macrocyclic polyaminocarboxylate 
derivatives, such as the anhydride or the C-linked isothiocyanate (Figure 1.4) 
Conjugates containing up to seventy gadolinium chelates have been reported. The 
relaxivities of these compounds range from 15 to 20 mM'ls'' at 20 MHz. These not 
particularly high values are a consequence of the flexible nature of the linear polymeric 
backbone, so that the motion of the paramagnetic ion is not efficiently coupled to that of 
the whole macromolecule. 
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Figure U. - Chemical structure ofpolylysine and representative chelate conjugates 
Dendrimers conjugates have been widely explored as potential new class of 
macromolecular MRI agents. 
6 The potential advantage of such compounds is due to the 
fact that dendrimers, such as Starburst polyamidoamine (PAMAM), have uniform 
surface chemistry and minimal molecular weight distribution and shape variation. In 
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contrast to linear polymers, dendrimers have a relatively rigid structure and the overall 
tumbling of the molecule should contribute more efficiently to the rotational correlation 
time. However, the values found fall short of those expected, again as a result of poor 
motional coupling. 
Gadolinium chelates have been coupled to natural polymers as well, such as 
proteins, polysaccharides and nucleic acids. For example, GdDTPA derivatives of 
human or bovine serum albumin (HSA or BSA) have been studied as blood pool agents 
in MR angiography, to image the blood flow in vessels, because of the high 
intravascular retention of these macromolecules. 6,28 
1.5.3. Targeted contrast agents 
The extracellular contrast agents, currently in clinical use, are non-specific in their 
biodistribution. The action of these agents derives from their diffusion throughout the 
extracellular fluid. The aim of the new generation of CA is strongly oriented to develop 
agents with high tissue and/or organ specificity. The idea is to develop CA able to 
detect malignant lesions and differentiate them from non-malignant ones. Conceptually, 
antibodies or other tissue specific molecules may be combined with gadolinium chelates 
to provide disease-specific MRI agents. Schematically they should be formed by three 
components, a Gd3+ complex, a spacer and a tissue-specific molecule or an antibody 
fragment (Figure 1.5). 
Gd Targeting vector 
Figure 1. S - Schematic representation of a targeted contrast agent. 
Curtet and co-workers30 have described the conjugation of polylysine-gadolinium 
chelates to anticarcinoembryonic antigen (CEA) monoclonal antibodies. In vivo studies 
conducted in nude mice grafted with human colorectal carcinoma LS 174T, showed that 
twenty-four hours after the injection (0.001 mmol/kg of gadolinium labelled 
immunoconjugate) the tumor uptake was 10-15% and the corresponding rl increase of 
15-20% was observed. 
Wu and co-workers31 have reported the preparation of metal chelate-dendrimer- 
antibody constructs for use in imaging and radioimmunotherapy. Generation 2 
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polyamidoamine (PAMAM) dendrimers were modified by reaction with bifunctional 
DTPA or DOTA chelates followed by conjugation to monoclonal antibodies. While this 
work was primarily directed toward radioimmunotherapy, the approach was noted to be 
useful for gadolinium as well. 
Wiener and co-workers32 described the preparation of folate-conjugated MRI 
5-- 
imaging agents using a dendrimer conjugation approach. They attached folic acid to a 
generation four ammonia core dendrimer, which was then reacted with an 
isothiocyanate DTPA derivative, to form the polymeric chelate f-PAMAM-TU-DTPA. It 
is accumulated in cells in a specific manner and it gave rise to an enhancement of the 
longitudinal relaxation rate of about 109%. 
Among the possible choices in the targeting vectors, the vitamin folic acid has 
attracted considerable attention in the last years. This is because many human cancerous 
tissues (including breast, cervical, ovarian, colorectal, renal and nasopharyngeal) 
express higher concentrations of the protein receptor which binds folic acid, 33-35 
compared to the healthy tissues. So folate-conjugated MRI agents represent a promising 
new approach to tumor targeting. 
1.6. The vitamin folic acid 
Folic acid (derived from the Latin folium-leaf) occurs in green leaves of many kinds, 
including grass. Mushrooms and yeast are other good sources, as well as a number of 
animal tissues such as liver and kidney. It was isolated for the first time from liver in 
1943,36 but its structure was completely elucidated only in 1948 by Stockstead. 37 Three 
moieties can be recognised in the molecule: pteridine, p-amino benzoyl acid and 
glutamic acid (Figure 1.6). 
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Figure 1.6 - Folic acid structure. 
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Folic acid (named also pteroylglutamic acid (PGA), folacin or vitamin B,, ) 
crystallises from water in the form of yellow, spear shaped leaflets. The free acid is not 
highly soluble in water (10 mg/l at 0 °C; 500 mg/l at 100 °C), whereas the disodium salt 
presents a much higher solubility (15 g/1). 
This vitamin comprises a large family of biologically active forms of folic acid. 
These differ in the oxidation state of the pteridine ring, in the number of glutamate 
residues or in the substitution at N5 and N1°. Folates function as essential coenzymes, 
which involve the incorporation of a single carbon fragment, in the syntheses of purines, 
pyrimidines and certain amino acids. Folic acid and folates are absorbed from the diet 
primarily via the proximal portion of the small intestine. Following their absorption 
from the digestive system, dietary folates are rapidly reduced by dihydrofolate reductase 
and by other enzymes to tetrahydrofolic acid. 
The cellular uptake of these compounds is assured by at least two independent 
transport mechanisms. Reduced folates are internalised via a carrier-mediated low 
affinity (Km - 1-5 µM) anion transport system that is found in nearly all cells. 38 Folic 
acid and 5-methyl tetrahydrofolate can also enter the cells via a high affinity (KD in the 
order of nanomolar) membrane bound folate binding protein (FBP) that is anchored to 
the cell membrane via a glycosylphosphatidylinositol (GPI) moiety. 39-42 Experiments 
conducted in MAI 04 cells, 43 have shown that 5-methyl tetrahydrofolate is taken up into 
the cell after binding to GPI-anchored FBP that has clustered in cell structures, known 
as caveolae. 44 The caveolae then seal the folate binding protein-folate complex off from 
the extracellular space and transport folate into the cell. Once inside, the folate 
dissociates from FBP and diffuses into the cytoplasm, where it is readily coupled to one 
or more glutamic acid residue, slowing diffusion out of the cell. The caveolae and FBP 
then migrate to the membrane surface for another round of folate uptake. 
Human FBP exists in two major isoforms, the a and the P. They possess almost 
70% amino acid sequence homology, but differ dramatically in their stereospecificity 
for folates species 45 Healthy tissues usually express low to moderate amount of the ß- 
form, whereas the a-FBP is generally overexpressed in a variety of carcinomas. 34 
These membrane proteins represent an interesting delivering system for 
pharmaceutical or diagnostic agents coupled to folic acid, because they can distinguish 
between normal and cancerous cells. FBP levels are low in many normal tissues, 
whereas they are high in many tumour cells. This difference allows selective 
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concentration of pharmaceutical or diagnostic agents in tumour cells compared to 
normal ones and thus facilitate treatment or visualisation of tumour cells. 
1.7. Lanthanide ions 
The paramagnetic Gd3+ ion has some spectroscopic limitations. For example, the 'H 
NMR spectra cannot be recorded because its long electronic relaxation time causes a 
broadening of the NMR lines to such an extent that no peaks are observed. Moreover, 
fluorescence studies are not useful in case of gadolinium (III) compounds. The 
difference in energy between its ground state (8S72) and its first excited state (6Prn) is 
too high. However, its neighbour ions Eu3+ and Tb3+ do not posses such limitations and 
having similar ionic radii, they can be used to elucidate the solution behaviour of the 
corresponding gadolinium species. 
Measurements of the radiative rate constant for decay of the luminescent 
europium or terbium excited state in H2O and D20 allow an estimate of the complex 
hydration state, whereas the analysis of high resolution absorption and luminescence 
spectra can help in understanding the structure and symmetry of the complex in 
solution. Therefore, when examining the properties of a new gadolinium complex, it is 
usual practice to prepare also the analogous Th and Eu complexes and study their 
photophysical and NMR properties in detail. 
1.7.1. Electronic configurations and spectroscopic transitions 
Luminescence in lanthanide (III) ions occurs through transitions between 4f states. 
Energy levels may be calculated by considering interelectronic repulsion, spin orbit 
coupling and the ligand field. For example, interelectronic repulsion splits the 
configurations 46 of Eu3+ and 4f8 of Tb3+ into (2s+l)F spectroscopic terms, where F=S, 
P, D, F when the quantum number L=0,1,2,3. The terms deriving from this 
electrostatic interaction are separated by about 104 cm"1. Spin-orbit coupling then splits 
these terms into J states, which are typically separated by 103 cm 1. There are 295 (2s+l)FJ 
spectroscopic levels for the 4f5 and 4e onfigurations. Their relative energies are 
predicted by Hund's rules. For example, for both Eu3+ and Tb3+ ions, the 
7F term is 
lowest in energy and the ground state levels are 7F6 for Tb3+ and 7Fo for Eu 3+ (Figure 
1.7). 
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Selection rules govern the various electronic transitions. In case of magnetic 
dipole allowed transitions these are: AS = 0; AL = 0; AJ = 0, ±1. In addition, a transition 
is only allowed if it conforms to the group theoretical rules, which are appropriate to the 
site symmetry of the lanthanide ion. 
1.7.2. Luminescence from Eu3+ complexes 
The investigation of the emission spectra of lanthanide complexes allow us to gain 
information about complex speciation, structure and the local symmetry. We will focus 
our attention mainly on the Eu3+ emission spectra, which have been recorded in this 
work. When the Eu3+ ion is excited from the 7Fo ground state to a higher state, it 
undergoes radiationless decay to the long lived 5D0 state, from which all luminescence 
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to the 7Fj arises in solution. The strongest transitions occur between states with rather 
low J values, so that detailed interpretation is possible without the need for analysis of 
crystal field splitting. The AJ =0 (580 nm), AJ =1 (590 nm), OJ =2 (618 nm) and AJ= 
4 (700 nm) transitions are particularly interesting. The latter two (termed 
hypersensitive) have an intensity, which is very sensitive to the chemical environment. 
The origin of this hypersensitivity has not been fully clarified yet. However, the analysis 
of several examples suggests that the intensity of this band is lower for axially 
symmetric complexes and increases with the degree of polarisability of the donor atom 
type 46 The magnetic dipole allowed transition .J=1 has an intensity, which varies 
relatively little from one coordination environment to another. 47 In addition, there are 
three transitions allowed in low symmetry, but only two if the complex possesses a C3 
or a C4 axis. The highest energy emission band is for the formally forbidden LJ =0 
transition. Probing this transition requires high-resolution laser spectroscopy. Usually 
twisted square antiprismatic complexes exhibit lower intensity for this transition 
compared to the square antiprismatic isomer. 
1.7.3. Hydration number 
In the late seventies Horrocks developed a method for determining the hydration 
number q of the luminescence lanthanides europium and terbium 48 Luminescence from 
excited Tb3+ and Eu3+ ions in solution is quenched by vibrational oscillators of water. 
The greater the number of water molecules bound to the metal centre, the more efficient 
is the quenching. Kropp and Windsor showed that the luminescence of Eu3+ and Tb3+ 
complexes was more intense in D20 than in H2O and that the luminescence lifetimes 
were about an order of magnitude longer in D20 49,50 
The luminescence lifetimes in H2O and D20 were measured for a series of 
europium and terbium complexes with a known number of bound water molecules. The 
plot of the hydration state q versus the difference in rate of lanthanide luminescence 
quenching (Ak) gave a straight line. Horrocks defined the slope of this line as the factor 
A, which reflected the sensitivity of a given lanthanide ion to vibrational quenching. 
The value of q can be estimated by using equation 1.21. 
q=A(kH=o-k)0) (1.21) 
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where A is equal to 4.2 ms -1 for terbium complexes and equal to 1.05 ms-1 for europium 
complexes. 
However, other energy matched exchangeable XH oscillators may also quench the 
excited state of lanthanide ions, including amide NH, 51,52 amine NH53,54 and CH. 53, 
55 These oscillators, in the context of complexes used in MRI, are more distant from the 
lanthanide centre and hence their quenching effect is less marked than the effect of 
directly bound OH oscillators. In addition the presence of unbound water molecules in 
the second sphere may contribute to the quenching. 53 As a consequence of these effects 
the equation (1.21) has been modified to account for the quenching effect of closely 
diffusing water molecules and the effect of other exchangeable XH oscillators (equation 
1.22). 
q= Al(kH2o - ko2o 
)- 0.25] (1.22) 
where A is equal to 1.2 for the europium complexes and 5 for terbium complexes. 
1.8. Objectives of the work 
The aim of this work is the development of new efficient contrast agents for MRI. In the 
first part of this thesis (Chapter Two) a new efficient di-hydrated complex is described. 
In the light of what has been discussed in the previous paragraphs, the relaxivity of a 
gadolinium complex may be improved by increasing the hydration number q. The 
gadolinium complex [Gd-8]3' (Figure 1.8) has been synthesised and fully characterised. 
Relaxometric studies revealed a significant high relaxivity, the highest measured for a 
complex of similar size so far, and a fast water exchange (im=30 ns). In addition, it 
showed both a good thermodynamic stability and a kinetic inertness. In contrast to other 
dihydrated complexes published in literature, [Gd"8]3- does not bind endogenous anions 
(such as phosphate, carbonate, lactate or citrate) at physiological pH. These properties 
make it a promising candidate as contrast agent for MRI. 
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Figure L8 - Ligands structures. 
In the second part of this work new targeting contrast agents have been developed. 
Gadolinium chelates have been coupled to the targeting vector folic acid. Since many 
human cancer cells have higher levels of FBP than normal ones26, they will present 
higher amounts of folic acid. Binding a gadolinium (III) complex to folic acid allows 
the possibility of tumor targeting. Currently, the conjugation of folate derivatives is 
carried out through reactions between a carboxylic group of folic acid and an amino 
group of a particular substrate. This amide conjugation is achieved by using dehydrating 
agents, such as DCC or EDC. Practicable routes for the syntheses of a new folate 
conjugate have been developed, using the simple model complex [Gd"9]. However, the 
main idea of the project was the synthesis of folate conjugates of the anionic gadolinium 
complex [Gd"6]-. 
The choice of this structure can be explained as follows. Firstly, its amino arm 
provides the "binding site" for folic acid. Secondly, the three terminal carboxylic acid 
groups can be linked to high molecular weight compounds to improve the rotational 
correlation time TR, and thus the relaxivity of the complex. Finally, the four carboxylic 
groups together with the four nitrogens of the cycle constitute the donor atoms for the 
gadolinium (III) ion. In addition, the existence of eight different stereoisomers of the 
ligand (6) must be considered. They are determined by the configuration at each of the 
carbon stereogenic centres: RRRR (SSSS), RSSS (SRRR) and the related 
diastereoisomers RSRS (SRSR) and RRSS (SSRR). Previous studies have demonstrated 
that the exchange rate ('rn, ) of water bonded to lanthanide ions (e. g. Eu and Yb) depends 
upon the nature and composition of the isomers of a given complex-56,57 In recent 
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work on lanthanide complexes of the ligand (7), it was shown that the water exchange 
rate was faster for the RRRR isomer (, r,,, =71,140 and 270 ns (298 K) for the (RRRR), 
(RRRS) and (RSRS) isomers respectively). 58 The (RRRR)-[Gd"6]- complex may 
therefore be expected to possess the shortest value of tim, and therefore will not limit the 
overall relaxivity to the same extent as the other isomers. 
1.9. References 
[1] Peters, J. A.; Huskens, J.; Raber, D. J. Prog. NMR Spectrosc. 1996,28,283. 
[2] Koenig, S. H.; Brown, R. D. Prog. NMR Spectrosc. 1990,22,487. 
[3] Kumar, K.; Tweedle, M. F. J. Pure Appl. Chem. 1993,65,515. 
[4] Young, S. W. Magnetic Resonance Imaging: Basic Principles; Raven Press: 
New York, 1988. 
[5] Aime, S.; Botta, M.; Fasano, M.; Terreno, E. Chem. Soc. Rev. 1998,27. 
[6] Caravan, P.; Ellison, J.; McMurry, T. J.; Lauffer, R. B. Chem. Rev. 1999,99, 
2293. 
[7] Petersein, J.; Saini, S.; Weisslader, R. MRI Clin. N. Am. 1996,4,53. 
[8] Stark, D. D.; Bradley, W. G. Magnetic Resonance Imaging; C. V. Mosby: New 
York, 1988. 
[9] Edelman, R.; Warack, S. New Eng. J. Med. 1993,328,708. 
[10] Diem, K.; Leutner, C. Documenta Geigy Scientific Tables; Gregory: Basel, 
1970. 
[11] Tweedle, M. F. In Lanthanide Probes in Life, Chemical and Earth Sciences, 
G. Bunzli and G. R. Choppin, Ed.; Elsevier: Amsterdam, 1989; Vol. 5. 
[12] DamadianProc. Nat. Acad. Sci. USA 1974,71,1471. 
[13] Aime, S.; Batsanov, A. S.; Botta, M.; Howard, J. A. K.; Parker, D.; Senenayake, 
K.; William, J. A. G. Inorg. Chem. 1994,33,4696. 
[14] Bertini, I.; Luchinat, C. NMR of Paramagnetic Molecules in Biological Systems; 
Benjamin-Cummings: Boston, 1986. 
[15] Solomon, I. Phys. Rev. 1955,99,559. 
[16] Bloembergen, N.; Morgan, L. O. J. Chem. Phys. 1961,34,842. 
[17] Bloembergen, N.; Puccel, E. M.; Pound, R. V. Phys. Rev. 1948,73,697. 
[18] Bloembergen, N. J. Chem. Phys. 1957,27,572. 
23 
[19] Koenig, S. H.; Brown, R. D. In Relaxometry of Tissue in NMR Spectroscopy of 
Cells on Organisms, ; R. M. Gupta, Ed.; CKC Press: Boca Raton, FL, 1987, pp 
75. 
[20] Freed, J. M. J. Chem. Phys. 1978,68,4034. 
[21] Young, I. K.; Clarke, G. J.; Cailes, D. R. Computed Tomography 1981,5,534. 
[22] Njornerud, A.; Oksendal, A. N. Presented at Cost D8 Meeting, Bergen, 1997 
[23] Elizondo, G.; Fretz, C. J.; Stark, D. D.; Rockloge, S. M.; Quay,. S. C.; Warah, 
D.; Tsung, Y. M. Radiology 1991,73. 
[24] Schaffer, M.; Mayer, D.; Beoute, S. Magn. Res. Med. 1991,22,238. 
[25] Weinman, M. J.; Schmitt, G. J. Magn. Res. Med. 1991,22,233. 
[26] Carr, D. M.; Brown, J.; Bydder, G. M.; Weinman, M. J.; Speck, U.; Thomas, D. 
J.; Young, I. R. Lancet 1984,1,484. 
[27] Hasso, A. N.; Stark, D. D. J. Magn. Res. Imag. 1993,135. 
[28] Merbach, A. E.; Toth, E. The Chemistry of Contrast Agents in Medical Magnetic 
Resonance Imaging; Wiley: New York, 2001. 
[29] Brinkley, M. Bioconj. Chem. 1992,3,2. 
[30] Curtet, C.; Maton, F.; Havet, T.; Slinkin, M.; Mishra, A.; Chetal, J. F.; Muller, 
R. N. Invest. Radiol. 1998,33,752. 
[31] Wu, C.; Brechbiel, M. W.; Kozak, R. W.; Gansow, 0. Biorg. Med Chem. Lett. 
1994,4,449. 
[32] Weiner, E. C.; Konda, S.; Shadron, A.; Brechbiel, M.; Gansow, 0. Invest. 
Radiol. 1997,32,748. 
[33] Franklin, W. A.; Wantub, M.; Edwards, D.; Christiensen, K. Int. J. Cancer 1994, 
8,89. 
[34] Ross, J. F.; Chonduri, P. K.; Rotman, M. Cancer 1994,73,2432. 
[35] Wang, S.; Luo, J.; Lantrip, D. A.; Waters, D. J.; Mathias, C. J.; Green, M. A.; 
Fucks, P. L.; Low, P. S. Bioconj. Chem. 1997,8,673. 
[36] Pfiffher, J. J.; Binkley, S. B.; Bloom, E. S.; Brown, 0. D.; Bird, A. D.; Emmet, 
A. J. Science 1943,97,404. 
[37] Stockstead, E. L. K.; Hutchings, Y.; Subbarow, S. J. Am. Chem. Soc. 1948,70, 
3. 
[38] Kisliuk, R. L. In Folate Antagonists as Therapeutic Agents, ; F. Sirotnack, J. J. 
Burcall, W. D. Emsinger and J. A. Montgomery, Ed.; Academic Press: Orlando, 
1984. 
[39] Kane, M. A.; Waxman, S. Lab. Invest. 1989,60,737. 
24 
[40] Henderson, G. B. Ann. Rev. Nutr. 1990,10,319. 
[41] Ratnam, M.; Marquardt, H.; Duhring, J. L.; Freisheim, J. H. Biochemistry 1989, 
28,8249. 
[42] Sadasivan, E.; Rothenberg, S. P. J. Biol. Chem. 1989,264,5806. 
[43] Kamen, B. A.; Schmith, A. K.; Anderson, R. G. W. J. Clin. Invest. 1991,87, 
1442. 
[44] Leamon, C. P.; Low, P. S. Biochem. J.. 1993,291,855. 
[45] Wang, X.; Schen, F.; Freisheim, J. H.; Gentry, L. E.; Ratnam, M. Biochem. 
Pharmacol. 1992,9,1898. 
[46] Bryden, C. C.; Reilley, C. N. Anal. Chem. 1982,54,610. 
[47] Bunzli, J: C. G.; Choppin, G. R. Lanthanide Probes in Life, Chemical and Earth 
Sciences; Elsevier: AMsterdam, 1989. 
[48] Horrocks, W.; Schmidt, G. R.; Sudnick, D. R.; Kittrell, C.; Pernheim, R. A. J. 
Am. Chem. Soc. 1977,99,2378. 
[49] Kropp, J. L.; Windsor, M. W. J. Chem. Phys. 1963,39,2769. 
[50] Kropp, J. L.; Windsor, M. W. J. Chem. Phys. 1965,42,1599. 
[51] Parker, D.; Williams, J. A. G. J. Chem. Soc., Perkin Trans. 21995,1305. 
[52] Dickins, R. S.; Parker, D.; De Sousa, A. S.; Williams, J. A. G. J. Chem. Soc., 
Chem. Comm. 1996. 
[53] Beeby, A.; Clarkson, I. M.; Dickins, R. S.; Faulkner, S.; Parker, D.; Royle, L.; 
De Sousa, A. S.; Williams, J. A. G.; Woods, M. J. Chem. Soc., Perkin Trans. 2 
1999,493. 
[54] Wang, Z.; Chopping, G. R.; Bernardo, P. D.; Zanonato, P. L.; Portonova, R.; 
Tolazzi, M. J. Chem. Soc., Dalton Trans. 1993,2791. 
[55] Hemilla, I.; Mukkala, V. H. J. Fluoresc. 1995,5,159. 
[56] Aime, S.; Barge, A.; Botta, M.; Parker, D.; De Sousa, A. S. Angew. Chem. Int. 
Ed. Engl. 1998,37,2673. 
[57] Aime, S.; Barge, A.; Bruce, J. I.; Botta, M.; Howard, J. A. K.; Moloney, J. M.; 
Parker, D.; De Sousa, A. S.; Woods, M. J. Am. Chem. Soc. 1999,121,5672. 
[58] Woods, M.; Aime, S.; Botta, M.; Howard, J. A. K.; Moloney, J. M.; Navet, M.; 
Parker, D.; Port, M.; Rousseaux, O. J. Am. Chem. Soc. 2000,122,9781. 
25 
Chapter Two: 
A Stable New High Relaxivity Di-Aqua Contrast Agent. 
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2.1. Introduction 
The relatively high doses required and the low efficiency of the commercially available 
MRI contrast agents, have prompted the search for new classes of these diagnostic 
compounds. 
As we have seen in Chapter One, the efficiency of a contrast agent can be improved 
by increasing the hydration number q. However, high hydration numbers reduce both the 
kinetic and thermodynamic stability of the complex with respect to dissociation, limiting 
the choice to di-hydrated (q=2) or tri-hydrated (q=3) species. Another disadvantage of 
these systems is that they are more likely to bind endogenous anions, such as phosphate or 
carbonate, displacing one or more of the water molecules and hence lowering the relaxivity. 
Heptadentate ligands are most appropriate for formation of q=2 complexes, because 
they should allow the coordination of two water molecules in the inner sphere of the metal. 
Moreover, heptadentate-based gadolinium complexes should present a relatively fast water 
exchange rate, with respect to analogous complexes based on octadentate ligands, giving an 
additional improvement. For these reasons, in the last few years, the interest in di-hydrated 
complexes has increasingly grown. 
Xu and co-workersl reported the syntheses and characterization of [Gd-TREN-Me- 
3,2, -HOPO] (10) (Figure 2.1), a complex with relatively high relaxivity (10 mM"1 sd), 
apparently good stability but poor water solubility (less then 0.1 mM at pH = 7.0). To 
further exploit the properties of this ligand, a number of functionalized derivatives have 
been synthesized, mainly to improve the solubility. Cohen and coworkers2 synthesized and 
characterized three new complexes [GdTREN-Me-3,2-HOPOSAM] (11), [GdTREN-Me- 
3,2-HOPOTAM]- (12) and [GdTREN-Me-3,2-HOPOIAM] (13), by replacing one of the 
hydroxypyridinone groups of (10) with moieties able to "tune" properties, such as denticity, 
charge, solubility and stability of the resulting complex. These ligands bind the metal in a 
hexadentate fashion, allowing for coordination of at least two inner sphere water molecules. 
The relaxivity values, although smaller then the parent compound [Gd-TREN-Me-3,2- 
HOPO] (10), were higher than those of all the currently available commercial contrast 
agents (8.8 MM" s4 for TAM (12), 7.2 mM-1 s'1 for SAM (11) and 7.7 mM71 s"1 for IAM 
(13) at 20 MHz and 25°C). 
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Figure 2.1- Ligands forming di-aqua complexes with Gd". 
Recently Aime and coworkers3 have reported the syntheses of a new ligand based on 
a pyridine containing macrocycle, bearing two acetate and one methylenephosphonate arms 
(PCP2A) (14). The interest around this complex was mainly due to its high stability (Log 
I{cdL = 23.4). In addition, it has a good value of relaxivity (8.3 mM" s") for a complex of 
this size. This can be explained by considering the additional contribution from water 
molecules in the second sphere, arising from the ability of the phosphonate group to form 
hydrogen bonds. 
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The neutral [GdDO3A] (15) was one of the first q=2 systems to be investigated. It 
does not present either a particularly high value of relaxivity (6.0 mm", s"I, 20 MHz, 298 K) 
nor a fast water exchange rate (iM = 160 ns) 4,5 However, it has been frequently 
functionalized and several examples of DO3A-like complexes have been reported in the 
literature. 
Aime and coworkers6 have synthesized two derivatives, which bear either a p-bromo 
benzyl (16) or a p-phosphonatomethylbenzanilido (17) substituent, with the aim of 
promoting further interaction with macromolecular substrates. They both exhibit a higher 
relaxivity (7.9 mM-' s"1 and 10.7 mM" s'' respectively) than the parent DO3A complex. 
In this work the complexes of the ligands shown in Figure 2.2 have been investigated 
and compared to the analogous monohydrated complexes based on the corresponding 
octadentate ligands. It has previously been established that lanthanide complexes of 
DO3MA (18) possess a high kinetic and thermodynamic stability (Log KGdL = 25.3)2 This 
forms a suitable starting point for an investigation of complexes, which are designed to 
resist anion or protein binding. Accordingly the complexes of the ligands (8) and (19) 
(Figure 2.2) have been considered, as the pendant carboxylate groups are expected to 
inhibit anion binding by electrostatic repulsion. The study has been limited to complexes 
with two or three methylene groups in the chain because longer hydrocarbon chains reduce 
the water solubility. Being heptadentate ligands, in their lanthanide complexes they should 
coordinate two water molecules. An additional improvement in the relaxivity may be 
expected from a second sphere contribution, since the three remote carboxylate arms can 
form hydrogen bonds with bulk water molecules. Moreover, the three terminal carboxylic 
acid groups provide sites for covalent linkage to high molecular weight compounds. By 
increasing the molecular weight of the complex an increment in the rotational correlation 
time, TR and hence in the relaxivity should be expected. 
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n=1 (19) gDO3A 
n=2 (8) aDO3A 
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Figure 22 - Ligands investigated. 
2.2. Strategies of syntheses 
The europium (III) and gadolinium (III) complexes of the ligand aDO3A (8) were 
synthesized according to scheme below (Figure 2.3). 
COOMe 
H, 'H CH3CN 
*3 --º 
HH Br 
NaHCO3 
(22) McOOC 
(23) 
LnCl3 
water 
HOOC 
Ln: Eu(III) (26); Gd(III) (27) 
Figure 2.3 - Synthesis of Ln (III) complexes of aDO3A (8). 
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The alkylation of the cyclen (22) was achieved using racemic 2-bromo dimethyl 
adipate (23) with sodium hydrogen carbonate as base. Each nitrogen in the macrocycle 
cyclen exhibits a different pKa. Although the exact value depends on the N-substituent, they 
are typically around 3,5,10 and 13.8 The reactivity of the four nitrogens is different and in 
theory can be modulated by the choice of the base. The use of a strong base increases the 
rate of the reaction, but reduces the selectivity yielding a high amount of the tetra-alkylated 
derivative. On the other hand by using a weak base it should be possible to improve the 
selectivity, by slowing the reaction rate. According to the procedure followed by Pillai for 
the syntheses of DO3A derivatives, sodium hydrogen carbonate was used as the base. 9 
Even though the reaction was not complete after four days and some tetra and di-alkylated 
derivatives were present in the crude, the tri-alkylated compound (24) was isolated in a 
reasonable yield (33%), following chromatographic purification. 
The ß-elimination of the bromo compound (23) competes with the SN2 reaction and 
contributes to reduce the final yield (Figure 2.4). The formation of the alkene (23a) was 
detected by ESMS. When a strong excess of base was used, the amount of alkene increased. 
An excess of base equal to 2.9 equivalents of cyclen. was found to be the best compromise. 
The tri-alkylated cyclen derivative (24) was isolated as a mixture of the RRR (SSS), 
RSR (SRS) and SSR (RRS) isomers after purification over silica gel, eluting with ammonia 
solution in tetrahydrofuran in the presence of methanol and dichloromethane. 
The methyl esters were efficiently hydrolysed in a1M lithium hydroxide solution at 
90°C. The progress of the reaction was followed by 'H NMR. Small portions of the reacting 
solution were collected over time, evaporated, dried and dissolved in D20. The 
disappearance of the methyl resonances between 3.65 and 3.75 ppm was checked and 
reaction was found to be complete after 24 hours. The crude solid was purified through a 
strong cationic exchange resin, eluting with a 12% ammonia solution; the pure ligand was 
collected in the form of its ammonium salt. 
COOMe B Me000 
COOMe 
MeOOC 
(23) 
Br (23a) 
Figure 2.4 - Competitive /3-elimination. 
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The gadolinium (III) and the europium (III) complexes of aDO3A (8) were 
synthesized from a water/methanol mixture (1: 1; v/v) at pH 5.5. Due to the insolubility in 
methanol, the complexes precipitated as soon as they formed. They were isolated by 
filtration at the end of the reaction. The formation of the complexes was followed by 
ESMS, which showed the complete disappearance of the ligand after 24 hours. 
The 'H NMR spectrum of the isolated Eu (III) complex showed the predominance (ca 
50%) of one isomer. However, it was not separated from the minor isomers present. In the 
absence of a crystal structure it is hard to understand which of the possible three 
diastereoisomers (RRR, RSR, RRS) is the most abundant, although for the analogous C4- 
symmetric complexes, the RRR (SSS) ligand and complex were found to be least soluble in 
water. 
The gadolinium and the europium complexes of gDO3A (19), aDOTA (20) and 
gDOTA (7) were synthesized by Dr. Mark Lowe and Dr. Ofer Reany in the group. 
2.3. Structure studies in solution 
Contrast agents function in an aqueous environment, so it is important to study the 
properties and structure in solution. The determination of the hydration number q and the 
understanding of which isomer is the most abundant in solution are fundamental issues to 
understand the biophysical properties of the complex. Unfortunately the gadolinium (III) 
ion has some spectroscopic "limitations". Its remarkably long electronic relaxation time, 
which makes it most suitable for use as a contrast agent in MRI, has the effect of 
broadening NMR spectra lines to such an extent that e. g. 'H NMR spectra of gadolinium 
complexes may not be recorded. 
In addition the Gd(III) ion is not useful in fluorescence studies. The difference in 
energy between its ground state (8Srrz) and its first excited state (6P7n) is quite high. The 
emission from the excited state occurs at 311 nm. However, its neighbors ions Eu(III) and 
Th (III), do not posses such limitations and since they have similar ionic radii, they can be 
used as valid models to allow a good estimation of the properties of the gadolinium 
complexes in solution. 
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2.3.1. 'H NMR studies 
Further information about the nature of complex solution structure can be obtained by 1H 
NMR studies. Derivatives of DO3A are heptadentate ligands and the resulting complexes 
can adopt three different coordination geometries; a pseudo-square antiprism, a pseudo 
twisted square antiprism and mono-capped octahedron, as indicated in Figure 2.5. These 
geometries can easily interconvert by arm rotation or ring inversion. 
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Figure 2.5 - Co-ordination geometries adopted by DO3A-like lanthanide complexes. (a) pseudo square 
antiprism, (b) pseudo twisted antiprism and (c) mono-capped octahedron. 
1H NMR analyses can detect the presence of different coordination isomers in 
solution and their time-averaged symmetry. Previous studies on C4-symmetric analogous 
complexes (7), have demonstrated that two major diastereoisomers are present in 
solution, 10 whose relative proportion is a function of the lanthanide ion, temperature and 
solvent. These two isomers, a regular monocapped square antiprismatic (M) and a twisted 
square antiprismatic (m), are characterized by different dipolar shifts. The complexes of the 
former series usually possess the bigger paramagnetic shifts for a given resonance. 
Particularly useful is the analysis of the most shifted axial ring proton. This resonates at 
around 30-50 ppm in the case of 9-coordinate square antiprismatic Eu (III) complexes and 
at around 20 ppm for related 9-coordinated twisted square antiprismatic complexes. 
Analysis of the 1H NMR spectra of the (RRRR)- (RRRS)- and (RSRS)-[Eu"7]' 
complexes provided evidence for the presence of two major isomeric species in a relative 
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ratio (Wm) of 1: 4,2: 1 and 4: 1 respectively. 10 For the (RRSS)-[Eu"7]' only one isomer (M) 
was detected in solution. 
The 1H NMR spectrum of [EuaDO3A]3' recorded in D20 solution at pD = 7.0 (Figure 
2.6) shows a prevalence (c. a. 50%) of one isomeric species, which possesses modest 
paramagnetic shifts (c. a. 20 ppm). 
Accordingly to what has been observed for the parent C4-symmetric analogues 
complexes (7), 10 it is reasonable to think that the major isomer in solution may be the RRR 
(SSS). However, in the absence of an X-ray crystal structure no definitive conclusion can 
be made. 
Recently, it has been demonstrated that the rate of the water exchange at the 
lanthanide ions is dependent upon the nature and composition of the isomers of a given 
complex. 10 Thus, for example zM for [Eu-7]- was equal to 68,140 and 270 ns (298 K) for 
the RRRR, RRRS and RSRS respectively. However, it can be anticipated, that in the case 
of the di-hydrated [EuaDO3A]3' a faster water exchange should be expected and thus the 
isomeric composition may not affect significantly the water exchange rate. 
The 'H NMR spectrum of [EuaDO3A]3- was recorded over time, in order to ascertain 
the stability of the complex in D20 solution at pD = 7.0. The spectrum did not change after 
several weeks, confirming that no significant dissociation had occurred. Moreover, since 
the spectra look identical with respect to the isomer composition, no isomer interconversion 
took place. 
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Figure Z6 - 
'H NMR spectrum of [EuaDO3AJ3" (200 MHz, in DZO, pD = 7.0). 
2.3.2. Emission spectra 
The emission spectra of lanthanide ions are particularly sensitive to the ligand field effect. 
Each transition observed in the spectra is informative of the structure. The spectra of 
[EuaD03A]3", [EugD03A]3- and [EuaDOTA]" were recorded following direct excitation at 
397 nm (293 K) in water at pH 7.20 (Figure 2.7). 
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Figure 2.7- Emission spectra in H2O at pH =7.20 of. " (a) [EuaDO3A]3, (b) [EugDO3AJ "3" and (c) 
[EuaDOTA]'. 
The intensity of the "hypersensitive" OJ=2 (618 nm) transition is particular sensitive 
to the chemical environment. The analysis of a great number of Eu3+ complexes suggests 
that the intensity is lower for axially symmetric complexes, is sensitive to the polarizability 
of the axial donor and increases by lowering symmetry. I l In addition, the number of bands 
in this transition is strongly determined by the site symmetry. The higher the symmetry the 
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lower the number of bands is observed. This is confirmed by looking at the spectra of the 
more symmetric [EuaDOTA]", in which the intensity ratio OJ=2/OJ=1 is about one and the 
less symmetric tri-substituted analogous [EuaD03A]3-, in which the intensity ratio 
AT=2/4T=1 is about three. However, [EugD03A]3- shows a lower intensity than expected 
for this transition, with an intensity ratio AJ=2/AJ=1 approximately equal to two. 
The intensity of the magnetic-dipole allowed AJ=1 (590 nm) transition does not 
change very much with coordination environment. However two or three bands can be 
observed depending on the symmetry of the complex. In complexes of low symmetry, three 
transitions are allowed, whereas for complexes with a C3 or C4 axis, only two transitions 
are permitted. 12 Again this observation is satisfied in the case of [EuaDOTA]', 
[EugDOTA]3- (two bands) and [EuaD03A]3- (three bands), but apparently not in the case of 
[EugD03A]3- (two bands). The spectra differ also in the form of the AJ=4 transition 
manifold. 
The chemical environment around the metal ion must be different in [EuaD03A] 3'and 
[EugD03A]3-, i. e. they possess different structures in solution. The total emission spectrum 
of [EuaD03A]3- closely resembles that of [EuDO3A] (q = 1.8), whereas the spectrum of the 
analogue [EugD03A]3- does not. A reasonable explanation for these differences can be 
found by considering the formation of an intra-molecular bond between one remote 
carboxylate group and the metal centre. This would result in a stable seven-membered ring 
in the case of [EugD03A]3-, which is much less likely in the case of [EuaD03A]3-, where 
an 8-ring chelate is required. 
2.3.3. Hydration number q 
Although solid-state X-ray structures can indicate the hydration number, it can be different 
in solution. For this reason a method for the determination of q in solution is needed. One 
method consists in measuring the luminescence lifetimes of Eu(III) or Tb(III) complexes in 
H2O and D20 solutions (see Chapter One). Using the empirical equation (2.1) it is possible 
to calculate the q value, with an uncertainly off 0.2. 
q=A[(kH=o-k4o)-Akron, ] (2.1) 
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The constant A is equal to 1.2 and 5 in the case of europium and terbium respectively, 
whereas the parameter Ak. R (0.25 ms-1 for Eu and 0.06 ms'' for Tb) takes into account the 
effect of unbound water molecules for relatively hydrophilic complexes. 
The values of the rate constants for the depopulation of the excited states of 
[EuaDO3A]3- and [EugDO3A]3' and the derived hydration number, q, are shown in Table 
2.1. 
Complex Kj2o (ms)' kD2o (ms)" q 
[EuaDO3A] 3.06 0.99 2.2 ± 0.2 
[EugDO3A]'- 2.51 1.20 1.2 ±0.2 
Table 2.1- Rate constants for the depopulation of excited states and calculated q values (295 K, 1 mM 
complex solution at pH = 7.20). 
This method gives an estimation of the hydration number, associated with an error of 
about 20%. According to the data shown in Table 2.1, [EuaDO3A]3- possesses two water 
molecules in the inner sphere, as expected, whereas [EugDO3A]3' has just one. Thus in 
[EugDO3A]3- the ligand behaves as if it was octadentate. It is reasonable to suppose that, 
the eighth binding site is provided by a remote carboxylate group, which forms a stable 
seven-membered ring, as shown in Figure 2.8. 
Figure 2.8 - Intra-molecular carboxylate binding in [EugDO3A] 
3. 
The stability of the seven membered ring drives the equilibrium towards the right so 
that the monohydrated q=1 species predominates in solution. On the other hand, in the case 
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of [EuaDO3A]3- intra-molecular carboxylate ligation gives a less stable eight-membered 
ring. This is disfavoured both entropically and enthalpically, as a result of ring strain. 
Intramolecular (7-ring) carboxylate ligation can be confirmed by fluorescence 
studies. According to the equilibrium shown in Figure 2.8, when the remote carboxylate 
binds intra-molecularly to the metal centre, it displaces a water molecule. The displacement 
of co-ordinated water molecules in lanthanide complexes can be signalled by an increase in 
the lifetime of the lanthanide excited state and the emission intensity. 
Emission spectra of [EuaDO3A]3- and [EugDO3A]3- have been recorded at different 
pH in a 0.1 M sodium chloride solution to maintain the ionic strength constant. The relative 
emission intensity (I/Io) at 618 nm of two analogue europium complexes was plotted as 
function of pH (Figure 2.9). 
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Figure 2.9 - Relative emission intensity (I/Ia) as function of pH in NaCl 0.1 M (A,,, =397 nm, gem=618 nm, 
295 K, [EuL] 1 mM) for [EuaDO3A]3 (triangles) and [EugDO3A]-'" (squares). 
The increment observed beyond pH 8.0 in the case of [EuaDO3A]3- is associated with 
the binding of carbonate deriving from the atmospheric carbon dioxide. The concentration 
of HC03 falls from c. a. 90% at pH 8.9 to less than 2% at pH 4.9. Accordingly, the effective 
concentration of HC03 in solution is determined by the pH of the solution and above pH 
9.0 significant amount of C032" are present (pKa = 10.2 at 298 K). Carbonate binding has 
been proven in several related studies, especially with cationic complexes where 
electrostatic attraction favors complex formation. 13 However, upon the same conditions 
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[EugDO3A]3- shows a quite different behaviour. The relative emission intensity does not 
change appreciably over the whole range of pH investigated, suggesting a lesser carbonate 
binding affinity. Binding of dissolved carbonate is inhibited by the intra-molecular binding 
of the remote carboxylate. However, a closer look to the profile reveals slight changes 
between pH 6.5 and 9.0. This suggests competition between the intra-molecular carboxylate 
arm ligation and the inter-molecular carbonate binding at the metal center. Because of the 
low concentration of carbonate dissolved in solution, the equilibrium is strongly shifted 
towards the intramolecular species. 
2.4 Anion binding studies 
Contrast agents operate in an environment in which ions, such as carbonate (30 mM), 
phosphate (0.9 mM), citrate (0.13 mM) and lactate (2.3 mM) are present. If they bind the 
metal centre, displacing one or both the water molecules, the efficiency of the contrast 
agent will decrease. So it is important to study the anion binding properties of such 
systems. The displacement of water molecules by coordinating anions can be detected by 
an increment in the emission intensity. It is well known that OH oscillators, as in bound 
water molecules, are the most effective quenchers of the luminescence of lanthanide ions. 14 
If they are displaced by anions, the quenching effect is reduced and the emission intensity is 
increased. Emission spectra of [EuaD03A]3- and [EugD03A]3- have been recorded at 
different pH in an anion containing solution that simulates an extra-cellular environment 
and the relative emission intensity (I/Io) at 618 nm was plotted as function of pH (Figure 
2.10). 
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Figure 2.10- Relative emission intensity (VId of [EuaDO3A]3 (squares) and [EugDO3A]3" (triangles) as 
function ofpH. (2. -397 nm, 2Cm=618 nm, 295K, H20,30 mMNaHCO3 , 100 mMNaCI, 
0.9 mMNaH2PO4, 
2.3 mM lactate and 0.13 mM citrate). 
Both complexes undergo an increment in the relative emission intensity beyond pH 
7.5, suggesting the displacement of water molecules by anions. The equilibrium shown in 
Figure 2.11 helps to rationalize the above experimental profiles. 
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Figure 2.11- Formation of the ternary adduct complex-anion. 
The pH response of [EugDO3A]3- exhibits a change towards higher pH, suggesting a 
lesser anion binding affinity, compared to [EuaDO3A]3-. Again, this behaviour supports the 
formation of an intramolecular binding process, discussed above. 
In the case of [EugDO3A]3", both the remote carboxylate and the anions in solution 
(possibly carbonate) "compete" for binding to the metal centre. It is only a consequence of 
the large excess of carbonate (30 times more concentrated than the europium complex) that 
the equilibrium is strongly shifted toward the formation of the ternary adduct at higher pH. 
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In order to unequivocally prove which anion is bound to the europium centre, 
emission spectra in single anion containing solutions at different pH have been recorded. In 
lactate (2.3 mM), phosphate (0.9 mM) and citrate (0.13 mM) solutions, the emission 
spectra did not show any variation with pH, indicating the absence of binding. The spectra 
recorded in phosphate solution are shown in Figure 2.12, as example. However, in 
carbonate solution (30 mM) significant changes were observed on higher pH (Figure 2.12). 
The intensity of the hypersensitive AT =2 transition increases by about three times from pH 
4.5 to pH 10.0. Significant changes are observed in the OJ =1 transition, which shows three 
bands at acidic and neutral pH, but just two major bands at alkaline pH. 
Taken together these emission spectra strongly suggest that it is indeed the carbonate 
anion, which is responsible for displacing the water molecules at higher pH and it forms the 
ternary adduct. 
In conclusion, these experiments suggest that the complexes investigated are likely to 
bind anions (particularly carbonate) in an extra-cellular environment. However, at 
physiological pH, the extent of inter-molecular anion binding is less then 5% and should 
not affect significantly the efficiency of these systems as contrast agents. 
Moreover, this series of experiments clearly exclude [GdgDO3A]'- as a possible q=2 
MRI contrast agent candidate. The length of its hydrocarbon chain promotes intramolecular 
carboxylate ligation, which then represents the eight co-ordination site for the metal center. 
The resulting complex is octadentate with just one water molecule in the inner sphere. On 
the other hand [GdaDO3A]3" possesses two water molecules in the inner sphere, which are 
"retained" at physiological pH in an extra-cellular-like environment, because the anion 
binding is suppressed by electrostatic repulsion. 
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Figure 2.12 - Emission spectra in single anions containing solution (NaHCO3 30 mM at the top and 
NaH2PO4 0.9 mM at the bottom). 
2.5 Stability of the complexes 
At clinical doses of about 0.1 mM"lkg"1, Gd3+ complexes used as contrast agents for MRI 
are not toxic, although individually their components, the metal ion and the free ligand, 
usually are. The Gd3+ aqua ion can inhibit neuromuscular transmission by blocking calcium 
channels15,16 and may be deposited as insoluble salts in skeleton, liver and spleen. 17 
Animal studies have demonstrated a long-term retention of gadolinium in the body, 18-20 
with a build up in the skeleton and the liver. For these reasons the complexes used as CA's 
must be very stable and the determination of their thermodynamic and kinetic stability 
becomes an important issue. 
A preliminary study was conducted following the stability of [EuaDO3A]3- by 
1H 
NMR. The 'H NMR spectrum of [EuaDO3A]3- was recorded over time in D20 solution at 
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pD = 6.80. No variation was observed over a period of several weeks, suggesting a "good" 
stability of this complex in aqueous solution. 
However, an in-vivo environment is a more complicated one. Endogenous 
extracellular ions such as Cue+, Cat+and especially Zn2+ can compete with Gd3+, expelling it 
from the complex through a transmetallation process. Among these ions Cu2+ is present in 
small concentration in the blood (1-10 µmol/L)21 and it is usually tightly bound, whereas 
Ca2+ has a relatively low affinity for this kind of organic ligands. 22 On the other hand, Zn2+ 
may be present in the blood at relatively high concentration (55-125 µmol/L) and can form 
stable complexes with these ligands. So it becomes "potentially dangerous", because it can 
displace the Gd3+ion. 
It is indeed important to study the stability of gadolinium complexes in the presence 
of zinc. A relaxometric method proposed by Laurent and co-workers has been followed. 23 
The technique is based on the measurement of the evolution of the paramagnetic water 
proton longitudinal relaxation rate (RIP) of a buffered solution (phosphate buffer pH = 7.0) 
containing equimolar amounts of the gadolinium complex and zinc chloride. If 
transmetallation occurs the diamagnetic zinc ion will displace gadolinium, which then 
precipitates in the form of its insoluble phosphate salt (equations 2.2-2.4). This will result 
in a reduction of the observed water proton relaxation rate. 
LigGd (")- -> Lig(x+3)- + Gd 3+ (2.2) 
Lig("+3)- + Zn2+ -* LigZn("+')- (2.3) 
Gd'+ + PO4 --4 Gd (PO4 );,, s, (2.4) 
In Figure 2.13 is shown a plot of the relative water proton longitudinal relaxation 
rates (RI p(t)/ R1p(O)) as 
function of time in the case of [GdaDO3A]3", [GdgDO3A]3- and 
[GdaDOTA]". 
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Figure 2 13 - Relative longitudinal relaxation rates as function of time at 65 MHz and 293 K for 
[GdaDO3AJ3'(squares), [GdgDO3A] 3- (circles) and [GdDOTA]' (triangles). 
Laurent and co-workers23 arbitrarily defined a kinetic index (K. I. ), which is the time 
required to reach 80% of the initial Rjp(t)/ Rip(0) value and a thermodynamic index (TI. ), 
which is the Rip(t)/ Rjp(0) value measured after three days (4320 min). These parameters 
are shown in Table 2.2 for [GdaD03A]3-, [GdgD03A]3- and [GdaDOTA]" in comparison 
with three commercially available contrast agents. 
Complex T. I. K. I. 
[GdaD03A] " 0.70 2760 
[GdgD03A]3- 0.97 00 
[GdaDOTA]- 0.99 00 
[GdHPDO3A] 0.99 00 
[GdDTPA]2-23 0.49 260 
[GdDOTA]- 23 0.99 00 
Table 2.2 - KI. and TL index measured at 65 MHz and 293 K. 
The thermodynamic indexes indicate that more than 98% of the paramagnetic 
relaxation rate is retained for the monohydrated macrocyclic complexes [GdDOTA]" 
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(Dotarem), [GdHPDO3A] (Omniscan) (known for their high thermodynamic stability), 
[GdaDOTA]" and [GdgD03A] 3-. The complex [GdaD03A]3' retains less than 70% of the 
initial value, suggesting a less thermodynamic stability. However, it is higher than the T. I. 
measured for the acyclic complex [GdDTPA]2" (Magnevist), which has been used 
commercially since 1988. 
By looking at the kinetic indexes (KI), the same sort of conclusions can be drawn. 
[GdDOTA]" (Dotarem), [GdHPDO3A] (Omniscan), [GdaDOTA]- and [GdgD03A]3- all 
show excellent kinetic stability, they practically do not undergo transmetallation. The di- 
hydrated [GdaD03A]3, instead exhibits a KI value of 2760, but this is more than ten times 
larger than the one measured for Magnevist. 
2.6. Relaxometric studies 
2.6.1. Relaxivity 
The efficiency of a contrast agent is usually expressed in term of relaxivity. As we have 
seen in Chapter One, it represents the enhancement of the water relaxation rate per unit of 
concentration and it is usually expressed in mM-'s-'. 
The observed longitudinal relaxation rate can be divided into a diamagnetic and a 
paramagnetic contribution, due to the presence of the paramagnetic species. The latter one, 
in absence of solute-solute interaction, has a linear dependence with the concentration of 
complex as shown in equation (2.5), (2.6) and (2.7). 
RIobs = Rid + R, p 
(2.5) 
RIP =rp [GdL] (2.6) 
Riobs = Rid +rir [GdL] (2.7) 
A plot of the observed longitudinal water relaxation rate Rlobs as function of the 
concentration of the complex results in a straight line, in which the slope represents the 
relaxivity (rip), as shown in Figure 2.14 for [GdaDO3A]3- (H20; pH = 7.20; 65 MHz; 
293K) 
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Figure 2.14- Observed longitudinal relaxation rate (R, ob. J as function of the concentration of complex (H20 
at pH = 7.20,65 MHz, 293 K). 
The calculated value in water (13.9 mM'1s"1) is significantly higher then those 
reported for gadolinium complexes of similar size and based on heptadentate ligands. 4 
These values are reported in Table 2.3 in comparison with the values calculated under the 
same conditions in an anionic background and in human serum. 
Complex r1 (mM' s) 
Water 
r1 p (mM' s') 
Anionic bkg 
rip (mM' s" ) 
Human Serum 
[GdaD03A] ' 13.9 10.6 11.6 
[GdgD03A]3- 6.4 4.8 7.1 
[GdaDOTA]' 8.9 11.9 
[GdgDOTA]' 8.8 11.1 
[GdD03A]*4 6.0 
[GdPCP2A]` 4 8.3 
[GdaD03A]3"` 12.3 
Table 2.3 - Relativity in water at pH = 7.20,65 MHz and 293K. 'At 20 MHz and 298K. 
The relaxivities measured at 65 MHz and 293 K (13.9 mM'ls-1) is about 12% higher 
than the one measured at 20 MHz and 298 K (12.3 mM-'s-1). This difference is mainly 
attributed to the temperature change. In fact, relaxivity tends to increase at lower 
temperatures for low molecular weight chelates. This is a consequence of slower tumbling 
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rates. 4 On the other hand, the difference in magnetic field (from 65 to 20 MHz) does not 
influence significantly the relaxivity, as it lies in the flat region of the NMRD profile (see 
Figure 2.18). 
The comparison between the relaxivity of [GdaDO3A]3- and its monohydrated 
analogue [GdaDOTA]- highlights the contribution of the additional water molecule, which 
brings an increment close to 40% in water solutions. The surprisingly high magnitude of 
this parameter could derive, however from an additional outer or second sphere 
contribution. The three remote carboxylate arms can "trap" water molecules in the second 
sphere by forming hydrogen bonds. This is known to occur with ligands bearing phosphate 
groups, such as [GdPCP2A]. 3 However, the effect exhibited by [GdaDO3A]3" is 
remarkably higher. 
In addition, these data confirm the different behaviour of [GdaDO3A]3- and 
[GdgDO3A]3-. The latter one being a monohydrated complex (as discussed in the previous 
paragraphs) exhibits a much lower relaxivity both in water and in human serum. 
In order to explore more deeply the properties of these complexes, the relaxivity was 
measured as function of pH. The pH dependence of relaxivity in water for [GdaDOTA]" (65 
MHz and 293 K) and [GdaDO3A]3- (20 MHz and 298 K) is shown below (Figure 2.15). 
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Figure 2.1 S- Rel axivityas function of pH for [GdaDO3A]3" (65 MHz; 293 K; triangles) and [GdaDOTA]" 
(20 MHz; 298 K; squares). 
The decrement observed over pH 8.5, in the case of the q=2 complex is due to the 
binding of dissolved carbonate deriving from the atmospheric carbon dioxide. As it has 
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been demonstrated previously by luminescence studies on the Eu (III) analogue complex, 
binding the metal centre, the carbonate anion displaces the two water molecules, reducing 
the relaxivity. 
On the other hand, the octadentate q=1 [GdaDOTA]" does not show any appreciable 
variations in relaxivity over the whole range of pH investigated, because of its lower anion 
binding affinity. 
How can in-vivo concentration of carbonate (30 mM) influence the relaxivity (i. e the 
efficiency) of [GdaDO3A]3-? In order to answer this question, the relaxivity was measured 
as function of pH in anionic background (i. e. the simulated extra-cellular solution) and in 
human serum (Figure 2.16). 
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Figure 2.16 - Relaxivity vs pH of [GdaDO3A]3" at 65 MHz, 293 K in human serum (squares) and anionic 
background (triangulars). 
The profile in anion solution shows a decrement in relaxivity above pH 8.0, which 
then reaches a minimum value close to 3 mM''s4 at pH 9.5, corresponding to a pure outer 
sphere contribution. The equilibrium shown in Figure 2.11 helps to understand this 
experimental behaviour. Again the carbonate anion displaces the two water molecules 
reducing the relaxivity of the complex. The system clearly changes from being a q=2 
complex in acidic and neutral media to a q=0 species at alkaline pH. However, at 
physiological pH the complex still possesses two water molecules in the inner sphere and 
thus the relaxivity remains close to its highest value. So the efficiency of [GdaDO3A]3' as 
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contrast agent for MRI is not affected significantly by the presence of in-vivo concentration 
(30 mM) of carbonate. 
The curve in human serum can be explained by the same sort of considerations. 
It should be noted at this point that defining relaxivity in terms of mM'1s"1 in protein 
solution (such as human serum) can be misleading. High concentrations of protein are 
dissolved in serum (i. e. Human Serum Albumin HSA 0.6 mM). Usually at the 
concentrations used more than 20% of the volume is occupied by protein and hence less 
than 80% by water. The molar concentration of 1 mmol of Gd3+ complex in a litre of serum 
is 1 mM, but the molal concentration would be 1.25 mmolal, so the reported relaxivity is 
overestimated by 25%. For these reasons the relaxivities quoted in human serum have been 
corrected by the same percentage. 
The slightly higher values observed in human serum may now be ascribed to an 
increment in the micro-viscosity of the medium, which increases the rotational correlation 
time TM, slowing the tumbling in solution and thus increasing the relaxivity. An important 
point to be noticed is that at physiological pH the high relaxivity of [GdaDO3A]3- measured 
in water, is "retained" in human serum, indicating suppression of protein/anion binding. 
Such features render this complex extremely attractive as a contrast agent for MRI. 
The comparison between the pH dependence of the relaxivity for [GdaDO3A]3- and 
the relative emission intensity of the analogous europium complex is shown in Figure 2.17. 
The nice correlation reveals a near mirror image relationship. Such behaviour is consistent 
with the idea that increases in rip are directly proportional to changes in the hydration state 
q, while the Eu emission intensity decreases in direct proportion. 
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Figure 2.17- Comparison between the pH dependence of the relaxivity ofJGdaDO3A]3' on the left and the 
relative emission intensity of the analogue [EuaDO3A] on the right. 
2.6.2. NMRD profiles 
To characterize the different contributions to the observed relaxivity NMRD profiles, over 
an extended range of frequencies at 25 °C, were measured for [GdaD03A]3-, [GdgD03A]3- 
and [GdaDOTA]' (Figure 2.18). 
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Figure 2.18 - NMRD profiles in water solution at pH = 7.0 and 298 K for [GdaDO3A]3 (black circles) 
[GdgDO3A]-" (white circles) at the top and for [GdaDOTA]" (black circles) at the bottom. 
The curves were fitted to the equations for inner and outer sphere paramagnetic 
relaxation (see Chapter One) to give the parameters listed in Table 2.4. The dashed lines in 
Figure 2.18 represent the outer sphere water cöntribution. 
Complex A2 (s 2)/10'19 TV (PS) TR (PS) 
[GdaDO3A] " 2.75 31 130 
[GdgDO3A]3- 3.14 16 130 
[GdgDOTA]' 2.30 10 116 
[GdaDOTA]" 1.23 20 154 
Table 2.4 - Best fitting parameters determined by analyses of NMRD profiles. 
In the analyses a reasonable choice was made for r (2.98 A), the distance between the 
metal centre and closed water molecules, based on known values of similar complexes. The 
parameters a (distance of the closest approach of diffusing water) and D (diffusion 
coefficient) were fixed to typical values of 3.8 A and 2.24.10'5 cm2s'' respectively, whereas 
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q was considered as two in the case of [GdaD03A]3' and as one in the case of 
[GdgD03A]3' and [GdaDOTA]', as has been measured by luminescence studies. 
The comparison of these profiles highlights the different behaviour for the two 
analogous D03A derivatives, which differ in the number of water molecules in the inner 
sphere. 
The calculated rotational correlation times tiR are in the expected range for complexes 
of similar molecular volume .4 
The profiles depend only slightly on the actual value of the water residence lifetime 
TM, which then cannot be determined with sufficient accuracy by the fitting process. 
An independent assessment of this important parameter can be obtained by variable- 
temperature proton-decoupled 170 NMR measurements of the water nuclear transverse 
relaxation rate. The quadrupolar 170 nucleus is NMR active and when it is co-ordinated to a 
paramagnetic ion (i. e. Gd3) its relaxation time is shortened. If the exchange of the bound 
water is sufficiently fast, then the effect will be transferred to the bulk water. Decrements in 
the transverse relaxation times T2 bring broadening in the linewidth of the signal arising 
from the bound oxygen. By measuring the effect of the temperature on the linewidth of an 
170 enriched solution containing the paramagnetic complex and correcting it for the natural 
linewidth, a profile of the paramagnetic transverse relaxation rate (R2p) can be obtained. 
Since the relaxation rate is dependent on the contribution from coordinated water 
molecules, it is also dependent on TM. 
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Figure 2.19 - Rep as function of temperature at 90 MHz and pH=7.0. 
The measured variation of Rep as a function of temperature at 90 MHz in 170 enriched 
solution at pH 7.0 for [GdaDO3A]3- (c. a. 10 mM) is shown in Figure 2.19. The curve was 
fitted to the Swift-Connick equations. 24-26 In the analysis, a standard value for the 
hyperfine coupling constant A/h (-3.8.106 rad s") was used, whereas the values obtained 
from the NMRD profiles for 02 and tiv were considered. The calculated values of the water 
exchange lifetimes at 298 K are reported in Table 2.5 and compared to those of other q=2 
complexes published in the literature. 5 The analysis of these data clearly indicates that the 
water molecules in [GdaDO3A]3- exchange very rapidly with the bulk solution and this 
certainly contributes to the high value of relaxivity measured. For example, [GdDO3A], 
which has q=1.8 and rip 6.04 mM'ls'' (20 MHz and 298 K) exhibits aw more than five 
times bigger than this system. 5 These differences could be due to a structuring effect of the 
remote carboxylate groups on the nature of the second sphere of hydration. 
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Complex [GdaDO3A] " [GdgDO3A] " [GdaDOTA]" [GdDO3A] [GdPCP2A] 
zM (ns) 30 230 200 160 68 
Table 25 - Water exchange rates calculated at 298 K and pH = 7.0.5 
2.7 High molecular weight contrast agents 
The conjugation of low molecular weight chelates to macromolecules changes their 
biophysical and pharmacological properties. Firstly, high molecular weight conjugates, 
tumbling more slowly in solution, increase the rotation correlation time TR and hence 
improve the relaxivity. Secondly, these molecules are retained in the vascular spaces 
longer, because of their molecular size and thus facilitate imaging of the blood vassels 
(Angiography). 
In developing new high MW complexes it is important first to find small chelates 
which display optimal values of q, rM and rs, because the amplification effect associated 
with the formation of the macromolecular adduct strictly depends on the relaxometric 
properties of the free complex. 
The fast water exchange rate and the minimization of anion/protein binding of 
[GdaDO3A]3-, suggest that it could be used as a potential candidate for high MW 
conjugates. With such a short water exchange lifetime, in fact, it should be possible to 
obtain high relaxivity values because the rotational correlation time of the complex will be 
drastically elongated upon the formation of a macromolecular adduct. 
The gadolinium complexes of aDO3A and for comparison of aDOTA have been 
coupled to the hydrophilic amine (28) to yield the high molecular weight derivatives 
[GdaDO3A-AG] (29) (MW = 4093.9) and [GdaDOTA-AG]' (31) (MW = 5350.6) 
respectively, according to the schemes in Figures 2.20 and 2.21. 
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Figure Z. 20 - Synthesis of [GdaDO3A-AG] (29). 
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Figure 2.21- Synthesis of [GdaDOTA-AGJ (31). 
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The amine (28) was kindly provided by Guerbet s. a. (Paris). 
The crude compounds were purified using gel exclusion chromatography (Sephadex 
G-25), which allows the complete elimination of the unreacted starting amine (28). ESMS 
and UV-vis spectroscopy were used to characterize the final compounds. 
The relaxivities measured in water were 27.7 mM"s'1 for [GdaDO3A-AG] (29) and 
23.4 mM'1s"1 in the case of the monohydrated analogue [GdaDOTA-AG]" (31) (65 MHz, 
293 K in water pH =7.20). However, these high values of relaxivities are not "retained" in 
human serum. [GdaDO3A-AG] (29) exhibits in fact a much lower relaxivity in this medium 
(15.5 mM"s"1). Consideration of the structure reveals that the complex is now neutral. The 
formation of three amide bonds has removed the three negative charges. So the high 
molecular weight complex is now more likely to bind endogenous anions, such as 
carbonate, phosphate or lactate compared to the parent low molecular weight species, 
because of a reduction in the electrostatic repulsion. In order to understand better the 
properties of the complex, the relaxivity was measured in water, in an anionic background 
solution and in human serum as function of pH (65 MHz, 293 K), as shown in Figure 2.22. 
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Figure 2.22- Relaxivity of [GdaDO3A AG] (29) as function ofpH in aerated water (circles), anionic 
background (triangles) and human serum (squares) at 65 MHz, 293 K. 
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The profile in water reveals a decrement in relaxivity beyond pH 8.5, possibly due to 
the dissolved carbonate binding deriving from atmospheric carbon dioxide, which displaces 
water molecules in the inner sphere, reducing the relaxivity. The increment observed 
beyond pH 10.0 may be associated with fast prototropic exchange of the amide NH proton, 
as has been suggested for related tetra-amide complexes. [Amin, 1994 #63; Aime, 1999 
#62; Peters, 1996 #64; Aime, 1998 #65] 
The profile in the anionic background (i. e. the simulating extra-cellular environment) 
shows a remarkable reduction in relaxivity above pH 6.5, which suggests a strong anion 
binding affinity. Meanwhile, the relaxivities over the whole range of pH investigated are 
lower than those observed in pure water. Possibly, carbonate is not the only anion involved 
in the binding and other species (lactate or phosphate) may participate to the formation of a 
ternary adduct. For example, at pH 4.9 the concentration of HC03 is less than 2%, but the 
relaxivity in anion solution is about 20% lower than in pure water. This reduction cannot be 
attributed just to the binding of carbonate and thus other anions, such as phosphate or 
lactate must be involved. However, in the absence of luminescence studies on the 
analogous europium complex, no definitive conclusion can be drawn. 
The profile in human serum can be explained by the same sort of considerations. The 
relaxivities were corrected for volume changes, as discussed previously and the small 
differences are in part due the changing in the micro-viscosity of the medium. In addition, 
the behaviour observed in" human serum, suggests that [GdaDO3A-AG] (29) does not bind 
any proteins contained in serum, e. g. human serum albumin (HSA). This was confirmed by 
a simple experiment. To a solution of complex in the anionic background at pH = 7.20 (rip 
= 17.6 mWls'1) HSA was added (0.6 mM). The relaxivity of the resulting solution did not 
change, confirming that the serum proteins do not bind the high molecular weight complex. 
The NMRD profiles of [GdaDO3A-AG] (29) and [GdaDOTA-AG]- (31) were 
recorded over an extended range of frequencies at 25°C (Figure 2.23). 
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Figure 2.23 - NMRD profiles recorded at 298 K for [GdaDOTA-AGJ (31) (at the top) and [GdaDO3A-AG] 
(29). 
The curves were fitted to the equations for the inner and outer sphere paramagnetic 
relaxation (Chapter One) to give the parameters reported in Table 2.6. 
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Complex A2 (s 2)/10"19 tiV (ps) TR (Ps) TM (ns) 
[GdaDO3A-AG] (29) 3.54 27 368 (100) 
[GdaDOTA-AG]' (31) 1.20 30 585 (100) 
Table 2.6 - Bestfitting parameters determined by analyses of NMRD profiles. 
The high field region of the profile (5-50 MHz) is particularly important, because in 
clinical imaging the fields used are typically between 20 and 60 MHz. For small chelates 
this region is mainly controlled by 'rR. The characteristic "hill" observed in the case of high 
molecular weight compound indicates a larger rR value. The low field region, however, is 
most influenced by the value of A2 (electronic spin relaxation time at zero field). The 
factors, which govern this parameter, are still not fully understood. However, some 
generalizations can be drawn. 4 DOTA-like chelates, with high symmetry, have smaller 
values of 02. Practically this results in a higher low field relaxivity. This is confirmed by 
looking at the NMRD profiles in Figure 2.23. [GdaDOTA-AG]' (31), which has a smaller 
value of A2, exhibits a higher relaxivity at low fields (0.01-0.1 MHz), compared to 
[GdaDO3A-AG] (29), which has a higher A2 value. 
As has already been pointed out, the profiles are only slightly dependent on the actual 
value of the water residence lifetime tim, which then cannot be determined with sufficient 
accuracy by the fitting procedure. We were not able to record variable-temperature proton- 
decoupled 17 O NMR measurements of the water transverse relaxation rates. So the values 
of tiM reported in Table 2.6 are not significant. 
2.8. Conclusion 
The drawbacks encountered in developing q=2 systems are mainly due to their poor 
thermodynamic and kinetic stability, with respect to dissociation of the free gadolinium ion. 
Moreover, these complexes are more likely to bind endogenous anions, such as carbonate, 
phosphate or lactate, displacing water molecules in the inner sphere and reducing the 
relaxivity. For these reasons, despite the high relaxivity measured in water for some of the 
di-hydrated complexes published in the literature so far, none of them seem to possess all 
the characteristics needed for an effective contrast agent. 1-3,5,6 
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[GdaDO3A]3- represents instead a promising candidate as a contrast agent for MRI. It 
possesses the highest value of relaxivity so far measured for a q=2 complex in water. More 
importantly, its high relaxivity is retained in human serum, because the binding of 
endogenous anions (e. g. HCO3"/CO2 2) or proteins (HSA) is suppressed by electrostatic 
repulsion. In addition, this complex seems to be sufficiently stable, showing a kinetic 
inertness ten times higher than [GdDTPA]2" (Magnevist) which has been in commercial use 
since 1988. 
In conclusion, [GdaDO3A]3- is the first q=2 gadolinium complex that is likely to be 
suitable as contrast agent for MRI. Moreover, due to its fast water exchange rate and the 
minimisation of the anion/protein binding, it is an attractive candidate for high molecular 
conjugates. 
A high molecular weight derivative has been synthesised and characterized. 
However, despite its high relaxivity in water at physiological pH (27.7 mm-'s-1), it is not 
able to retain the high value in human serum (15.6 mM''s't), because of its high affinity for 
anion binding. For these reasons, despite the substantial differences in molecular size of 
the low and high molecular weight parent complex, their relaxivities in human serum at 
physiological pH differ by just 20%. Thus [GdaD03A]3- is a very good system in itself. 
However, the promising high relaxivity of [GdaDO3A-AG] measured in water, renders this 
complex an interesting one. The aim is to modify opportunely its structure in order to 
reduce or suppress the anion binding and thus retain the high relaxivity even in an in-vivo 
environment. This could be a feature of a complex possessing a negatively charged 
phospholirate linkage, in place of the carboxylate moiety. 
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Chapter Three: 
Regioselective Protection of Folic Acid 
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3.1. Introduction 
The majority of contrast agents currently in clinical use are small chelates that remain in the 
extracellular fluids and show little specificity in their biodistribution, being excreted rapidly 
via the kidneys. l A new generation of these diagnostic agents is being developed as 
specifically targeted contrast agents, which can selectively enhance the MRI signal 
intensity in particular tissue types. As discussed in Chapter One, this can be achieved by 
linking a targeting vector to a gadolinium complex. The vector used in this work is the 
vitamin folic acid (5) (Figure 3.1). 
Folic acid and its related compounds are required for the survival and growth of 
eukaryotic cells. They are involved in the biosynthesis of purine and certain amino acids. 
They enter the cell via a family of transport proteins, the Folate Binding Proteins (FBP). 2 3 
Cancerous cells overexpress FBP's and as a consequence folate species. 4-6 The conjugation 
of a gadolinium complex to folate derivatives enhances the cellular uptake of the diagnostic 
agents and permits a selective targeting of unhealthy cells, as seen in Chapter One. The aim 
is to bind via amide bond formation, a gadolinium chelate, which possesses a pendant 
amino group, to a carboxylic group of folic acid with control over regiochemistry. 
It has been demonstrated, that when folate species are covalently linked to a molecule 
via their a or y carboxylic groups, the affinity for the cell surface receptors change 
appreciably compared to the free folate. 7-9 
In developing a method to enhance transmembrane transport of exogenous molecules, 
Low and coworkersl0 coupled folic acid to a variety of exogenous molecules including, 
peptides, nucleic acids, analgesics, antihypertensive agents, antiviral agents, plasmids and 
diagnostic agents. The synthetic methods proposed by the authors were not regioselective, 
and mixtures of either the a- or the y-regioisomers were obtained. The distinction between 
the two isomers of DF-folates, for example (e. g. those where deferoxamine is coupled to 
the folate moiety through the a- or the y-carboxyl group of folate) was based on their 
competition with free folate for the cell surface FBP. It was found that the a-conjugate was 
unable to compete with free folate. 
Wang and coworkers11,12 studied the uptake of 67Ga-deferoxamine-folate into KB 
tumor cells (a human nasopharyngeal epidermal carcinoma cell line that overexpresses the 
FBP) as a potential radiopharmaceutical. The compound showed a low, non-specific 
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binding. In a second paper the authors reported13 the preparation of FITC-EDA-folate 
derivatives containing a fluorescein moiety (FITC) linked to folate via either the a- or the 
y- carboxylate group. The two isomers were incubated with KB cells. The y isomer showed 
half maximal binding to KB cells, but the a isomer had virtually no affinity for the cell 
surface receptors. 
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Figure 3.1 - Structure of folic acid (5) andfolinic acid (5a). 
A _.. 
In a recent patent published by Bracco, 14 the inventors proposed regiospecific 
synthesis of the folate conjugates of several gadolinium complexes. Both the a and the y 
isomers were synthesized and their ability to bind to FBP in tumor cells was compared in- 
vitro. In contradiction to the results published by Wang and coworkers13 the a isomer 
conjugates bound to FBP to the same extent as the y one in a variety of in vitro studies. 
Moreover, the bis derivative (functionalized on both the a and y groups) was also able to 
bind to FBP. In addition, the urinary clearance of the a-isomers from the body was 
significantly and unexpectedly higher than that observed for the corresponding y-isomers. 
These studies confirmed the different behaviour showed by folate derivatives, which 
are covalently bound through the a-carboxylate compared to those, which are linked 
through the y position. It is then important to synthesize both the a- and y-folate derivatives 
and study their characteristics separately. 
The synthesis, characterization and relaxometric studies of folate conjugates of 
different gadolinium chelates are presented in Chapter Four. In the present one we focus on 
the development of new methods to regioselectively protect folic acid. 
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3.2. Regioselective protection of Folic Acid 
In order to bind selectively a gadolinium chelate to folic acid (or folate derivatives) through 
one carboxylic group, the protection of the other acid group is required. 
In the structure of folic acid, a glutamate moiety can be recognized. Synthetic 
methods that allow the selective protection of one carboxylate of glutamic acid are well 
known and have been widely used in peptide chemistry. Some of them can be applied to 
folic acid. However, this vitamin is rather difficult to handle, mainly due to its poor 
solubility. In addition, side reactions can take place at the other functional groups present in 
the molecule. Finally, folate derivatives are light and air sensitive and appropriate 
precautions must be considered. For each of these reasons, modifications of the 
conventional methods used for glutamic acid have been developed. 
3.2.1. Method A: Use of alkylating agents 
Nefkens and co workers had earlier found a practicable route for the regioselective 
esterification of N-substituted glutamate derivatives. 15 The two carboxylic groups (a and 
y) of these molecules present a difference in pKa (in the order of 0.4), the a groups having 
lower values. So in the presence of one equivalent of a base, the a groups will be 
preferentially deprotonated. The reaction with an alkylating agent occurred in a selective 
derivatization and a-esters were obtained in good yield, after purification over silica gel. 
A similar procedure was later adopted by Fitzhugh and coworkers for [(6S)-5 formyl- 
5,6,7,8-tetrahydropteroyl]mono L-glutamic acid, folinic acid, (5a), (Figure 3.1) to give the 
corresponding a-benzyl ester in reasonable yield (30%). 
In this work, similar conditions have been adopted to synthesize both the a- and the 
y-benzyl monoesters of folic acid, according to the scheme in Figure 3.2. 
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Figure 3.2- Regioselective O-benzylation of folic acid. Method A: X=Br, Y=Cs2CO3. Method B: X=OH, 
Y=HBF4. 
Due to the poor solubility of folate species, the reaction was carried out in DMSO, 
according to the procedure followed by Rosowsky and coworkers16 for the syntheses of 
several diesters of folinic acid. Caesium carbonate was used as base, whereas benzyl 
bromide was employed as alkylating agent. Since folic acid and its derivatives are light and 
air sensitive, the reaction was carried out under an inert atmosphere and in the dark. The 
progress of the reaction was followed by analytical reverse phase HPLC. The formation of 
a mixture of the two mono-benzyl esters a and y (32a-b) was observed in ratio 4: 1 (tr = 
21.1 and 22.1 min), in addition to the diester (32c) Or = 28.9 min) and unreacted folic acid 
(t, =14.8 min). The crude material, which was precipitated by adding acetonitrile, was 
purified by reverse phase semi preparative HPLC, using a mixture of acetonitrile-water as 
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eluent. Trifluoroacetic acid (TFA) was added to water in small concentration (0.1 %), in 
order to improve the separation. 
The chemical purity of each fraction was confirmed by the use of analytical HPLC. 
The first fraction (tr = 14.8 min) was demonstrated to be unreacted folic acid by the 
presence of a single peak (m/z = 441) in the ESMS spectrum. Moreover, the 1H NMR 
spectrum perfectly resembled the spectrum of the commercially available vitamin. 
The ESMS analysis (m/z = 621) of the last fraction (tr = 28.9 min) clearly indicated 
the presence of the diester. In addition, the 1H NMR spectrum revealed two singlets (5.08 
and 5.14 ppm) in a ratio 1: 1, corresponding to the benzylic protons (OCH2Ph). The integral 
values agreed with the diester structure. 
Pure mono-benzyl esters were obtained collecting the fractions at tr = 21.1 and 22.1 
min. The ESMS analysis of these fractions was consistent with the presence of the 
monobenzyl ester, a or y (m/z = 530). In order to understand which isomer corresponds to 
the two peaks in HPLC, detailed 'H NMR analysis were made. In the case of the less 
retained monoester, the shifting to lower field of the proton Ha, demonstrated (by analogy 
with reported literature values on related compounds13) that the esterification most 
probably occurred at the a carboxylic group. Moreover, the two benzylic protons 
(OCH2Ph) gave rise to a singlet at 5.09 ppm. The more retained monoester gave rise to a 
two proton singlets for the benzylic protons (OCHZPh) at 5.04 ppm and the presence of an 
unshifted signal for the singlet assigned to the Ha methine proton at 4.35 ppm is consistent 
with the presence of the benzyl ester in the y-position. 
Despite the simplicity of this reaction, a mixture of the two regioisomers was 
obtained, which is difficult to separate. Silica gel chromatography can be used to remove 
unreacted folic acid and the diester. However, all the attempts made to separate the two 
isomers using column chromatography failed. Semipreparative reverse phase HPLC is 
indeed the only practicable way to successfully purify the mixture. Improvement in the 
separation can be achieved by changing the eluent composition. However, this method is 
extremely expensive and it does not readily satisfy the need of reasonable amounts of pure 
compounds (i. e. of the order of 100-500 mg). 
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3.2.2. Method B: Use of tetraf uoroboric acid as catalyst 
Albert and co-workers17 found a simple and high yield way to synthesize ß-aspartates and 
y-glutamates, using tetrafluoroboric acid as catalyst. 
The same conditions were adapted for the benzyl esterification of folic acid, as shown 
in Figure 3.2. A mixture of a and y monobenzyl ester (32a, b), dibenzyl ester (32c) and 
unreacted folic acid was obtained, as confirmed by analytical reverse phase HPLC. Under 
these conditions, the major product was the diester, with benzyl alcohol used as both the 
reagent and the solvent for the reaction. Moreover, the ratio between the a and y isomers 
was inverted compared to the method A (a/y = 0.5). So the catalyst tetrafluoroboric acid 
favours the y-benzyl esterification. It was suggested that the boron coordinates both the 
nitrogen of the a amino group and the oxygen of the a carboxylate of the glutamate moiety 
leaving the y-carboxylate group free to react, as shown in Figure 3.3. 
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Figure 3.3 - Schematic representation of the possible intermediate in the reaction catalized by 
tetrafluoroboric acid. 
The purification of the crude material was achieved by reverse phase semipreparative 
HPLC, as in method A. The fractions collected were analyzed by ESMS and 1H NMR as 
discussed previously. 
This procedure is complementary to method A. Here the y isomer is synthesized in 
higher amounts compared to the a one. However, the purification of the crude material 
remains problematic. Small amounts of pure monoesters were obtained (10-20 mg), but the 
procedure is affected by the same limitations seen in Method A. 
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3.2.3. Method C: Enzymatic hydrolysis 
Enzymes are nowadays widely used in organic syntheses, because they can catalyze 
efficiently and specifically a wide range of types of reactions, usually avoiding difficult 
separation procedures. Monoesters of N-protected a-aminoacid can be obtained by 
enzymatic hydrolyses of the corresponding diesters. For example, Alkalase from 
B. licheniformis was used for the regioselective hydrolyses of dibenzyl ester of N- 
unprotected aspartic and glutamic acid by Chen and coworkers. 18 Miyazawa and 
coworkers19 have instead used several microbial proteases (e. g. from Bacillus, Aspergillus, 
Rhizopus and Penicillium species) to catalyze the regioselective hydrolysis of diesters (the 
dimethyl, diethyl or diisopropyl esters) of N-benzyloxycarbonylated a-aminocarboxylic 
acid (glutamic, aspartic, a-aminoadipic or a-aminosuberic acid) to produce y- or w- 
monoesters. 
In this work a modified procedure has been applied to the di-esters (dimethyl and 
dibenzyl) of folic acid, as shown in Figure 3.4. 
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Figure 3.4 - Enzymatic hydrolyses of diesters of fol is acid 
As Miyazawa and co-workers have demonstred, 19 the alcohol moiety of the esters 
has little influence on the regioselectivity of the hydrolysis, mediated by each of the 
microbial proteases examined. The choice of the starting diester is mainly dependent upon 
its solubility and availability. 
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The dibenzyl ester of folic acid (33a) was synthesized using two equivalent of benzyl 
bromide and caesium carbonate as base in DMSO, as shown in Figure 3.4. The crude was 
easily purified over silica gel and the pure compound fully characterized. When a similar 
procedure was repeated for the syntheses of the dimethyl ester (33b), using methyl iodide 
as the alkylating agent, a more complex mixture was obtained. This contained both the 
dimethyl ester (33b) and the dimethyl ester N1°-methylated (33c), as confirmed by ESMS 
(m/z = 468 and 482) and by 'H NMR, which showed the presence of a singlet at 3.22 ppm. 
All attempts made to separate the two compounds using silica gel chromatography failed. 
This problem was not encountered in the synthesis of the dibenzyl ester, possibly because 
of the steric hindrance associated with alkylation of the bulkier benzyl group, inhibiting 
therefore alkylation at nitrogen. 
The dimethyl ester of folic acid (33b) was therefore synthesized following another, 
simpler strategy. By simply refluxing folic acid in methanol in the presence of catalytic 
amount of hydrochloric acid, the dimethyl ester was obtained in quantitative yield. The 
reaction did not require any further purification and the pure diester was simply precipitated 
from the solution by adding ethyl acetate. ESMS, IH NMR and elemental analysis 
confirmed the formation of the dimethyl ester. 
The enzymatic hydrolyses of the diesters were carried out in a mixture of phosphate 
buffer pH = 7.0 and DMSO, using Protease (from Rhizopus species) according to the 
procedure proposed by Miyazawa and co-workers. 19 The use of a co-solvent in enzymatic 
reaction can increase the rate of the reaction, mainly by an improvement in the solubility. 
However, high amount of non-aqueous solvents could dramatically reduce the activity of 
the enzyme. Different ratios were tried and the progress of the reactions was followed by 
analytical reverse phase HPLC. The ratio of phosphate buffer pH=7.0/DMSO 8: 2 (v/v) was 
found to be the best compromise between solubility and reaction rate, for the dimethyl ester 
substrate. The unreacted di-methyl ester and the enzyme were removed by centrifugation 
and the y-monoester (34b) was precipitated by acidification of the solution (to pH 3.5). No 
further purification was required and analytically pure y-methyl ester of folic acid (34b) 
was obtained in reasonable yield (64%). Due to the lower solubility of the dibenzyl ester, 
higher amounts of DMSO were needed. At a ratio of phosphate buffer pH=7.0/DMSO 1: 1 
(v/v), in which the starting material was reasonably soluble, the reaction did not seem to 
progress. 
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Compared to the non-enzymatic procedures, previously discussed, this method does 
not suffers from low yields, tedious manipulation, difficult separations and high costs and 
can be applied on a reasonably high scale (0.5-1.0 g). In addition, the y-methyl ester (34b) 
represents a good starting material to obtain the a isomer. A possible strategy involves 
synthesizing the y-tert-butyl-a-methyl diester followed by selective cleavage of the methyl 
group by mild alkaline hydrolyses (pH = 9.0). 
3.2.4. Others procedures 
Another common procedure used to protect selectively the a carboxylic group of glutamic 
or aspartic acid is represented by the use of metal cations, such as Zn2+and Cue+. These 
cations coordinate both the a-N or the amide carbonyl group and the a-carboxylic group of 
the glutamic moiety, leaving the y-carboxylate free to react, as shown in Figure 3.6. 
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Figure 3.6 - Schematic representation of possible structures in the protection of the a- position by using 
metal cations, M=Zn2+, Cue+. 
This method has been applied to folic acid itself. However, two major problems are 
believed to have resulted in its failure. First, the nitrogens N5 and the oxygen of the 
pteridine moiety and the para-amino group can coordinate the metal ions, as shown 
in 
Figure 3.7. Secondly, in the presence of high concentration of metal ions (such as Cu2+ or 
Zn2+), insoluble folate salts precipite. 
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Figure 3.7-Alternative sites of metal ion complexation offolic acid 
3.3. A different approach: the pteroic acid route 
A completely different approach to bind a gadolinium chelate regioselectively to folic acid 
has been developed. The target molecule we want to synthesize is schematically shown in 
Figure 3.8. The disconnections indicated would reduce the synthesis to two major steps, 
which would involve amide bond formation between the moiety A (pteroic acid), B 
(glutamic acid) and C (gadolinium chelate). A similar procedure has been described by 
Bracco14 for the synthesis of several gadolinium conjugates. 
Glu (B) 
4 
Gd chelate (C) 
Gd 
Figure 3.8 - Target molecules. 
The route developed in this work independently (and prior to the appearance of the 
Bracco patent14) consists of the coupling of the two moieties C and B, followed by the 
conjugation to the moiety (A). To avoid side reactions, with consequent formation of 
oligomers, the amino group and one carboxylate group in glutamic acid must be protected. 
The N-protected mono-esters of glutamic acid (35a) and (35b) (Figure 3.9) were selected 
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Pteroic acid (A) 
to consitute moiety (B), because they are commercially available, cheap and allow the 
synthesis of both the a and y derivatives. Pteroic acid (A) is commercially available too, 
but is quite expensive. However, several synthetic procedures for its preparation have been 
described in the literature. 20-22 
This synthetic approach is described more in detail in the next Chapter and in the 
experimental section (Chapter Five). 
The reverse approach, in which A is first coupled to B and then to C is not 
practicable. In fact, the first step would require the use of a diester (e. g. dimethyl, dibenzyl) 
of glutamic acid to avoid intermolecular reaction between molecules of glutamic acid, 
which would then result in the syntheses of a diester of folic acid. 
HO 
ORS 
tBocNH 
OR2 
0 
(35a-b) 
a) R1= Bn; R2 =H 
b) R1= H; R2 = Bn 
Figure 3.9 - N-tBoc monesters of Glu, used as moiety (B). 
3.4. Discussion 
The conventional synthetic methods used for the regioselective protection of glutamic or 
aspartic acid cannot be successfully applied to folic acid. Its poor solubility, the presence of 
several functional groups and its light and air sensitivity render it difficult to handle. 
Mixtures of the a and y isomers can be purified only by using reverse phase 
semipreparative HPLC, a very expensive method of low efficiency. However, a simple and 
high yield method has been developed. By using the enzyme Protease, the y methyl ester of 
folic acid (34b) can be synthesized regioselectively from the corresponding diester, 
avoiding tedious purification procedures. The monoester thus synthesized can be directly 
coupled to a gadolinium chelate. 
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An alternative multistep approach has been developed too. In this case a gadolinium 
chelate is firstly coupled to an N-protected glutamate monoester and then, following 
deprotection of the amino group of the gluatmic moiety, it is coupled to pteroic acid. This 
method presents the advantage of using commercially available starting materials to 
synthesise each of the isomers on a practicable 50-100 mg scale. 
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Chapter Four: 
Folate Targeted Contrast Agents. 
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4.1. Introduction 
Folic acid has been regioselectively linked to the gadolinium complexes of the ligands (9) 
and (6) (Figure 4.1), prepared following the procedures described in Chapter Three. Each 
ligand contained a pendant primary amine, which represents the site of conjugation to folic 
acid. 
The monoamide [Gd"9] is a monohydrated complex (q=1), for which a long water 
exchange time should be expected. As has been demonstrated for several amide derivatives 
of DOTA, the replacement of one carboxylate group by an amide moiety reduces the water 
exchange rate of the gadolinium complex by a factor of between three and four. 1-4 The 
long value of tM in [Gd"9] is likely to limit the overall relaxivity of its folate conjugates. 
Nevertheless, [Gd"9] was considered to be a good model system with which to develop 
practicable synthetic routes to couple a gadolinium chelate to folic acid, as well as to test 
the affinity of folate conjugates for Folate Binding Protein (FBP). 
O t%ýOH 
HNC/NH2 
N N'( 
Hp 
rO 
HO 
O 
(9) 
OOH POOH 
HOOC OOH 
H00 NHZ 
OOH 
T(OOH 
Figure 4.1 - Ligands investigated 
(s) 
Folate conjugates of gadolinium chelates are designed to specifically target cancerous 
tissues and/or organs which overexpress FBP (Chapter Three). The MRI signal intensity is 
determined by the quantity of the paramagnetic species that can be localized in the target 
tissue, which in turn is limited by the amount of FBP present. Low relaxivity chelates, 
when used as the basis for such folate targeting contrast agents, would require high doses to 
bring sufficient reduction in the Tt relaxation time. The desired increment in signal 
intensity could be achieved either by attaching multimeric gadolinium chelates to a single 
folate residue, or by the use of enhanced relaxivity chelates. 5 
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The anionic complex [Gd"6]' has been chosen as an example of a complex that should 
provide higher intrinsic signal intensity. The enhanced relaxivity arises mainly from its 
faster water exchange rate. It is structurally similar to [Gd"7]', having replaced a 
carboxylate with a primary amine group. The RRRR-isomer of [Gd"7]', which contains the 
highest proportion of the twisted antiprismatic (m) isomer in solution, showed the fastest 
water exchange (tM = 68 ns; 298 K) compared to the other diastereoisomers. 6 So the 
RRRR-a substituted derivatives of DOTA should be preferred, because their water 
exchange rates are likely to be sufficiently fast as not to limit the overall relaxivity of the 
derived higher molecular weight conjugates. An additional enhancement in relaxivity may 
also arise from the increase in the rotational correlation time, TR. The ligand (6) has been 
designed with three remote carboxylate groups, which provide linkage points for high 
molecular weight compounds, such as the amine (28) (kindly provided by Guerbet s. a. ). 
Another advantage of using [Gd"6]' as base for targeting contrast agents is related to its 
charge. Negatively charged chelates may interact more strongly with the binding sites of 
proteins, 4 compared to neutral complexes, and then may be carried more efficiently into the 
cells. For all these reasons [Gd"6]' represents a promising candidate upon which to develop 
folate targeting contrast agents. 
4.2. Synthesis of [Gd"9] and its folate derivatives 
4.2.1. Synthesis of [Ln "9] 
The gadolinium and the europium complexes of the ligand (9) were synthesized according 
to the scheme outlined in Figure 4.2. 
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tBocNH 
H BuLC 
+ 
jJo 
tBuO H 
OO 
OtBu 
(36) CI 
(38) 
CH3CN 
Cs2CO3 
KI 
LnCI3 
pH = 3.0 
Figure 4.2 -Synthesis of [Ln "9] Ln = Eu3 and Gd3+. 
The N-alkylation of DO3AtBu (36) was effectued using the chloroamide (38) in the 
presence of caesium carbonate as base. All the attempts made in acetonitrile solution were 
accompanied by rather low yields (< 30%) and no appreciable improvements were obtained 
by increasing either the temperature or the reaction time. However, the addition of small 
quantity of potassium iodide to the stirring solution resulted in a significant increase in the 
final yield. Nucleophilic substitution of the chlorine by iodide gave the intermediate a- 
iodoamide in which the iodide is a leaving group leading to a speeding up of the reaction 
rate. The progress of the reaction was followed by TLC and ESMS, which indicated the 
completion of the reaction after 18 hours. The triester (37) was isolated in high yield 
(-80%) after purification over silica gel. 
The cleavage of both the carbamate and the t-butyl esters was carried out using 
trifluoroacetic acid in DCM at room temperature. The reaction was followed by TLC and 
by 'H NMR. Small portions of the reacting solution were collected over time, evaporated 
and dissolved in CDC13. The disappearance of the t-butyl and t-Boc resonances at 1.44 and 
1.64 ppm respectively was checked and the reaction was found to be complete after 18 
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TFA 
CHZCI2 
hours. The free ligand (9) was extracted from aqueous solution and isolated in the form of 
the trifluoroacetate salt. 
The europium complex was synthesized from water solution. Its formation was 
followed by 1H NMR, which showed the disappearance of the free ligand after 24 hours. 
The reaction was repeated in the case of the analogous gadolinium chelate. Purification was 
achieved by passing 'the crude material through a strong anionic exchange resin, which 
yielded the complexes in the form of the free amine. 
The pendant a-chloroamide (38) was synthesized starting from the commercially 
available 1,4-diamino butane (39) (Figure 4.3). Slow addition of a dioxane solution of 
(BOC)20 to an excess of 1,4 diamine, resulted in a mixture of mono- and di-protected 
amine. The "unwanted" N, N bis-t-Boc compound was removed by filtration in 
water/dioxane, and the mono-protected amine (40) was finally isolated in low yield (15%). 
Its free amino group was then coupled to chloroacetic acid (41), previously activated by 
using the conventional coupling agents (EDC and NHS) to yield the chloroamide (38). 
HsN 
NH2 
(BOC)20 
º 
(39) 
H2N 
NHtBoc + Ci ""'/OH 
(40) 0 (41) 
EDC 
NHS 
H 
(38) tBocNH )rCI 
0 
Figure 4.3 -Synthesis ofN-(N-t-butoxycarbonyl-1,4-diaminobutyl)-2-chloro acetamide (38). 
4.2.2. Synthesis of the [Gd-9]-}4folate conjugate 
The folate y-conjugate of [Gd"9] was synthesized according to the pathway outlined in 
Figure 4.4. 
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0 
0 of 
tBocNH 
(35a) 
0 
EDC HOBt 
water/dioxane 1: 1 
0 
[Gd9] 
0 
tBocNH 
(42) 
H COOBn 
TFA 96% 
13) 
a)R, =Bn 
b)R, =H 
1) EDC NHS 
2) Pd(OH)JC; N2H4 
I off 
HN& 
HNC N (44) 
H2N NN 
Figure 4.4 - Synthesis of the [Gd9J- -folate conjugate. 
Following the approach described in Chapter Three, the gadolinium chelate [Gd"9] 
was first coupled to the commercially available a-benzyl-N tBocglutamate (35a). The free 
y-carboxylate was activated using EDC and HOBt in a water/dioxane mixture 1: 1 (v/v) 
maintaining the pH constantly at 6.0. The resulting activated ester was reacted in situ with 
[Gd"9]. Formation of the amide (42) was monitored and confirmed both by ESMS (m/z = 
971) and HPLC (tr = 16.5 min) and purification of the crude material was achieved by 
chromatography over alumina. The cleavage of the tBoc protecting group was performed in 
acidic solution, using trifluoroacetic acid. Under such strongly acidic conditions the 
gadolinium chelate could undergo decomplexation. However, due to its high 
thermodynamic and kinetic stability and to the short time required for the reaction (few 
minutes), no free ligand was detected either by ESMS nor by TLC and the compound (43) 
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was isolated in quantitative yield in the form of its TFA salt. The corresponding free amine, 
obtained passing the salt through a strong anionic exchange resin, was then coupled to 
pteroic acid (44). 
Harvison and coworkers, 7 in synthesizing a series of y-substituted folic acid 
analogues have used N1°-trifluoroacetyl pteroic acid instead of pteroic acid because of its 
higher solubility. However, the presence of the electron withdrawing N1°-trifluoroacetyl 
group, may reduce the nucleophilicity of the para carboxylate, resulting in incomplete 
formation of the activated ester. Moreover, the additional step required to synthesize the 
trifluoroacetyl derivative is characterized by a low yield and separation problems, whereas 
pteroic acid is commercially available even though expensive. However, different synthetic 
procedures have been published in the literature for the preparation of pteroic acid. For 
example, it can be obtained by treating folic acid with acetic anhydride in acetic acid to 
give the acetylated azlactone, which is then cleaved under mild basic condition to yield 
pteroic acid. 8 Alternatively, it can be obtained enzymatically from folic acid using 
carboxypeptidase G. 9,10 For these reasons pteroic acid itself was preferred in this work. 
Attempts to further optimize the yields of the coupling reaction, between pteroic acid 
and the gadolinium chelate (43), by varing the reaction conditions (i. e. time, temperature 
and reagent concentration) were made. l1 Typically pteroic acid was activated in DMSO (c 
= 6-15 mM) in the presence of a dehydrating agent (DCC, EDC) and a coupling adjuvant 
(NHS, HOBt) at a temperature between 0 °C and 25 °C for a period of time between 3 and 
24 hours. The activated ester, which was detected by ESMS, was then reacted in situ to the 
gadolinium chelate (43) in the presence of a base, such as triethylamine. Temperatures of 
between 25 °C and 50 °C and reaction times between 12 and 48 hours were compared. The 
formation of the amide (45a) was followed by ESMS (m/z = 1141) and HPLC (t, = 13.8 
min). The best conditions found are detailed in the experimental section (Chapter Five). 
The crude material was precipitated by adding organic solvents (ethyl acetate or 
acetonitrile). Unreacted pteroic acid co-precipitated as well. All attempts made to purify the 
mixture, either by silica gel or reverse phase chromatography or by gel filtration, failed 
because of the poor solubility of the compounds. The unreacted pteroic acid was therefore 
not removed completely and the mixture was used directly in the next step. 
Deprotection of the a carboxylate (Le. as its benzyl ester) was first performed in a 
diluted sodium hydroxide solution (pH = 9.0). The hydrolysis of the benzyl group was 
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followed by HPLC and ESMS, which showed the completion of the reaction after 20 hours. 
However, this method cannot be applied in this case because racemization at the chiral 
centre (the cc-carbon) occurs, as it shown in Figure 4.5. This was confirmed by measuring 
the optical rotation [a]D20 over time, in sodium hydroxide solution (pH=9.0). Starting from 
an initial value of + 14.6 (c = 0.4 g/100 ml in NaOH 0.02 M), 12 the optical rotation 
gradually decreased to 0° after one hour, when racemization was complete. 
OH- 
HH 
oJ 
`lN OBn 
CO2. 
OBn 
col- 
H 
OBn 
s 
CO z 
Figure 4.5 - Racemization at the a-carbon in basic aqueous solution. 
An alternative method of deprotection was required. Previous attempts made on the 
a-benzyl ester of folic acid in DMF/water mixture, using H2 or ammonium formate in 
presence of palladium over carbon as catalyst failed, maybe because of the low solubility of 
the starting materials in these solvents. The use of DMSO, in which folate derivatives are 
more soluble, could also poison the catalyst, reducing its activity. However, when a-0- 
debenzylation was performed in the presence of N2H4, using palladium hydroxide over 
carbon in DMSO solution, the reaction worked successfully in quantitative yield. The 
catalyst was removed over celite, and the crude material precipitated by adding organic 
solvents (ethyl acetate or acetonitrile). Pteroic acid, deriving from the previous step, was 
separated at this stage by silica gel chromatography to yield the pure [Gd"9]-y-folate. 
An alternative method of purification, which exploits the different masses of the 
compounds to be separated (MW (45b) = 1051 and MW (44) = 311), is represented by gel 
filtration. It was successfully performed on a small scale (10-20 mg), by using Sephadex G- 
25 and water as eluent. 
The synthetic procedure described in this paragraph could be repeated for the 
synthesis of the a-[Gd-9] folate, using y-benzyl-N tBoc-glutamate (35b) as starting 
material. However, a different approach was followed in the end as discussed below. 
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4.2.3. Synthesis of the [Gd"9]-a folate conjugate 
The [Gd-9]-a-folate was synthesized according to the scheme in Figure 4.6. 
0 Hx 
/N 
H 
HA N 
H2N N... 000r (34b) 
OMe 
[Gd9] 
1) EDC/NHS 
2) NaOH 0.02M 
HNC: 
r' 
HA 
N 
HzN NN 
Figure 4.6 - Synthesis of the [Gd "9]-a folate conjugate. 
0 
In order to optimize the coupling reaction conditions, the y-methyl ester of folic acid 
(34b) was first reacted with the simple and cheap amine, hexylamine. The a carboxylate 
was activated using different dehydrating agents (EDC, DCC) and coupling adjuvants 
(NHS, HOBt) in DMSO solution at temperature between 0 °C and 25 °C. The resulting 
activated ester, which was detected by ESMS, was then reacted in situ with hexylamine at 
temperature between 25 °C and 50 °C for a period of time between 12 and 48 hours. The 
formation of the amide was followed by ESMS, HPLC and 1H NMR. The best conditions 
found for this "model reaction" were repeated in the coupling of the monoamide complex 
[Gd"9] (see Chapter Five) and the [Gd-9]- a-folate was obtained in modest but satisfactory 
yield (33%), after purification over silica gel. 
Cleavage of the y-methyl ester in (46a) was easily achieved in sodium hydroxide 
solution 0.02 M (pH = 9.0). Racemization at the a-carbon is less likely to occur in this 
case, because the pKa of the hydrogen in an a position to an amide is higher than the pKa of 
the a-hydrogen in an ester. The mild alkaline hydrolysis was followed by ESMS and HPLC 
and was found to be complete in 24 hours. 
This procedure could be repeated for the synthesis of the [Gd"9]-y-folate. The a-ester 
of folic acid required in this case could be synthesized as discussed in Chapter Three. 
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a)R, =Me 
b)R, =H 
4.2.4. Synthesis of the [Gd "9]2 -z y-folate conjugate 
The MRI signal intensity depends on the amount of paramagnetic species that can be 
localized in the target tissue. In the case of folate targeted contrast agents this is limited by 
the amount of FBP present in the target tissue. As already discussed, a possible way to 
increase the signal intensity consists in using multimeric gadolinium chelates. 5 However, 
the main interest in the dimer [Gd"9]2 -a, y-folate relates to a study of its affinity for FBP. It 
represents a reference point to allow a comparison with the binding affinity of its mono- 
folate analogues. 
For these reasons [Gd"9]2 -a, y-folate has been synthesized according to the sequence 
shown in Figure 4.7. Folic acid was directly coupled to two equivalents of the monoamide 
complex [Gd"9], using the same conditions discussed in the previous paragraph. The 
dimeric chelate was isolated in satisfactory yield (32%) after purification over silica gel. 
EDC/NHS 
DMSO H21 
Figure 4.7- Synthesis of the [Gd"9]2-a , P-Jblate conjugate. 
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4.3. Synthesis of [Gd"61' and its folate derivatives 
4.3.1. Synthesis of [Ln -6]- 
Syntheses of tetra-alkylated derivatives of cyclen, such as (22b), may be obtained 
following two different strategies (Figure 4.8). 
H% H H% H R2` R2 H` R1 H` H 
%H H 'R1 R2J1R1 R1 R1 H 
%H 
(22) (22a) (22b) (22c) (22) 
Figure 4.8 - Different approaches to synthesize tetra-alkylated cyclen derivatives. 
In the first route, the mono-alkylated compound (22a) may be synthesized first. In 
this case a preliminary protection of the other three nitrogens may be required, because of 
the difficulties in a selective mono-alkylation step. Molybdenum hexacarbonyl in dibutyl 
ether can be used for this purpose. 13 The metal coordinates three nitrogens of the ring, 
leaving the fourth free to react with the alkylating agent. The removal of the molybdenum 
complex requires oxidation in air and acidic hydrolysis. The three remaining nitrogens may 
then be further alkylated to yield (22b). In a second approach, the tri-alkylated derivative 
(22c) may be synthesized first. In order to alkylate selectively three of the four nitrogens, a 
preliminary mono-protection of the amine group is, in theory, required. Several methods for 
the mono-protection of cyclen have been published in the literature. For example, Atkins 
and coworkers14 developed a procedure, which involved the formation of 1,4,7,10- 
tetraazacyclo[5.5.1.0]tridecane (22d) (Figure 4.9), followed by its hydrolysis to yield the 1- 
formyl monoprotected cyclen (22e). The remaining three free nitrogens can undergo further 
alkylation under standard conditions, before the protecting group is removed. 
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H` H (CH3)2NCH(OCH3)2 
C cyclohexane 
H #U%H 
(22) 
H 
HýI 
HHUH 
(22d) (22e) 
Figure 4.9 - Example of mono protection of cyclen. 
However, it has also been demonstrated that cyclen can be selectively alkylated three 
or four times depending on the nature of the base employed (Chapter Two). This represents 
an easy one step route to synthesize tri-alkylated derivatives of cyclen. Although further 
purification is required, the yields of these reactions are generally good (- 35%). Once the 
tri-alkylated derivative (22c) is made, the fourth nitrogen can be easily alkylated. 
This approach has been chosen in the present work, as shown in Figure 4.10. 
The tri-alkylated compound (49) was synthesized according to the procedure 
employed for the analogous adipate derivative (24) (Chapter Two). The use of racemic 
dimethyl-a-bromoglutarate (48) (NaHC03/CH3CN) led to formation of a mixture of 
diastereoisomers. Alkylation of the fourth nitrogen was achieved by using the racemic 
methyl a-bromo-N-benzoyl-5-amino valerate (50), in the presence of caesium carbonate as 
base. The reaction was followed by TLC, which showed the disappearance of the starting 
tri-alkylated material after three days. The compound (51) was isolated in high yield 
(-80%) after purification over silica gel. 
Cleavage of the methyl ester groups was achieved in lithium hydroxide solution. The 
hydrolysis was followed by 1H NMR, which showed disappearance of the methyl proton 
resonances between 3.60 and 3.75 ppm after 24 hours. The benzoyl amide group, which is 
stable in strong alkaline conditions, was then subsequentially removed under strongly 
acidic conditions. Again the amide hydrolysis step, performed in 6M hydrochloric acid 
solution, was followed by 
'H NMR. The aromatic proton resonances at 7.45 ppm and 7.80 
ppm were checked and the reaction was found to be complete after 24 hours. The ligand 
(6) 
was isolated in the form of the free amine after purification through a strong cationic 
exchange resin (Dowex 50W), eluting with 12% ammonia solution. 
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NaHCO3 
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\H Bý COOMe 
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1) LiOH 
10 
2) HCI 
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Figure 4.10- Synthesis of [Ln -6f Ln = Eu3+ and Gd3+. 
NaHC03 
CH3CN 
(51) 
Both the europium and gadolinium complexes were synthesized in aqueous solution 
at pH 5.5. The complexation reaction was followed by ESMS and, in case of europium, by 
IH NMR as well. Both complexes were recrystallized from acidic aqueous solution (pH = 
3.0), and were isolated as a mixture of diastereoisomers. No further separation of the 
isomers was attempted. 
(s) 
PhCOHN 
Br COOMe 
(50) 
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4.3.2. Synthesis of methyl a-bromo-N-benzoyl-5-amino-valerate (50) 
The methyl ester of a-bromo-N-benzoyl-5-amino-valerate (50) was synthesized starting 
from the commercially available 5-amino valeric acid (52) (Figure 4.11). The amino group 
was protected using a benzoyl protecting group, to give high stability to hydrolysis. 
Standard conditions (benzoyl chloride in water/THF solution at pH between 8-10) worked 
successfully and gave the desired compound (53) in good yield (88%). 
HZNý/COOH 
PhCOCI 
phCONH ,, 
COOH 
(52) (53) 
1) SOCI2 
2) NBS/HBr 
3) MeOH 
PhCONH^COOMe 
(50) Br 
Figure 4.11 - Synthesis ofmethyl a-bromo-N-benzoyl-5-amino valerate (S0). 
A first attempt to a-brominate the N-benzoyl-5-amino valeric acid (53) was made via 
the classical Hell-Volhard-Zelinsky approach, 15-19 in which the carboxylic acid was 
treated with free bromine in presence of a catalyst, such as red phosphorus. However, this 
procedure was characterized by low yields (<20%). The strenuous experimental conditions 
(high temperature and extended reaction times) resulted in partial hydrolysis of the amide 
group. N-Bromosuccinimide (NBS) is known to a-brominate a variety of acyl chlorides 
(formed in situ by the reaction of thionyl chloride with carboxylic acid) in good yields. 20 
NBS was chosen as the brominating agent, not only because is easy to handle, but also 
because it a-brominates more efficiently than molecular bromine, requiring lower 
temperatures and reaction times. Under these milder conditions, the extent of the amide 
hydrolysis was significantly reduced, resulting in a higher final yield. The methyl 
esterification was easily achieved by treating the corresponding acyl chloride with 
methanol. Pure compound was obtained after purification over silica gel. 
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4.3.3. Synthesis of the [Gd-6]- -a-folate conjugate 
The three remote carboxylic groups in [Gd"6]" must be protected before coupling folate 
derivatives, in order to avoid infra or intermolecular reactions involving the complex itself. 
Surprisingly, methyl esterification was successfully achieved suspending the complex 
[Gd"6]" in methanol, in presence of catalytic amounts of hydrochloric acid (Figure 4.12). 
The reaction was followed by TLC and ESMS and was found to be complete within an 
hour. Purification was achieved by a column chromatography, over alumina. 
Direct coupling of the tri-ester complex (54) to the y-methyl ester of folic acid should 
result in the formation of the corresponding folate a-derivative. However, all attempts 
made in DMSO and using the same conditions for the monoamide complex [Gd"9] 
(Paragraph 4.2.2) failed. The steric hindrance associated with coupling to the secondary 
carboxylic acid and/or the short hydrocarbon amine chain may be responsible for the failure 
of this reaction. A possible solution could be found by introducing a spacer, between the 
complex and the folate moiety. This approach, however, has not been followed in this 
work. 
McOH/HCI 
(Gd6] 
H2 
(54) 
Figure 4.12 - Methyl esterification of the remote carboxylate in [Gd "6J'. 
4.3.4. Synthesis of the [Gd-6]-y-folate conjugate 
NH2 
The failure of the previous reaction can be turned to advantage in the syntheses of the folate 
y-derivative of [Gd-6]'. In theory, by reacting folic acid itself with the tri-methyl complex 
(54), the y position may react selectively, because of the steric problems mentioned below. 
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Therefore the mixture of a and y benzyl esters of folic acid (ratio 4: 1) previously 
synthesized was used as the starting material. It was reacted with the tri-ester gadolinium 
complex (54) in DMSO, using the usual conditions (Figure 4.13). The reaction was 
followed by ESMS, which revealed the formation of the amide (56a) (m/z = 1385) after 24 
hours. More importantly, HPLC indicated the presence of one isomer, confirming that the 
a-carboxylate did not react. The crude compound was purified over silica gel to yield the 
[Gd"6]-y-folate in satisfactory yield (44%). The hydrolysis of the three methyl and of the a- 
benzyl esters was easily achieved in sodium hydroxide solution (pH = 9.0). 
4 
i4) 
(56a-b) 
a: R, =Bn; RZ Me 
b: R1=H; R2= H 
Figure 413 - Synthesis of the [Gd-61-7folate conjugate. 
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1) EDC, NHS 
2) NaOH pH 9.0 
4.4. Solution structures of Europium (III) complexes 
The emission spectrum of the complex [Eu-9] has been recorded in water solution (pH = 
(- 7.50), following direct excitation at 397 nm (Figure 4.14). The analysis of the AJ =I 
590 nm) transitions are particularly interesting. The intensity of this magnetic-dipole 
transition varies very little from one co-ordination environment to another. 21 However, two 
or three transitions are allowed depending on the complex symmetry. For example, the 
emission spectrum of [EuDOTA]" (recorded under the same conditions) presents two 
overlapping pairs of bands, related to the square antiprismatic (M) isomer and a weaker set 
related to the twisted square antiprismatic (m) isomer in a ratio 4: 1. A similar shape and 
ratio of the AT =1 transition bands was observed in the emission spectra of [Eu-9], 
suggesting that the square antiprismatic (M) isomer is predominant in solution. 
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Figure 4.14 - Emission spectrum of [Eu . 91 in H2O at pH = 7.20. 
The 1H NMR spectrum of [Eu-91 was recorded in D20 at pD=7.0. As previously 
demonstrated for [EuDOTA]' two major isomers are present in solution, 22-25 which can be. 
distinguished by observing the resonances of the most shifted axial ring protons (30-50 
ppm for the square antiprismatic 
isomer (M) and about 20 ppm for the twisted square 
i 
r ..,. i , ý, 
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antiprismatic isomer (m)). The four singlets, observed for the axial ring protons between 30 
and 37 ppm are similar to those reported for other monoamide derivatives of DOTA, 26 and 
suggest the prevalence of the square antiprismatic isomer (M), a result which is consistent 
with the emission spectra. 
The IH NMR spectrum of [Eu-6]- was recorded in D20 at pD = 7.0 and it clearly 
evidenced the presence of all the eight stereoisomers. 
The hydration number q has been evaluated by measuring the luminescence lifetimes 
of the europium complex in H2O and in D20 solutions (Chapter Two). The empirical 
equation (1.22) has been used to calculate the hydration number, however an additional 
correcting parameter A'. has been considered to take into account the quenching effect of 
the closest amide NH oscillator (0.08 ms"1) 27 The values for the rate constants for the 
depopulation of the exctited states of the [Eu-9] and the [Eu-6]- and the derived hydration 
numbers q are reported in Table 4.1. Both the monamide complex, [Eu"9], and the anionic 
complex, [Eu-6]-, possess one water molecule in the inner sphere as expected. 
Complex kH2o (ms)' kD2o (ms)' q 
[Eu-9] 1.55 0.41 0.97 ± 0.2 
[Eu-6]- 1.58 0.45 0.96 ± 0.2 
Table 4.1- Rate constants for the depopulation of the excited states of [Eu9J, [Eu . 6]" and the derived q value. 
4.5. Relaxometric studies 
4.5.1. Relaxivity of [Gd"9J and its folate derivatives 
The relaxivity of the monoamide complex [Gd"9] and its folate derivatives has been 
measured at 65 MHz and 293 K in water, in an anionic background (i. e. a simulated 
extracellular anion environment) and in human serum (Table 4.2). 
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Complex rip (water) rip (anionic bkg) rip (human serum) 
[Gd"9] 5.3 5.2 
[Gd"9]-a-Folate 7.0 5.7 7.1 
[Gd"9]-y-Folate 6.8 5.6 7.0 
[Gd"912-a, y-Folate 14.9 14.8 13.6 
Table 4.2 - Relaxivity (mM' 
') at 65 MHz, 293 K and pH = 7.20. 
The free amino complex [Gd"9] exhibits a relaxivity in water (5.3 mM'ls 1) similar to 
the values found for related DOTA monoamide derivatives. 5 The absence of change in the 
anionic background suggests that no binding of endogenous anions (such as, carbonate, 
phosphate, lactate and citrate) has occurred at the metal center. 
The a and the y-[Gd-9] folates exhibit practically identical relaxivity, as expected for 
complexes of the same molecular weight and which are structurally very similar. For both 
complexes the relaxivity measured in the anionic background was about 20% lower than 
the value measured in water. This decrement is unlikely to be related to the binding of any 
of the anions present in solution. Instead, it could be due to a partial reduction of the second 
and outer sphere contribution, arising from the presence of the folate moiety. 
Anelli and coworkers28 have reported a series of monoamide derivatives of DOTA, 
used in hepatobiliarity X-ray contrast imaging, in which the amino group is linked to an 
iodinated aryl ring. They found a two to three-fold increment in the relaxivity in human 
serum compared to the values in water solution. This significant difference was due to the 
strong binding of such gadolinium chelates to Human Serum Albumin (HSA) present in 
serum. 
In case of the [Gd"9] folate derivatives, no such increment was found. The relaxivity 
in human serum was practically identical to the value in water, indicating little or no 
binding to HSA. 
The [Gd"9]2-a, y-folate shows a relaxivity of 14.9 mM-ls'' (7.5 mM-ls"' per 
gadolinium), which is not so different from the relaxivity of the mono-folate analogues. 
A 
plot of rip versus molecular weight, for a series of monomeric and multimeric gadolinium 
chelates, is shown in Figure 4.15, whereas Table 4.3 reports the parameters plotted. 
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Figure 4.15 - Plot of relaxivity versus MW for a series of multimeric and monomeric chelates. 
Ligand MW r1p Ligand MW r1p 
[Gd"4] 588 3.7 [GdDO3A]2L9 (64) 1469 6.9 
[GdDO3AMA] (18) 585 3.5 [GdDO3A]2L6 (60) 1202 5.8 
[Gd"65] 647 4.1 [GdDO3A]2L7 (62) 1264 4.9 
[GdD03A]2L2 (57) 1231 5.1 [Gd"9] 631 5.3 
[GdDO3A]2L5 (61) 1257 5.4 a-[Gd"9]-Folate 1051 7.0 
[GdDO3A]2L3 (59) 1103 6.4 y-[Gd"9]-Folate 1051 6.8 
[GdDO3A]2L4 (58) 1201 6.6 a-y-[Gd"912-Folate 1663 7.5 
[GdD03A]2L8 (63) 1367 6.2 [GdDO3A]3L2 2259 8.5 
Table 4.3 - Relaxivity and molecular weight for a series of monomeric and multimeric Gd chelates. 
S 
The structures of the ligands reported are shown in Figure 4.16. The plot indicates 
that relaxivity generally increases with the molecular weight (Le. the rotational correlation 
time TR) of the complex. However, the relationship is not always linear. Rigidity plays an 
important role in determining the relaxivity of multimeric gadolinium complexes. For 
example, [GdDO3A]2L4 (58) and [GdDO3A]2L5 (61) posses identical chelate structure and 
almost the same molecular weight. However, the first complex, having a less flexible 
linker, exhibits the higher relaxivity (6.6 mM'ls-1) compared to the second one (5.4 mM''s" 
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'). Similarly, the flexibility of the linker between the two chelates in [Gd"912-a, y-folate 
explains the "limited" increment in relaxivity. 
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Figure 4.16 - Structures of the multimeric ligands reported in Table 4.3. 
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In order to explore more deeply the properties of these complexes, the relaxivity was 
measured as function of pH. The pH dependence of relaxivity (at 20 MHz, 298 K in water 
at pH = 7.0) for [Gd"9]-cc-folate and [Gd"912-a. 7-folate is shown in Figure 4.17. 
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Figure 4.17-pH dependence of relaxivity for [Gd"9J-a folate (diamonds) and [Gd "9Ji-cx y-folate (squares) 
In both cases the relaxivity remains constant in the range between pH 3.0 and 8.0, 
then it shows an increase above pH 8.0. A base catalyzed prototropic exchange, involving 
deprotonation of the co-ordinated amide NH, accounts for such a variation. 29 
4.5.2. NMRD profiles of the [Gd "9]folate conjugates 
In order to characterize the different contributions to the observed relaxivity, NMRD 
profiles over an extended range of frequencies at 25 
°C were measured for [Gd"9]-a-folate 
and [Gd"912-a. 7-folate (Figure 4.18). 
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Figure 4.18 - NMRD profiles for a-7-[Gd "9]? -folate (upper) and a-[Gd "9J folate (298 K), showing the fit to 
the experimental data. 
The NMRD profile of the [Gd-9]-y-folate has not been recorded. However, it should 
not be different from that recorded for the a-isomer. 
The curves were fitted to the equations for inner and outer sphere paramagnetic 
relaxation (see Chapter One) to give the parameters listed in Table 4.4. 
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Proton Larmor Frequency (MHz) 
Complex 2(s 2)/10'19 Tv (ps) -tR (ps) 
[Gd"9]-a-folate 2.44 23 100 
[Gd"9]2 -a, y-folate 2.94 23 100, 
[GdDO3A]2L7 (62) 2.10 15 106 
[GdDO3A]2L6 (60) 1.70 19 171 
Table 4.4- Best fitting parameters determined by analyses of NMRD profiles. 
In the analyses a reasonable choice was made for r (2.98 A), the distance between the 
metal center and closed water molecule, based on known values of similar complexes. The 
parameters a (distance of the closest approach of diffusing water) and D (diffusion 
coefficient) were fixed to typical values of 3.8 A and 2.24.10"5 cm2s"1 respectively, whereas 
q was considered one, as had been measured by luminescence studies. 
The rotational correlation times iR calculated from the profiles are identical for the 
two complexes [Gd"9]-a-folate and [Gd-9]2-a, y-folate (100 ps), despite the significant 
difference in molecular weight. On the other hand, [GdDO3A]2L7 (62) and [GdDO3A]2L6 
(60) (Table 4.4) exhibit different rotational correlation times, despite their similar masses. 
The absence of a linear relationship between tR and the molecular weight, predicted 
by the Debye formula (equation 1.20), can be explained in terms of the internal flexibility 
of the molecules. The rotational correlation time as evaluated experimentally, corresponds 
to the rotational motion of the Gd-coordinated water 0 (or H) vectors and it does not 
represent the correlation time for the whole molecule. This motion, which determines 
proton relaxivity, can be considerably faster than the motion of the whole molecule, which 
is instead related to the molecular mass. 
In the case of [Gd"912-a, y-folate, the two chelates are separated by a flexible "linker" 
and then are free to rotate independently each other. Their rotation is faster than the 
tumbling of the whole molecule. So the increment of about 40 % in molecular weight is not 
accompanied by a corresponding increment in TR and thus in the relaxivity. On the other 
hand, the less flexible linker present in [GdD03A]2L6 (60) accounts for the significant 
increment in TM and thus in relaxivity, compared to the [GdDO3A]2L7 (62), which 
possesses similar mass, 
but a more flexible linker. 
As already pointed out, the profiles are only slightly dependent on the actual value of 
the water residence lifetime TM, which then cannot be determined with sufficient accuracy 
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by fitting procedures. As discussed in Chapter Two, tiM can be measured independently by 
variable temperature proton decoupled 170 NMR measurements of the water nuclear 
transverse relaxation rate. The measured variation of Rep as function of T at 90 MHz in 170 
enriched solution at pH 7.0 for [Gd"9]-a-folate (c. a. 10 mM) is shown in Figure 4.19. 
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Figure 4.19- R, as function of temperature for [Gd "9]-a folate (90 MHz; pH 7.0) showing the fit to the 
experimental data. 
The curve was fitted to the Swift-Connick equation. 30-32 In the analysis a standard 
value for the hyperfine coupling constant A/h (-3.8.106 rad s 
1) was used, whereas the 
values obtained from the NMRD profile for A2 and Tv were considered. The calculated 
value of the water exchange lifetimes at 298 K are reported in Table 4.5 and compared to 
those published for similar complexes. 5 
Complex [Gd-9]- a-folate [Gd-9]2 a, y-folate [GdDOTA]" [GdDO3A]2L7 
(62) 
, rM (ns) 850 (850) 244 714 
Table 4.5 - Water exchange lifetime ru at 298 K 
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As discussed previously, the presence of an amide carbonyl as a coordinating donor, 
reduces the water exchange rate of the gadolinium complex by a factor between three and 
four. 1-3 This is clearly shown by the difference observed between [GdDOTA]- and the 
monoamide derivative [Gd-9]-a-folate, which shows a shorter water exchange rate. 
In a dissociatively activated water exchange process, which is usually the case for 
octadentate gadolinium chelates, the bound water molecule must "depart" from the inner 
sphere, before the subsequent arrival of a second molecule. The corresponding eight co- 
ordinate transition state structure plays a crucial role. The more unstable it is the higher the 
activation energy needed for its formation. An amide group is usually considered to be less 
strongly bound to the metal center than a carboxylate. This may result in a higher energy 
transition state, which makes more difficult for the inner sphere water molecule to leave, 
and thus results in a higher value of rm. 
Recently it has been demonstrated by NMR and luminescence studies that the rate of 
water exchange at the metal center depends on the nature and relative abundance of the 
isomers present in solution. 22,33,34 For example, the water exchange lifetime at 298 K for 
the tetraamides (66a-c) (Figure 4.20) is the order of 160 µs for the major square 
antiprismatic isomer (M) and about fifty times faster for the isomeric twisted square 
antiprismatic (m). The prevalence of the square antiprismatic (M) isomer, detected by NMR 
and luminescence studies is consistent with relatively long value of TM measured for both 
the [Gd"9]-a-folate and the [Gd"912-a, y-folate. 
HOOC\ /-COOH 
HOOC H RE 
(65) 
Figure 4.20 - Mono and tetraamide ligands. 
a)R=H 
b) R= Me 
c) R= NHCHMePh 
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4.5.3 Relaxivity of the [Gd-6]" and its folate conjugates. 
The relaxivity of [Gd"6]' and its y-folate derivative was measured at 65 MHz and 293 
K in water, in an anionic background solution and in human serum (Table 4.6). 
Complex r1 (water) R1 p (anionic bkg) rlp (humanserum) 
[Gd"6]' 8.5 7.4 9.6 
[Gd"6]' y-folate 9.5 8.8 11.1 
RRRR-[GdgDOTA]' 8.7 (11.1) 
Table 4.6 - Relaxivities (in mM's 1) at 65 MHz, 293 K and pH = 7.20. 
Both the anionic complex [Gd"6]" and the analogous complex [GdgDOTA]", due to 
their similar structure and molecular volume, exhibit almost identical relaxivities in water 
solution. The [Gd"6]"-y-folate shows instead a higher relaxivity, which is related to the 
increased molecular weight. In the anion solution, both [Gd-6]' and the [Gd"6]y-folate show 
a decrease in relaxivity of about 15%. This reduction is very unlikely to be due to the 
binding of anions to the metal centre, because of the electrostatic repulsion. However, it 
may be explained by the partial lost of the second or outer sphere contribution. 
The higher relaxivities measured in human serum are a consequence of either the 
increased micro-viscosity of the medium or the formation of weak adducts with proteins 
present in serum (e. g. serum albumin). 
4.6. Interaction with proteins 
The interaction of gadolinium chelates with proteins has been widely investigated in recent 
years .4 
The main interest, from the MRI point of view is determined by the expectation that 
paramagnetic macromolecular complexes should lead to a marked enhancement of the 
relaxation rate of tissue protons. 
The large molecular size of the protein-complex adducts 
results in a slowing 
down of the molecular motion (TR) and thus in an increase of the 
relaxivitY. 
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In the case of the folate conjugates of the gadolinium complexes prepared in the 
present work, the study of the interaction with specific proteins (e. g. FBP) must be 
considered, because the delivering of these compounds into the target tissues or organs 
depends on the extent of such an interaction. 
The three most important techniques that are used to determine the protein binding of 
metal chelates are represented by equilibrium dialysis, 35 ultrafiltration35 and proton 
relaxation enhancement (PRE) 36 The first two are separation methods, in which a 
membrane or a filter is used to allow separation of free and bound complex with subsequent 
analysis of the unbound substrate. The long time required and the possible interference of 
the membrane on the binding equilibrium represent the main drawbacks of such methods. 
The proton relaxation enhancement (PRE) method does not include a separation step. 
The extent of the binding between a protein and a substrate is exploited by the detection of 
the enhancement in the observed water proton relaxation rate (Rlobs). This method is widely 
used in the field of MRI contrast agents, and it has also been used in the present work. The 
experimental procedure consists in carrying out a titration, in which the observed water 
proton relaxation rate is measured as a function of the concentration of added protein. In 
aqueous solution, the substrate (S) and the protein (P) reach the equilibrium (equation 4.1), 
regulated by the association constant KA (equation 4.2): 
S+PH SP (4.1) 
_ 
[s-P] 
KA [S]. (4.2) 4.2) 
in which [nP] represents the concentration of the equivalent and independent binding sites 
on the protein. The longitudinal water proton relaxation rate (Rlobs) is given by the sum of 
the contributions arising from the unbound and the bound species, as well as the 
diamagnetic contribution of the protein itself (Rip) (equation 4.3): 
R, 
ob = 
(rI[S]+r, b[SP])000+R1 (4.3) 
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where ri and rib represent the millimolar relaxivities of the unbound and bound substrate 
respectively. The combination of the equations (4.3) and (4.2) allows the calculation of the 
binding parameters, KA and n, from the observed relaxation rate (equation 4.4): 
R' a(KASr+nKAPT+1)- 
(K Se+nKAP,. +1)'-4KýSnPr 
-(rl"-rl+riST)1000+RI., 
(4"4) 
A 
By fitting the experimental curve to equation (4.4), a good estimate of the relaxivity 
of the substrate bound to the protein (rib) may be obtained. However, the determination of 
the association constant (KA) and of the number of interaction sites on the protein (n) is not 
accurate by this experiment, especially when the affinity constant is small. A more accurate 
evaluation of these parameters may be obtained by another experiment, in which a fixed 
concentration of protein is titrated with the paramagnetic compound .4 
The non-covalent interactions between the folate conjugate complexes, [Gd"9]-oc- 
folate and [Gd-6]-y-folate and serum albumin were investigated first. These proteins are 
highly concentrated in the blood (ca. 50 g dm'3) and their interaction with several 
gadolinium chelates has been widely investigated 4' 37 It has been demonstrated that 
chelates bearing hydrophobic residues as well as negative charges are more likely to bind to 
these proteins 38 
The [Gd-9]-a-folate was titrated with human serum albumin (HSA), in phosphate 
buffered solution at pH = 7.0 and 25 °C (Figure 4.21). 
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Figure 4.21 - PRE titration of [Gd "9]-a folate with Human Serum Albumin (HSA) at 20 MHz, 298 K in 50 
mMphosphate buffer solution pH = 7.0, [GdL] = 0.125 mM. 
The binding curve was fitted to equation (4.4) and the calculated parameters were 
compared to those reported for related complexes (Table 4.7). 
Complex rl (MM-IS-1) KA (M' ) 
[Gd"9]-a-folate 6.3 (9.102) 
[GdDOTA(BOM)] (67) < 1.102 
Cis-[GdDOTA(BOM)2] (68) 35.2 3.2.102 
Trans-[GdDOTA(BOM)2] (69) 44.2 3.6.102 
[GdDOTA(BOM)3] (70) 53.2 9.2.104 
Table 4.7 =Calculated values of r, b and KA. 
39 
In the series of the DOTA(BOM) complexes (Figure 4.22), the introduction of f3- 
benzyloxy-a-propionic hydrophobic residues favours the formation of the macromolecular 
adduct with HSA. 
39 This is clear from the increment in both rib and in the association 
constant, KA. In particular the tri-substituted [GdDOTA(BOM)3] (70) shows the largest 
values, suggesting a higher affinity for this complex. 
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DOTA(BOM) (67) : R1=R3=H; R2=BOM 
cis-DOTA(BOM)2 (68) : R1=H; R2=R3=BOM 
trans-DOTA(BOM)2 (69) : R2=H; R1=R3=BOM 
DOTA(BOM)3 (70) : R1=R2=R3=BOM 
BOM = "'ýO I 
Figure 4.22 - Structures of the series of DOTA(BOMI. 
The monoamide [Gd-9]-a-folate complex does not show any appreciable change in 
relaxivity from the unbound chelates (rt = 6.5 mM"'s'lat 20 MHz) to the protein adduct (rib 
= 6.3 mM"'s4 at 20 MHz). This suggests that the [Gd"9]-a-folate does not interact with the 
protein HSA, as predicted by observing the relaxivity in human serum, compared to water. 
Similarly, the anionic complex [Gd"6]--y-folate was titrated with bovine serum albumin 
(BSA) in phosphate buffered solution at pH 7.20 (Figure 4.23). The observed PRE 
enhancement was not significant, suggesting again a very weak interaction between the 
protein and the complex. The presence of a negative charge, which usually improves the 
interaction with serum albumins, does not have any significant effect in this case. 
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Figure 4.23 - PRE titration of [Gd"6]" -y-folate (c = 0.06 mM) with bovine serum albumin (BSA) in 50 mM 
phosphate buffered solution pH = 7.0 at 298 K and 65 MHz. 
As already discussed the study of the specific interaction of the gadolinium complex 
conjugates with folate binding proteins (FBP) represents an important aim of this project. 
The two isomers [Gd"9] a- and y-folate were separately titrated with FBP, in phosphate 
buffered solution at pH = 7.0 (Figure 4.24). 
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Figure 4.24- PRE titration of [Gd "9J-7-folate (triangles) and [Gd "9J-a folate (squares) with FBP, and of 
[Gd"91-a folate (circles) with HAS as control, in phosphate buffer solution pH= 7.0,65 MHz, 293 K 
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The plot reveals only minor differences between the two isomers. In addition, the 
observed PRE measured in the presence of FBP is not significantly higher than that 
observed in the case of HSA, which does not experience any interaction with the complex 
[Gd"9]-cc-folate (see below). These results clearly show that neither the a- nor the 7-isomer 
interact specifically with folate binding proteins. However, we must consider that the 
enhancement in the longitudinal proton relaxation rate and thus in relaxivity arising from 
the lengthening of TR (i. e. binding of proteins) can only be fully exploited if the water 
exchange lifetime and the electronic relaxation time have optimal values. These parameters 
depend mainly on the properties of the complex, rather than on the structure of the binding 
site of the protein. The very long water exchange time (850 ns) of the [Gd"9]-a-folate may 
be the limiting factor that prevents higher relaxation rates from being obtained. 
In order to understand more deeply the affinity of these complexes for the cell surface 
folate receptors, in-vitro cell uptake experiments have been carried out on both the a- and 
y-monoisomer and on the a-y-bis derivative. These experiments are currently en route at 
Guerbet s. a., but no details can be drawn because of confidentiality reasons. 
Finally, the anionic [Gd-6]'-y-folate complex was titrated with FBP, using the same 
conditions (Figure 4.25). 
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Figure 4.25 - PRE titration of [Gd-6]- -y-folate with FBP (squares) and with BSA (triangles) in phosphate 
buffer solution pH =7 . 0,65 MHz, 293 K 
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The anionic complex [Gd-6]"-y-folate exhibits a clear and significant PRE effect (ca. 
80% increase) in the presence of FBP, compared to that observed in the presence of the 
control bovine serum albumin (BSA). This result has demonstrated that the FBP is capable 
of recognizing specifically the anionic complex. In this case the shorter water residence 
lifetime -M, of the gadolinium complex may be responsible for the observed increase in the 
relaxation rate. Thus [Gd-6]'-y-folate is a particularly interesting candidate as an MRI 
targeted contrast agent. 
4.7. Conclusion 
Two different practicable synthetic routes to allow the regioselective coupling of folic acid 
to a gadolinium chelate have been developed, using the model system [Gd"9]. The 
relaxometric properties of both the a and y isomers and their affinity for the specific folate 
binding protein (FBP) have been fully investigated. The results have shown a very weak 
interaction between the complexes and the protein and no appreciable difference in affinity 
between the two isomers has been observed. 
In vitro studies to further investigate the affinity of these complexes for the cell 
surface receptors are currently en route at Guerbet s. a. 
The anionic complex [Gd"6]" has been synthesized and coupled regioselectively to 
folic acid. Due to its optimal intrinsic relaxometric properties (i. e. faster water exchange, 
enhanced relaxivity), it represents a better candidate as a targeted MRI contrast agent. Its 
affinity for the folate binding proteins has been explored and compared to the unspecific 
bovine serum albumin. The results have clearly demonstrated that the receptor protein FBP 
is capable of recognizing the anionic complex [Gd"6]"-y-folate, with a significant 
enhancement of relaxivity in the bound form. 
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5.1. Experimental procedures 
5.1.1. Materials and solvents 
Folic acid dihydrate 97%, benzyl bromide 98%, benzoyl chloride 98%, caesium 
carbonate anhydrous 99%, dimethyl sulfoxide anhydrous, diisopropylamine 99%, 
benzyl alchool, tetrafluoroboric acid diethyl ether complex 65%, sodium sulphate 
anhydrous, 1,4-diaminobutane, N-bromosuccinimide 99%, N-hydroxy succinimide 
99%, 1, (3-dimithylaminopropyl)-3-ethyl carbodiimide hydrochloride 99%, 5-amino 
valeric acid 97%, acetyl chloride, potassium hydroxide, thionyl chloride, sodium 
thiosulphate, sodium hydrogen carbonate, lithium hydroxide, gadolinium (III) chloride 
hexahydrate, europium chloride hexahydrate, potassium iodade, chloroacetic acid, 
palladium hydroxide over carbon, protease (from Rhizopus species type XVIII), pteroic 
acid, a-benzyl ester of gluatamic acid, trifluoroacetic acid, hydrazine were purchased 
from Aldrich and were used without further purification. 
All the solvents used were dried over the appropriate drying agent: 
dichloromethane, acetonitrile and triethylamine over calcium hydride; tetrahydrofuran 
and diethyl ether over sodium with benzophenone as indicator; methanol and ethanol 
from the corresponding magnesium alkoxide. N, N-Dimethylformamide and 
dimethylsulfoxide were used directly from the "sure-seal" bottles. Water was purified 
by the Purite TM system. 
5.1.2. Chromatography 
Column chromatography was carried out using "gravity" silica (Merck) or neutral 
alumina (Merck). Cation exchange chromatography was performed using Dowex 50W 
strong ion-exchange resin, which was pretreated with 3M HCI. Thin layer 
chromatography was carried out on neutral alumina plates (Merck) or on silica plates 
(Merck) and visualized by iodine or UV irradiation. Gel filtration chromatography was 
performed using Sephadex G25 or G10. The resin was swallowed in water, stirring for 
three hours at room temperature. 
Analytical HPLC chromatograms were recorded on a Varian liquid 
chromatography system. 
The components include a Varian 9010 Solvent Delivery 
System, a Varian 9065 Polychrom, and a PC station. A Hypersil 5µm ODS 20cm 4.6 
mm column was used. 
The flow was regulated at 1.0 ml/min, and the wavelength of the 
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detector at 254 nm. The mobile phase was composed by acetonitrile (A) and water + 
0.1 % of TFA (B); the following linear gradient was used: 
t=0min, A%= 10, B% = 90; t= 10 min, A%= 30, B%= 70; t= 20 min, A% = 50, 
B%=50. 
Semi preparative HPLC chromatograms were performed on a Varian liquid 
chromatography system. The components include a Varian 9010 Solvent Delivery 
System, a Varian 9065 Polychrom, and a PC station. A semi-preparative Dynamax-60A 
C18 reversed phase column was used. The flow was fixed atlO ml/min and the 
wavelength of the UV-detector was regulated at 254 nm. The mobile phase was 
composed by acetonitrile (A) and purite water + 0.1% of TFA (B); the following linear 
gradient was used: t=0 min, A% = 10, B% = 90; t= 10 min, A% = 30, B% = 70; t= 20 
min, A%= 50, B%=50. 
5.1.3. Characterisation and measurements 
'H and 13C spectra were recorded using a Bruker AC 250 spectrometer operating at 
250.13 and 62.9 MHz respectively, Varian Gemini 200 operating at 200 and 50 MHz 
respectively, Varian VXR operating at 200 MHz or a Varian VXR 400 operating at 
399.96 and 100.58 respectively. Variable temperature 'H NMR studies were performed 
on a Varian VXR 400, a JEOL EX-90 and a JEOL EX-400 instrument. Signals are 
reported in ppm to higher frequency of TMS, indicating the relative integral, the 
multiplicity (s singlet, d doublet, t triplet, q quadruplet, m multiplet), and the coupling 
constants J (Hz). 
The longitudinal water proton relaxation rates were measured either using a Stelar 
Spinnraster spectrometer (Mede, Pavia, Italy) operating at 0.5 T, or a modified Varian 
VXR instrument tuned to 65.6 MHz, by means of the standard inversion-recovery 
technique (16 experiments, 2 scans). A typical 90° pulse width was 3.5 µs and the 
reproducibility of the T1 data was ± 0.5%. The temperature was controlled with a Stelar 
VTC-91 air-flow heater equipped with a copper constant thermocouple (uncertainty of ± 
0.1 °C). The concentration of the complex was typically 0.1-0.4 mM. It was measured 
accurately by digesting the complex in HNO3 5M for a period of time between few 
hours and few days. The relaxation rate of the digested solution was measured and the 
concentration calculated 
from the equations 2.5-2.7 in Chapter Two (Rid = 0.40 s"1; rip 
(Gd3+) = 12.66 mWs 
1. 
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The proton 1/Ti NMRD profiles were measured on the Koenig-Brown field- 
cycling relaxometer over a continuum of magnetic field strength from 0.00024 to 1.2 T 
(corresponding to 0.01-50 MHz proton Larmor frequency). The relaxometer works 
under computer control with an absolute uncertainty in 1 /Tl oft 1%. 
Variable temperature 170 NMR measurements were recorded on a JEOL EX-90 
(2.1 T) spectrometer equipped with a5 mm probe, by using a D20 external lock. 
Solution containing 2.6% of 170 isotope (Yeda, Israel) were used. The observed 
transverse relaxation rates were calculated from the signal width at half-height. 
Electrospray mass spectra were acquired using a VG Platform (II) instrument, 
with water, methanol or acetonitrile as a carrier solvent, typically with a cone voltage of 
60 V and a source temperature of 110 °C. Accurate masses were determined at the 
EPSRC National MS Service at Swansea. 
Infrared spectra were recorded on a Perkin-Elmer 1600 FT spectrometer using 
GRAMS-Analyst softwere; the solids were incorporated into KBr disks. 
Melting points were determined on a Reichert Kofler Block. 
Elemental analyses were determined on a Carlo Erba 1106. The calculated 
percentages are indicated between brackets. 
Luminescence pH titration were carried out in a background of constant ionic 
strength (I = 0.1 NaCl, 295 K) or in an anionic background. Solution were made basic 
by addition of IM NaOH and titrated to acidic pH using small aliquots (typically 0.5 
µL) of 1M or 0.1 M HCI. Excitation wavelengths of 397 nm were used to obtain 
emission spectra. Excitation and emission slits were 2-5 and I nm band-pass, 
respectively. Points were recorded at lnm intervals with a 0.25 s integration time. The 
pH was measured with a Jenway 3320 pH meter calibrated with pH 4,7 and 10 buffer 
solution. 
Excited state lifetime measurements for europium complexes were made on the 
Instrument SA Fluorolog. Lifetimes were measured by excitation of the sample by a 
short pulse of light (397 nm) followed by monitoring the integrated intensity of light 
(594 or 619 nm) emitted during a fixed gate time or delay time. The obtained decay 
curves were fitted to a simple mono-exponential decay curve using Microsoft Excel. 
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5.2. Chapter Two experimental 
5.2.1.1,4,7-Tris-([4'methoxycarbonyl]-1 'methoxycarboylbutyl)-1,4,7,10- 
tetraazacyclododecane (24) 
1,4,7,10 Tetraazacyclododecane (cyclen) (22) (1.37 g; 7.95 mmol), sodium hydrogen 
carbonate (2.0 g; 23.8 mmol) and few 4A molecular sieves were suspended in dry 
acetonitrile (15 ml). A solution of dimethyl a-bromo adipate (23) (6.03 g; 23.84 mmol) 
in acetonitrile (5 ml) was slowly added over one hour under argon. At the end of the 
addition the temperature was raised to 75 
°C and the suspension was stirred under argon 
for 48 hours. The mixture was then cooled, filtered and the solvent removed under 
reduced pressure. The dark oil was taken up in DCM (25ml) and washed with water 
(5x25 ml). The organic layer was recovered, dried over potassium carbonate and 
evaporated to yield a pale yellow oil (5.60 g). It was purified by column 
chromatography over silica, eluting first with DCM/THF 7: 3 (v/v) and then adding 3% 
of methanol and 0.5% of ammonia solution. A pale brown oil was obtained (1.62 g; 
30%). 
Rf= 0.34 (Si02; THF: DCM: MeOH: NH3 6: 3: 0.5: 0.5). 
ESMS (+) m/z = 689 (M+H)+ 
'H NMR (CDC13; 300 MHz; 8): 1.60-1.85 (18H, br, CH2); 2.35-2.60 (16H, br, NCH2); 
2.60-3.24 (3H, br, CH); 3.65-3.75 (18H, s, CO2CH3). 
13C NMR (CDC13; 200 MHz; 8): 173.5,170.9 (C02), 63.5,59.0,51.5,51.3,51.0,46.2, 
33.2,30.0,21.0 (br, aliphatic Q. 
IR (thin film) vmax(cm ): 2919,2850,1729 (CO stretching); 1460; 1266; 1178; 918; 
825. 
5.2.2.1,4,7-Tris-(4'carboxy-1 'carboxybutyl)-1,4,7,10-tetraazacyclododecane (8) 
The hexaester (24) (0.52 g; 0.75 mmol) was suspended in a 1M lithium hydroxide 
solution (30 ml). 
The suspension was heated at 80 °C for 18 hours. The solution was 
concentrated to about 
5 ml and then passed through a strong cationic exchange resin 
(Dowex 50 W) eluting with 12% ammonia solution. The fractions were collected and 
the solvents removed under reduced pressure to yield the ammonium salt as a colourless 
solid (0.33 g; 73%). 
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ESMS (-) m/z = 301 (M-2H)2", 603 (M-H)', 640 (M-Cl)". 
1H NMR (D20; 200 MHz; S): 1.47-2.74 (34H, br, cyclen ring, CH2); 3.02 (1H, m, CH); 
3.17 (2H, m, CH). 
5.2.3. (1,4,7-Tris-(4'carboxy-1 'carboxybutyl)-1,4,7,10-tetraazacyclododecane) 
Gadolinium (27) 
To the ligand (8) (49 mg; 81 µmol) a solution of gadolinium (III) chloride hexahydrate 
(30 mg; 81 µmol) in a mixture of water-methanol (2m1; 1: 1 v/v) was added. A milky 
suspension was obtained. The pH was adjusted to 5.5. The mixture was heated at 90 °C 
for 18 hours. The solid in suspension was filtered off, washed with methanol and dried. 
It was then dissolved in water and the pH was raised to 10.0 by adding a 1M sodium 
hydroxide solution. The colloidal gadolinium hydroxide, which formed was removed by 
filtration through a membrane filter. The solution was neutralised and passed through a 
weakly acidic cationic exchange resin (Amberlite IR-50), eluting with water. The 
fractions were recovered and freeze-dried to yield a colourless solid (33 mg; 53%). 
ESMS (-) m/z = 378 (M-2H)2-, 756 (M-H)". 
Elemental Analysis: C26H41N4O12Gd"3H20: C%: 38.53 (38.50); H% 5.26 (5.79); N% 
6.89 (6.96). 
IR (KBr disc) vmax(cm 1): 3448 (OH), 2935,2875,1720 (CO stretching); 1590,1530, 
1483,1450,1410,1390,1210,1070,977,780. 
5.2.4. (1,4,7-Tris-(4'carboxy-1 'carboxybutyl)-1,4,7,10- 
tetraazacyclododecane)Europium (III) (26). 
To the ligand (8) (15 mg; 25 µmol) a solution of europium (III) chloride hexahydrate (9 
mg; 25 pmol) in a mixture of water-methanol (2m1; 1: 1 v/v) was added. The pH was 
adjusted to 5.5. The suspension was heated at 90 
°C for 18 hours. The solid in 
suspension was filtered off, washed with methanol and dried. It was then dissolved in 
water and the pH was raised to 
10.0 by adding IM sodium hydroxide solution. The 
colloidal europium 
hydroxide formed was removed by filtration through a membrane 
filter. The solution was neutralised and passed through a weakly acidic cationic 
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exchange resin (Amberlite IR-50), eluting with water. The fractions were recovered and 
then freeze-dried to yield a colourless solid (13 mg; 69% 
ESMS (-) m/z = 375 (M-2H) 2', 752 (M-H)'. 
Elemental Analysis: C26H41N4O12Eu"3H2O: C% 38.32 (38.6); H% 5.14 (5.82); N% 6.68 
(6.93). 
'H NMR (D20; pD 6.0; 200 MHz; 8), (as mixture of diastereoisomers): 46.02 (1H, br s, 
H. ), 38.23 (IH, br s, Ham), 28.01 (IH, br s, Ha, ), 21.32 (IH, br s, Hax), 19.91 (IH, br s, 
H. ), 16.16 (1H, br s, H. ), -2.93, -3.57, -4.10, -5.52, -6.06, -10.99, -19.82, -23.12. 
IR (KBr disc) vmax(cm 1): 3445 (OH), 2984,2925,1689 (CO stretching); 1598,1535, 
1410,1315,1223,1076,983,880. 
5.2.5. (1,4,7-Tris-(4'carboxy-1 'carboxybutyl)-1,4,7,10- 
tetraazacyclododecane)Gadolinium (III) - triamide (29) 
The gadolinium complex (27) (15 mg; 20 µmol) and the amine (28) (66 mg; 60 µmol) 
were dissolved in a mixture of water/dioxane 6: 4 (v/v), then EDC (15 mg; 79 µmol) and 
HOBt (1 mg; 9 µmol) were added. The pH was adjusted to 6.0 and the solution was 
stirred at room temperature for 24 hours. The mixture was transferred into a flask 
containing EtOH (50 ml) and the white solid obtained was recovered, washed with more 
ethanol and dried. The crude was purified by size exclusion chromatography (Sephadex 
G-25) eluting with water. The fractions were collected and freeze-dried to yield a 
colourless solid (35 mg; 42%). 
Relaxivity (65 MHz, 293 K, in H2O pH = 7.20) = 27.7 mM'ts't. 
5.2.6. (1,4,7,10-Tetrakis-(4'carboxy-1 'carboxybutyl)-1,4,7,10- 
tetraazacyclododecane)Gadolinium (III) - tetraamide (31) 
The gadolinium complex (30) (10 mg; 11 µmol) was dissolveld in DMSO (0.5 ml) and 
NHS (8 mg; 67 pmol) was added. The solution was stirred at 50 °C for three hours. The 
solution was then cooled and 
EDC (13 mg; 67 µmol) was added. The solution was 
stirred overnight at room temperature. 
The amine (28) (50 mg; 44 µmol) was then added 
and the mixture stirred at room 
temperature for 24 hours. The mixture was transferred 
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into a flask containing EtOH (50 ml) and the white solid which formed was recovered, 
washed with more ethanol and dried under vacuum. 
Relaxivity (65 MHz, 293 K, in H2O pH = 7.20) = 23.4 mM"s 1. 
5.3. Chapter Three experimental 
5.3.1. a-Monobenzyl-N-(4-[2-amino-4-oxo-3,4-dihydro pteridin-6 ylmethyl)-amino)- 
benzoyl}glutamate (32a) (Method A) 
Folic acid dihydrate (3.00 g, 6.29 mmol) (5) was slowly dissolved in anhydrous DMSO 
(150 ml). Caesium carbonate (2.05 g, 6.29 mmol) was added, and after the complete 
dissolution of the inorganic salt, a solution of benzyl bromide (1.18 g, 6.90 mmol) in 
DMSO (10 ml) was added drop by drop over thirty minutes. The mixture was stirred at 
25 °C for 48 hours, under argon, in the dark. At the end of this period the mixture was 
transferred into a flask containing acetonitrile (200 ml) in order to precipitate the 
products. A yellow solid was obtained; it was separated from the liquid phase by 
centrifugation and washed with ethyl acetate (3x20 ml). The crude product was purified 
by column chromatography over silica gel, using isopropanol-chloroform-water- 
diisopropylamine (60-20-10-10) as eluent. The yellow solid obtained (mixture a-y 4: 1) 
was washed with dilute hydrochloric acid, and then with ethyl acetate (3x20m1), to yield 
a yellow solid (1.10 g; 33.0%). 
Analytical HPLC: tr = 21.1 min (a-monoester) and 22.1 min (y-monoester) (ratio 4: 1). 
ESMS (-) m/z = 530 (M), 552 (M+Na)+. 
1H NMR (d6DMSO, 300 MHz; S)*: 1.96 (1H, m, Hp1); 2.01(1H, m, H02); 2.28 (2H, t, 
, 
); 5.09 (2H, s, a-OCH2); 6.63 (2H, d, Hbb'); 6.93 1ir), 4.35 (1H, in, Ha); 4.46(2H, d, He 
(1H, t, Hd); 7.32 (5H, cm, CHF; 7.62 (2H, d, Hcc"); 8.28 (1H, d, Ha); 9.13 (1H, S, Hf); 
10.01 (1H, s, Hh). 
`Spectrum of the pure a-benzyl ester obtained by semi-preparative HPLC. See Figure 
5.1 for labels. 
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5.3.2. y-Monobenzyl-N-(4-[2-amino-4-oxo-3,4-dihydro pteridin-6 ylmethyl)-amino)- 
benzoyl)-glutamate (32b) (Method B) 
The reaction was carried out adapting the same conditions used by Albert. ' 
Folic acid (5) (1.43 g, 3.00 mmol) and anhydrous sodium sulphate (0.40 g) were 
suspended in benzyl alcohol (5.6 ml, 54.0 mmol). Then under argon, in the dark, 
tetrafluoroboric acid diethyl etherate complex 85% (0.6 ml, 4.0 mmol) was added using 
a syringe and the mixture was stirred at room temperature for 48 hours in the dark. The 
mixture was diluted with THE (20 ml) and triethylamine (1 ml) was added. The solvent 
was removed under vacuum, until a yellow slurry was obtained. It was suspended in 
water (50 ml) and then filtered on a Buchner funnel. The yellow solid was washed with 
ethyl acetate (3x50 ml), and dried under reduced pressure. The crude product was 
purified by chromatography column over silica gel, using isopropanol-chloroform- 
water-diisopropylamine (60-20-10-10) as eluent. A mixture of a-y esters (ratio 1: 2) was 
obtained. 
Analytical HPLC: tr= 21.1 min (a-monoester) and 22.1 min (y-monoester) (ratio 1: 2). 
ESMS (+) m/z = 530 (M), 552 (M+Na). 
1H NMR (d6DMSO, 300 MHz; S)`: 1.96 (1H, m, Hp1); 2.01(1H, m, H02); 2.28 (2H, t, 
Hy); 4.04 (1H, m, Ham, ); 4.46 (2H, d, He); 5.04 (2H, s, y-OCH2); 6.63 (2H, d, Hbb'); 6.93 
(IH, t Hd); 7.32 (5H, cm, CH2 h); 7.62 (2H, d, H., ); 8.28 (IH, d, Ha); 9.13 (IH, s, Hf); 
10.01 (1H, s, Hh). 
`Spectrum of the y-benzyl ester purified by semi preparative HPLC. See Figure 5.1 for 
labels. 
5.3.3. Dimethyl N-(4-[2-amino-4-oxo-3,4-dihydro pteridin-6 ylmethyl)-amino)- 
benzoyl)-glutamate (35c) 
Folic acid dihydrate (3.30 g; 6.92 mmol) was suspended in dry methanol (200 ml) and 
under stirring concentrated 
hydrochloric acid (0.1 ml) was added. The suspension was 
refluxed for two hours. 
In order to precipited the solid, ethyl acetate (300 ml) was 
added. The resulting yellow compound was treated with more ethyl acetate and 
dried to 
yield a yellow powder 
(3.57 g; 99%). 
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'H NMR (d6DMSO; 300 MHz; 8)': 2.02 (2H, m, Hap, ); 2.41 (2H, t, H7); 3.57 (3H, s, y- 
OCH3); 3.61 (3H, s, a-OCH3); 4.39 (1H, m, Ha); 4.50 (2H, d, He); 6.65 (2H, d, H, "); 
7.01 (1 H, t, Hd); 7.65 (2H, d, Hbb'); 8.24 (1 H, d, Ha); 8.67 (1 H, s, Hf). 
ESMS (-) : m/z = 468 (M-H)'. 
Analytical HPLC : tr = 13.2 min. 
Elemental analyses C21HBN7O6 -1/2 H2O: C%: 52.47 (52.72); H%: 5.04 (5.05); N%: 
19.30 (20.50). 
Mp: > 250 °C. 
*See Figure 5.1 for labels. 
5.3.4. y-Monomethyl N-(4-[2-amino-4-oxo-3,4-dihydro pteridin-6 ylmethyl)-amino)- 
benzoyl)-glutamate (34b) 
The dimethyl ester (33b) (200 mg; 0.43 mmol) was slowly dissolved in a mixture of 
phosphate buffer at pH=7.0 and DMSO in ratio 8: 2 (v/v; 30 ml). The temperature was 
maintained at 37 °C and the enzyme protease (from Rhizopus species Type XVIII 
Fungal -SIGMA) (400 mg) was added and the suspension was stirred for four days at 37 
°C in the dark. At the end of this period the reaction was stopped, the enzyme and the 
unreacted diester in suspension were removed by centrifugation. The dark yellow 
solution was transferred into a flask and acetonitrile (200m1) was added. The solid 
obtained was recovered, washed with more acetonitrile and dried. Then it was 
suspended in water (5m1) and the pH was lowered to about 3.0 adding diluted 
hydrochloric acid. A solid formed which was recovered by centrifugation, washed with 
acetonitrile and dried to yield a yellow solid (125 mg; 64%). 
lH NMR (d6DMSO; 300 MHz; ö)*: 2.02 (2H, m, Hßß, ); 2.41 (2H, t, H1); 3.57 (3H, s, y- 
OCH3); 4.39 (1H, 4.50 (2H, d, He); 6.65 (2H, d, Hc, "); 7.01 (1H, t, Hd); 7.65 
(2H, d, Hbb'); 8.24 (1 H, d, Ha); 8.67 (1 H, s, Hf). 
ESMS (-): m/z = 454 (M-H)'. 
Analytical HPLC: t1 = 11.8 min. 
[2= +14.6 (c = 0.396 g/100m1 in NaOH 0.02M). 2 
Mp: > 250 °C. 
'See Figure 5.1 for labels. 
124 
COOH 
ü 
Nß 
Ha 
Y 
COOH 
Figure S. 1- Labels of the protons of folic acid 
5.4. Chapter Four experimental 
5.4.1. Synthesis of [Ln "9] 
5.4.1.1. N-t-butoxycarbonyl-1,4-diaminobutane (40) 
Commercially available 1,4-diaminobutane (10.0 g, 113 mmol) was dissolved in 
dioxane (60 ml) under argon. Then a solution of (BOC)20 (12.0 g, 55.0 mmol) in 
dioxane (25 ml) was slowly added over two hours. At the end of the addition the 
solution was stirred for one hour at room temperature. Then the solution was 
concentrated to 50 ml, and water (90 ml) was added to precipitate any N, N bis-t-Boc- 
1,4-diaminobutane. The solid was filtered, and the dioxane was removed under reduced 
pressure. The aqueous solution was saturated with sodium chloride, extracted with ethyl 
acetate (5 x 20 ml) and the organic solvent removed under reduced pressure to give an 
oil. This was taken up into water, acidified to pH=3 with hydrochloric acid, washed 
with ethyl acetate and the saturated with sodium chloride. The pH was raised to 14 with 
potassium hydroxide and the aqueous layer extracted with ethyl acetate (5x20 ml). The 
fractions were combined, dried over potassium carbonate and the solvent removed to 
yield a pale yellow oil (4.32 g; 20%), which was used directly. 
'H NMR (CDC13; 300 MHz; 8): 1.19 (2H, t, NH2); 1.38 (9H, s, (CH3)3); 1.42 (4H, m, 
CH CH2NH2); 2.65 (2H, t, CHZNH2); 3.05 (2H, dt, CHhNH); 4.35 (1H, br. s, NH). 
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5.4.1.2. N-(N-t-butoxycarbonyl-1,4-diaminobutyl)-2-chloro acetoamide (38) 
Commercially available chloroacetic acid (1.47 g; 15.5 mmol) was dissolved in DCM 
(70 ml), then HOBt (2.52 g; 18.6 mmol) and EDC (3.57 g; 18.6 mmol) were added and 
the solution was stirred at room temperature for two hours. After this period a solution 
of N-t-butoxycarbonyl-1,4-diaminobutane (40) (2.93 g; 15.5 mmol) in DCM (20 ml) 
was added dropwise over thirty minutes, followed by the addition of triethylamine (0.1 
ml). The mixture was stirred at room temperature for 18 hours, concentrated to a small 
volume and water (40 ml) was added. The white solid which formed was filtered off, 
whereas the emulsion was transferred into a separatory funnel. The organic phase was 
recovered, washed with water (4x40ml), dried over potassium carbonate, the solvent 
was evaporated under reduced pressure, to yield a colourless solid (3.28 g; 80%). 
1H NMR (CDC13; 300 MHz; 8): 1.45 (9H, s, (CH3)3); 1.55 (4H, m, (CH2CH2); 3.19 (2H, 
m, (CHZ)NH`Boc); 3.34 (2H, m, CH; NH000H2C1); 4.05 (2H, s, CH2C1); 4.60 (1H, 
br. s, NHtBoc); 6.62 (1H, br. s, NHCOCH2C1). 
Rf= 0.76 (Si02; DCM: MeOH 9: 1). 
Elemental analysis C11H21N203C1: C%: 50.09 (49.90); H%: 8.14 (7.99); N%: 10.54 
(10.58). 
IR (KBr disc) v,,. (cm 1): 3377,3331 (CONH; NH stretching); 3307,2980,2941,2914 
(CH2 stretching); 1683,1645 (COOC(CH3)3 stretching CO); 1544,1526 (CONH 
stretching CO); 1366 (C(CH3)3 stretching); 754 (C-Q. 
Mp : 72-74 °C. 
5.4.1.3.1,4,7-Tris(tert-butoxycarbonylmethyl)-1 D-[N-(4-t- 
butoxycarbonylaminobutyl)carbamoyl]-1,4,7,1 0-tetraazacyclododecane (37) 
The triester (36) (1.20 g; 2.33 mmol), caesium carbonate (1.67 g; 5.13 mmol), 
potassium iodide (0.77 g; 
4.66 mmol) and a few 4A molecular sieves, were suspended 
in dry acetonitrile (50 ml). Then a solution of (38) (1.20 g; 4.66 mmol) in acetonitrile 
(50 ml) was added by cannula transfer. The mixture was stirred at 80 
°C under argon for 
18 hours. After cooling and filtering, the solvent was removed under reduced pressure 
to yield a colourless solid (2.70 g). 
The material was purified by chromatography 
column (Si02; 
THF: DCM: MeOH: NH3 6: 3: 0.5: 0.5) to yield a colourless solid (1.32 g; 
76%). 
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Rf= 0.45 (Si02; THF: DCM: MeOH: NH3 6: 3: 0.5: 0.5). 
ESMS (+) m/z = 765 (M+Na)+. 
Elemental analysis: C37H7oN6O9"H2O: C%: 58.62 (58.40); H%: 9.20 (9.47); N%: 10.32 
(11.00). 
1H NMR (CDC13; 200 MHz; S)`: 1.44 (27H, s, `Bu); 1.53 (4H, m, Hd, c); 1.64 (9H, s, 
tBoc); 2.03-2.96 (cyclen ring); 3.01 (2H, m, Hc); 3.21 (2H, m, H f); 3.42 (2H, s, Hh). 
; See Figure 5.2 for labels. 
Figure 5.2 - Labels of the protons of (37). 
5.4.1.4.1,4,7-Tris(carboxymethyl)-10-[N-aminobutylcarbamoyl]-1,4,7,10- 
tetraazacyclododecane (9) 
The triester (37) (1.32 g; 1.78 mmol) was dissolved in DCM (15 ml), then TFA (2.7 ml; 
35.6 mmol) was added dropwise using a syringe. The solution was stirred at room 
temperature for 18 hours. Solvent and the excess TFA were removed under reduced 
pressure to give a pale yellow oil, which was taken up in DCM (20 ml) and dried. This 
operation was repeated three times. The oil was taken up in water (20 ml) and washed 
with DCM (4x20 ml). The aqueous phase was recovered and the water removed under 
reduced pressure to yield a pale yellow oil (1.50 g; 95%). 
Rf = 0.23 (Si02; THF: DCM: MeOH: NH3 6: 3: 0.5: 0.5). 
ESMS (+) m/z = 238 (M+2H)2+, 475 (M+H)+. 
HR-ESMS (+) (m/z): (M+H) calcd for C20H38N607 475.2880; found 475.2874. 
1H NMR (D20; 200 MHz; S)`: 1.31 (2H, m, Hd); 1.43 (2H, m, He); 2.12-3.01 (cyclen 
ring); 3.02 (2H, m, He); 3.30 (2H, m, Hf); 3.54 (2H, s, Hh). 
IR (thin film) vmax(cm''): 3392,3116 (NH2 and OH stretching); 1681,1445,1204 (CO 
stretching); 1586 (CONH); 1323; 1136; 1083; 949; 841; 722. 
*See Figure 5.2 for labels. 
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5.4.1.5. (1,4,7-Tris(carboxymethyl)-1 D-[N-(4-aminobutyl)carbamoyl]-1,4,7,10- 
tetraazacyclododecane)-Gadolinium [Gd9J 
The amino acid (9) (1.67 g; 1.88 mmol) was dissolved in water (30 ml), and gadolinium 
(III) chloride (0.42 g; 1.13 mmol) was added. The pH was monitored and it was lowered 
to about 3.0 adding 1M hydrochloric acid solution. The suspension was boiled under 
reflux for 24 hours. The hot solution was cooled and filtered, then the water was 
removed under reduced pressure to yield a colourless solid, which was passed through a 
strong anionic exchange resin, using purite water as eluent (1.20 g; 89%). 
Rf = 0.23 (Alumina; DCM: MeOH 8: 2). 
ESMS (+) m/z = 630 (M+H)+. 
Elemental analysis C20H35N607Gd"2H20: C%: 36.07 (36.14); H%: 6.04 (5.94); N%: 
14.31 (12.8). 
Mp: > 250 °C. 
IR (KBr disc) vmax (cm'): -3400; 3115 (broad band; H2O bound; NH2 stretching); 
2937,2868 (CH stretching); 1681,1446,1203 (C=0 stretching), 1586 (CONH), 1323; 
1293; 1136; 1083; 949; 841; 800. 
5.4.1.6. (1,4,7-Tris(carboxymethyl)-10-[N-(4-aminobutyl)carbamoylJ-1,4,7,10- 
tetraazacyclododecane)-Europium (III) JEu9J 
The amino acid (9) (50 mg; 56 gmol) was dissolved in water (3 ml), and europium (III) 
chloride hexahydrate (12 mg; 34 µmol) was added. The pH was monitored and it was 
lowered to about 3.0 adding 1M hydrochloric acid solution. The suspension was boiled 
under reflux for 24 hours. The hot solution was cooled and filtered, then the water was 
removed under reduced pressure to yield a colourless solid, which was passed through a 
strong anionic exchange resin, using purite water as eluent (28 mg; 80%). 
Rf= 0.20 (Alumina; DCM: MeOH 8: 2). 
ESMS (+) m/z = 625 (M+H)+. 
Elemental analysis: C20H35N607Eu"2H20: C%: 35.92 (36.3); H%: 5.89 (5.92); N%: 
14.31 (12.74). 
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1H NMR (D20; pD = 6.0; 200 MHz; 5), partial assignement: 34.23; 33.21; 32.56; 31.46 
(4H, s, Ham); -0.68; -2.02; -2.89; -4.02 (4H, s, Hey ); -5.64; -6.20; -6.94; -7.52 (4H, s, 
Heq); -11.21; -12.52; -15.39; -16.42 (4H, s, H , ). 
5.4.2. Synthesis of[Gd"9]-yfolate conjugate 
5.4.2.1. Coupling (1,4,7-Tris(carboxymethyl)-10-[N-(4-aminobutyl)carbamoylJ- 
1,4,7,10-tetraazacyclododecane}gadolinium (III) to a-benzyl-N-'Boc glutamate; 
synthesis of (42) 
The gadolinium complex [Gd"9] (1.20 g; 1.67 mmol) was dissolved in a mixture of 
water/dioxane 1: 1 (v/v; 100 ml). To the stirred solution a-benzyl-N tBoc glutamate 
ester (35a) (0.55g; 1.64 mmol) was added. The pH was raised to 6.0 adding a 0.1 M 
NaOH solution. Then under stirring, EDC (0.52g; 2.71 mmol) and HOBt (24mg; 0.18 
mmol) were added. The solution was stirred at room temperature for 20 hours. Solvents 
were removed under reduced pressure to yield a yellow oil which was purified by 
chromatography over alumina using DCM/MeOH 8: 2 as eluent (1.20 g; 76%). 
Rf=0.30 (Alumina; DCM: MeOH 8: 2). 
ESMS (+) m/z = 971 (M+Na)+, 497 (M+2Na)+, 475 (M+2H)+. 
Analytical HPLC: tt = 16.5 min. 
IR (KBr disc) vm. (cm 1): -3400 (broad band; H2O bound); 2870,2740, (CH2 
straching), 1680 (C=O stretching). 
5.4.2.2. Synthesis of (43) 
The gadolinium complex (42) (0.80 g; 0.84 mmol) was dissolved in a 96% TFA 
solution in water (10 ml). The solution was stirred for fifteen minutes at room 
temperature. Solvents were removed under reduced pressure to give an oil, which was 
taken up in DCM (10 ml) and dried under reduced pressure. This operation was 
repeated three times with 
DCM and three times with diethyl ether. The oil was 
dissolved in water (20 ml) and the solution was washed with diethyl ether (3x20 ml). 
The aqueous phase was concentered and passed through a strong anionic exchange 
resin. The fractions were recovered and 
freeze-dried to yield a colourless solid (0.81 g). 
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ESMS (+) m/z = 425 (M+2H)+, 447 (M+2Na)+, 849 (M+H)+, 871 (M+Na)+. 
Analytical HPLC: t1 =10.1 min. 
5.4.2.3. Coupling of the complex (43) to Pteroic Acid (44). Synthesis of (45a). 
Pteroic acid (44) (100 mg; 0.32 mmol) was slowly dissolved in DMSO (50 ml), then 
EDC (68 mg; 0.35 mmol) and HOBt (4 mg) were added. The mixture was stirred in the 
dark for three hours at 25 °C, then a solution of the complex (43) (322 mg; 0.38 mmol) 
in DMSO (5 ml) was added by cannula transfer and 3-4 drops of triethylamine by 
syringe. The mixture was stirred at 25 
°C for 48 hours; then the yellow solution was 
transferred into a flask containing acetonitrile (250 ml). The yellow solid obtained was 
separated from the liquid by centrifugation, washed with acetonitrile (3x20 ml) and 
dried to yield a yellow solid (250 mg), which was used directly in the next step. 
Unreacted pteroic acid coprecipitated with the product (43) and it was removed in the 
next step. 
ESMS (-) m/z = 311 (Pteroic acid), 570 (M-2H)2", 1141 (M-H)'. 
Analytical HPLC: t, = 8.8 min (Pteroic acid); 13.8 min (43). 
5.4.2.4. Synthesis of (45b) 
The conjugate complex (45a) (250 mg; 0.22 mmol) was dissolved in DMSO (20m1). 
Then palladium hydroxide over carbon (250 mg) and hydrazine (0.5 ml) were added. 
The mixture was stirred in the dark at room temperature for 40 hours. The catalyst was 
filtered over celite; the solvent and the excess hydrazine were removed under reduced 
pressure to yield a yellow solid. The crude was purified over silica, eluting with iso- 
propanol: 3.5% ammonia solution (7: 3; v/v). 
Rf= 0.48 (Si02i iso-propanol: NH3 3.5%). 
ESMS (-) m/z =1050 (M-H)"; 525 (M-2H)2". 
Analytical HPLC: tr = 6.8 min. 
Elemental Analysis: C39H52N13O12Gd-3H2O: C%: 42.12 (42.33), H%: 4.81 (5.24), N%: 
16.32 (16.5). 
Mp: > 250 °C. 
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5.4.3 Synthesis of the [Gd"9]-a folate conjugate 
5.4.3.1. Coupling offolic acid y-methyl ester to [Gd"9] 
The y methyl ester (34b) (150 mg; 0.33 mmol) was dissolved in dry DMSO (4ml), then 
NHS (57 mg; 0.49 mmol) was added and the mixture was stirred for thirty minutes at 
50°C. After cooling, EDC (94 mg; 0.49 mmol) was added and the solution was stirred 
for three hours at room temperature. At the end of this period the gadolinium complex 
[Gd"9] (186 mg; 0.29 mmol) was added together with three drops of triethyamine; the 
solution was stirred at room temperature for 48 hours. The yellow solution was then 
transferred into a flask containing ethyl acetate (100 ml), in order to precipitate the 
crude compound. The solid was recovered by centrifugation, washed with ethyl acetate 
(3x20m1) and dried to yield a pale yellow solid (480 mg), which was purified by 
chromatography column over silica, using iso-propanol: ammonia 3.5% (7: 3; v/v). The 
pure compound was obtained as a yellow solid (105 mg; 33%). 
Rf= 0.35 (Si02; iso-propanol: NH3 3.5% 8: 2). 
ESMS (-): m/z = 531 (M-2H)2-, 1065 (M-H)". 
Analytical HPLC: tr = 9.3 min. 
Mp: > 250 °C 
5.4.3.2. Hydrolysis of (46a). 
The gadolinium complex (46a) (100 mg; 94 µmol) was dissolved in a 0.02M NaOH 
solution (5 ml) and stirred for 24 hours at room temperature. The solution was then 
neutralized by adding diluted hydrochloric acid and the water solution was removed 
under reduced pressure to yield a crystalline yellow solid (96 mg; 97%). 
ESMS (-): m/z = 524 (M-H)2,1051 (M-H)-. 
Analytical HPLC: 6.2 min 
Elemental Analysis: C39H52N13O12Gd"2H20: C%: 41.89 (42.3), H%: 4.76 (5.24), N%: 
15.98 (16.42). 
Mp: > 250 °C. 
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5.4.4. Synthesis of -[Gd 9]2-c4 y folate (47) 
Folic acid dihydrate (5) (20 mg; 0.042 mmol) and NHS (14 mg; 0.13 mmol) were 
dissolved in dry DMSO (lml) stirring at 50 °C for thirty minutes. After cooling of the 
yellow solution EDC (24 mg; 0.13 mmol) was added and the solution was stirred for 
three hours at room temperature. At the end of this period the [Gd"9] (53 mg; 0.84 
mmol) together with one drop of triethylamine were added; the solution was stirred at 
room temperature for 48 hours. In order to precipitate the crude compound, the yellow 
solution was then transferred into a flask containing ethyl acetate (100 ml). The solid 
was recovered by centrifugation, washed with ethyl acetate (3x20m1) and dried, to yield 
a pale yellow solid (48 mg), which was purified by column chromatography over silica, 
using iso-propanol: anumonia 3.5% (7: 3; v/v). The pure compound was obtained as a 
yellow solid (22 mg; 32%). 
ESMS (-): m/z = 830 (M-211)2', 1661 (M-H)'. 
Analytical HPLC: 12.4 min. 
Elemental analysis: C59H85N19O18Gd2.3H2O C%: 40.95 (41.50); H%: 4.74 (5.33); N%: 
14.21 (15.60). 
Mp: > 250 °C. 
5.4.5. Synthesis of [Gd -6]- 
5.4.5.1. N-benzoyl-5-amino pentanoic acid (53) 
Commercially available 5-amino pentanoic acid (5.01 g; 42.8 mmol) was dissolved in 
water (50 ml) and pellets of potassium hydroxide were added to raise the pH to about 
10. A solution of benzoyl chloride (7.27 g; 51.7 mmol) in THE (10 ml) was added to the 
stirred solution. The pH was monitored and some drops of an aqueous solution of 
potassium hydroxide (1M) were added to keep the pH in the range 8-10. The mixture 
was stirred for about three hours and the pH was monitored during the whole process. 
Concentrated hydrochloric acid was added to lower the pH to about 3.0, and the 
formation of a white precipitate was observed. The white solid obtained was filtered on 
a Buchner funnel, washed three times with water and 
dried under vacuum, to yield a 
colourless solid 
(8.37 g; 88%). 
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Rf= 0.64 (Si02; DCM : THE 7: 3) 
M. p. = 105-106 °C 3 
lH NMR (CDC13; 200 MHz; 6): 1.64 (4H, m, CH2CH2); 2.34 (2H, t, CH2000H); 3.34 
(2H, m, CH2NH); 6.30 (1H, s, NH); 7.38 (2H, m, H aromatic); 7.68 (2H, d, H aromatic). 
5.4.5.2. Methyl 2-bromo-N-benzoyl-5-amino pentanoate (50) 
The a bromination was carried out using NBS, following the procedure proposed by 
Harpp and coworkers. 4 
N-Benzoyl-5-amino pentanoic acid (53) (1.32 g; 5.97 mmol) was dissolved in 
carbon tetrachloride (5 ml). Thionyl chloride (2.84 g; 23.9 mmol) was added slowly. 
The solution was stirred at 60 °C for one hour. After this period NBS (1.27 g; 7.16 
mmol) and 1-2 drops of hydrobromic acid were added. The mixture was stirred for two 
hours at 50 °C. The solvent was removed under vacuum until an orange slurry was 
obtained. This was dissolved in chloroform and washed with a solution of sodium 
thiosulphate (50 ml, 2M) in order to reduce the excess bromine. The organic layer was 
dried over magnesium sulphate and the solvent was removed under vacuum to yield a 
pale yellow oil. The methyl ester was obtained by treating the oil in dry methanol at 
room temperature for 24 hours. The solvent was removed under reduced pressure and 
the solid was purified by column chromatography over silica gel, using ethyl 
acetate/hexane (1: 1) yielding the desired ester as a colourless solid (0.67 g; 36%). 
Rf = 0.35 (Si02; Ethyl acetate: Hexane 1: 1) 
M. p. = 60-61 °C 3 
1H NMR (CDCI3; 200 MHz; S): 1.74 (2H, m, CH, CHBr); 2.04 (2H, m, CH2CH2NH); 
3.44 (2H, m, ff NH), 3.75 (3H, s, OCH3), 4.21 (1H, dd, CHBr), 6,43 (1H, s, NH); 7.44 
(3H, m, H aromatic); 7.72 (2H, d, H aromatic). 
13C NMR (CDC13; 200 MHz; S): 26.35 C(CH CH2CHBr); 32.36 (CH2CHBr); 39.31 
(cHzNH), 53.22 (OCH3), 57.04 (CHBr); 127.24-134.64 (C aromatic); 168.18 (COPh); 
170.41 (OOCH3). 
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5.4.5.3.1,4,7-Tris-([3'methoxycarbonylJ-]'methoxycarbonylpropyl]-1,4,7,10- 
tetraazacyclododecane (49) 
1,4,7,10 Tetraazacyclododecane (cyclen) (22) (0.80 g; 4.6 mmol) and sodium hydrogen 
carbonate (1.18 g; 14.0 mmol) were suspended in acetonitrile (5 ml) together with a few 
4A molecular sieves. A solution of dimethyl a-bromoglutarate (48) (3.08 g; 12.9 
mmol), in acetonitrile (10 ml) was added by cannula transfer under argon and the 
mixture was stirred at 70 °C for three days. After this period the mixture was filtered 
and the solvent was removed under reduced pressure. The residue was taken up in DCM 
(20 ml) and washed with hydrochloric acid (pH=3). The organic layer was dried over 
potassium carbonate and the solvent removed. The residue yellow oil was purified by 
column chromatography, over silica gel. The column was washed with DCM and then 
with 30% THE in DCM. The product was obtained as a pale yellow oil (0.92 g; 29%) by 
elution with 5% NH3,5% methanol, 30% THE in DCM. 
Rf =0.40 (Si02; DCM: THF: MeOH: NH3 6: 3: 0.5: 0.5). 
ESMS (+) m/z = 647 (M+H)+. 
'H NMR (CDC13; 200 MHz; 6): 1.72-3.54 (28H, m, cyclen ring and 3xCH2CH2); 3.62 
(9H, s, 2xCH2CO2CHJ; 3.66 (6H, s, CHCO2CH ); 3.70 (3H, s, CHCO CH ; 3.89 (2H, 
dd, 3JH_H=6.0 Hz, 3JH_H=4.8 Hz, 2xCH); 4.31 (1H, dd overlapping, 3JH_H=5.8 Hz, 3JH_ 
H=5.8 Hz, CH). 
IR (thin film) vmax (cm'): 3443 (NH); 2953,2848,1732,1745 (C=O stretching), 1453, 
1253,1209,1169,919. 
54" S. 4.1,4,7-Tris-([3'methoxycarbonylJ-1 'methoxycarbonylpropyl]-10- 
([3 'methoxycarbonyll-1 'butylamino-N-benzoyl)-1,4,7,10-tetraazacyclododecane 
(51) 
1,4,7-Tris-([3'methoxycarbonyl]-1'methoxycarbonylpropyl]-1,4,7,10- 
tetraazacyclododecane (49) (0.52 g; 0.81 mmol) and caesium carbonate (0.27 g; 0.81 
rnmol) were added to acetonitrile 
(10 ml) under argon, in the presence of a few 4A 
molecular sieves. A solution of methyl-2-bromo-N-benzoyl-5-amino pentanoate (50) 
(0.25 g; 0.81 mmol) in acetonitrile (5 ml), was added by cannula transfer and the 
mixture was stirred under argon at 
75 °C for three days. The residue was cooled, filtered 
and washed with 
MeCN (4x20m1). The solvent was removed under reduced pressure, 
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and the yellow oil was purified by column chromatography over silica gel. The column 
was washed with DCM 40%, THE 60% and the product was obtained by elution with 
5% NH3,5% MeOH, 30% DCM in THF. A pale yellow oil was obtained (0.60 g; 84%). 
Rc =0.54 (SiO2; DCM: THF: MeOH: NH3 6: 3: 0.5: 0.5). 
ESMS (+) = 880 (M+H)+, 902.2(M+Na)+. 
HR-ESMS (+) (m/z): (M+H) calcd for C42H65N5015 880.4555; found 880.4554. 
'H NMR (CDC13; 200 MHz; 8): 1.75-2.85 (32H, m, cyclen ring, CH, CH2CH000CH3); 
3.44 (2H, m, CHZNH), 3.60 (9H, s, CH2C02CH3); 3.62 (9H, s, CHCO2CH ); 3.75 (3H, 
s, CHCO2 CH ); 3.85 (2H, dd, 2xCH); 4.30 (1H, dd, CH); 4.35 (1H, dd, CH); 6.40 (1H, 
s, NH); 7.45 ppm (3H, m, H aromatic); 7.80 ppm (2H, d, H aromatic). 
IR (KBr disc) vmax (cm"): 2952,2846 (CH2 stretching); 1681,1437,1203 (C=O 
stretching), 1731 (CONH), 1461; 1537; 1257; 1120; 985. 
5.4.5.5.1,4,7-Tris-([3'carboxyl-]'carboxypropyl]-10-([3'carboxyl-]propylamino)- 
1,4,7,10-tetraazacyclododecane (6) 
1,4,7-Tris-([3'methoxycarboxy]-1'methoxycarbonylpropyl]-10-([3'methoxycarbonyl]- 
1'propylamino-N-benzoyl)-1,4,7,10-tetraazacyclododecane (51) (0.60 g; 0.68 mmol) 
was suspended in lithium hydroxide solution (20m1; 1M) and stirred at 100 °C for 24 
hours. The mixture was cooled, filtered and the water removed under reduced pressure. 
The solid was dissolved in water (5 ml) and passed through a Dowex 50W cationic 
exchange resin in strong acid form, eluting with 12 % ammonia solution, to yield a 
colourless solid (0.47 g; 98%). 
The solid (0.47 g; 0.66 mmol) was dissolved in hydrochloric acid (15 ml; 6M) and 
stirred at 100 
°C for 24 hours. The solution was then cooled and washed with ethyl 
acetate (4x30 ml). The aqueous phase was recovered and the pH adjusted to 7.0 by 
adding sodium hydroxide pellets. Then it was concentrated to about 5 ml and passed 
throught Dowex 50W cationic exchange resin in a strong acid form, eluting with 12% 
ammonia solution, to yield a colourless solid (0.37 g; 95%). 
1H NMR (D20; 200 MHz; S): 1.70-2.80 (32H, m, cyclen ring, CHZCH2CH000H); 3.85 
(2H, dd, 2xCH); 4.30 (IH, dd, CH); 4.35 (IH, dd, CH). 
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5.4.5.6. {1,4,7-Tris-([3'carboxyl-l 'carboxypropylJ-10-([3'carboxy]-1 propylamino)- 
1,4,7,10-teiraazacyclododecane)-gadolinium [Gd "6j 
The ligand (6) (0.34 g; 0.50 mmol) was dissolved in water (5ml), then a solution of 
gadolinium (III) chloride hexahydrate (0.19 g; 0.50 mmol) was added. The pH was 
adjusted to 5.5 and the mixture was stirred at 100 °C for 24 hours. The suspension was 
filtered and the pH was incresed to 10.0 in order to remove the free gadolinium in the 
form of its insoluble hydroxide. The solid was filtered off throught a membrane filter. 
The solution was neutralized and freeze-dried. The solid was recrystallized from slightly 
acidic aqueous solution (pH 5.0) and was isolated as a mixture of diastereoisomers (0.31 
g; 76%). 
ESMS (-) m/z = 414 (M-2H)2", 831 (M-H)', 852 (M-Cl)- 
IR (KBr disc) vmax (cm 1): -3400 (OH and NH2 stretching), 2952,2846 (CH2 
stretching); 1605,1383, (C=O stretching), 1087; 987. 
5.4.5.7. {1,4,7-Tris-([3'carboxy]-1 'carboxypropylJ-10-([3'carboxy]-1 propylamino)- 
1,4,7,10-tetraazacyciododecane)-europium (III) [Eu6f 
The ligand (6) (46 mg; 68 µmol) was dissolved in water (Iml), then a solution of 
europium (III) chloride hexahydrate (25 mg; 68 µmol) was added. The pH was adjusted 
to 5.5 and the mixture was stirred at 100 °C for 24 hours. The suspension was filtered 
and the pH was increased to 10.0, in order to remove the free europium in the form of 
its insoluble hydroxide. The solid was filtered off throught a membrane filter. The 
solution was neutralized and freeze-dried. The solid was recrystallized from slightly 
acidic aqueous solution (pH 5.0) and was isolated as a mixture of diastereoisomers (30 
mg; 54%). 
ESMS (-) m/z = 412 (M-2H)2", 825 (M-H)", 860 (M-Cl)". 
IR (KBr disc) vm (cm'): -3400 (OH and NH2 stretching), 2952,2846 (CH2 
stretching); 1605,1383, (C=O stretching), 1087; 987. 
'H NMR (D20; pD = 6.0; 200 MHz; S) partial assignment: 39.5-41.2 (s, Hax isomer 
(M)); 20.0-28.1 (s, Hax isomer (m)); 8.1,6.4, -6.0; -7.9, -9.2; -11.3, -15.1; -17.7; -26.9; - 
27.3; -28.6. 
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5.4.5.8. { 1,4,7-Tris-([3'methoxycarboxyJ-l 'carboxypropyl]-10-([3'methoxycarboxy]- 
1 propylamino)-1,4,7,10-tetraazacyclododecane)-gadolinium (III) (54) 
The gadolinium complex [Gd"6]" (80 mg; 96 µmol) was suspended in dry methanol (5 
ml), then two drops of hydrochloric acid were added. The suspension was stirred at 70 
°C for one hour. The solution was cooled and the solvent removed under reduced 
pressure to yield a colourless solid (81 mg; 96%). 
ESMS (-) m/z = 872 (M-H)'. 
Elemental analysis C31H49N5O14Gd: C%: 41.63 (42.66); H% 5.11 (5.62); N% 7.67 
(8.03). 
5.4.6. Synthesis of the [Gd. 6]"-y folate conjugate 
5.4.6.1. Coupling of the a-benryl ester of folic acid to [Gd . 61' 
The a-benzyl ester of folic acid (mix a-y ratio 4: 1) (21 mg; 40 µmol) was dissolved in 
dry DMSO (1.5 ml). The temperature was raised to 50 °C and NHS (7 mg; 59 µmol) 
was added. The solution was stirred for 3 hours, then it was cooled to 0 °C and EDC (11 
mg; 59 µmol) was added. The mixture was stirred overnight at room temperature, and 
the tri-methyl ester (54) (52 mg; 59 µmol) was added with two drops of triethylamine. 
The mixture was stirred for another 24 hours at room temperature and then the yellow 
solution was transferred into a flask containing acetonitrile (50 ml). The solid obtained 
was recovered, washed with more solvent and dried. The crude material was purified by 
column chromatography over silica gel, eluting with iso-propanol-ammonia 3.5%, 8: 2 
(v/v), to yield a yellow solid (24 mg; 44%). 
Rf= 0.56 (Si02; isopropanol: NH3 3.5% 8: 2). 
ESMS (-) m/z = 691 (M-2H)2', 1385 (M-H)'. 
Analytical HPLC: 6.3 min. 
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5.4.6.2. Hydrolysis of (56a) 
The tri-methylester (56a) (24 mg; 17 µmol) was dissolved in sodium hydroxide solution 
(10 ml; 0.02 M). The pH was adjusted to 9.0 and the solution was stirred at room 
temperature for 24 hours. The solution was neutralized and washed with DCM (3x10 
ml). The aqueous phase was recovered and freeze-dried to yield a yellow solid (19 mg; 
90%). 
Rf= 0.15 (Si02; isopropanol: NH3 3.5% 8: 2). 
ESMS (-) m/z = 626 (M-2H)2-, 1253 (M-H)-. 
Analytical HPLC: tr = 3.14 min. 
Elemental analysis: C47H60N12O19Gd"2H2O C%: 42.12 (43.74); H%: 4.84 (5.00); N%: 
12.86 (13.03). 
Mp: > 250 °C 
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